

## Contents

Personal information.....	2
Education.....	2
Work experience and positions.....	2
Health care activity.....	2
Research interests.....	2
Teaching.....	2
Organizational skills and competences.....	3
Membership of national and international research consortia.....	3
Congress and Conference chairmanship.....	4
Membership in the organizing/scientific committee of national and international congresses.....	4
Grants.....	4
Invited speaker at Continuing Medical Education (CME) events.....	5
Invited lectures at national and international conferences.....	10
Invited speaker at roundtables and consensus meetings.....	11
Scientific publications list.....	12
Articles indexed in PubMed (author only, articles as member of the Working Group are omitted).....	13
Papers presented at national and international conferences based on the selection by the scientific committee (Speaker/First author).....	29
Papers presented at national and international conferences based on the selection by the scientific committee (non-Speaker/non-First author).....	31
Editorial activity.....	58
Associate Editor.....	58
Reviewer.....	58
Awards.....	58
Patents.....	59

## Personal information

Name ZAZZI, MAURIZIO  
Date of birth 22 NOVEMBER 1962  
Address 10, VIA DEL PINO 104, MONTERIGGIONI 53035 (SIENA), ITALY  
Telephone (39) 340 9312918  
Fax (39) 0577 233870  
E-mail MAURIZIO.ZAZZI@UNISI.IT  
Nationality ITALIAN  
ORCID [HTTPS://ORCID.ORG/0000-0002-0344-6281](https://orcid.org/0000-0002-0344-6281)

## Education

- 31/10/1985: Degree in Biological Sciences, full marks cum laude
- 31/10/1999: Postgraduate School in Microbiology and Virology, full marks cum laude

## Work experience and positions

- 01/11/2002 – present. Associate Professor of Microbiology, University of Siena, Via Banchi di Sotto 55, 53100 Siena, Italy
- 15/05/1990 – 30/10/2002. Biologist at the Service of Microbiology and Virology, Azienda Ospedaliera Senese (formerly USL 30), Policlinico S. Maria alle Scotte, Viale Bracci 1, 53100 Siena, Italy
- 01/04/1988 – 31/03/1990. Fellowship. Program “Lymphokines and synthetic vaccines”, topic “Adenovirus as a vector for influenza vaccine”. ENI, Rome, Italy.
- 01/01/1988 – 31/03/1988. Fellowship. Program “Isolation and characterization of influenza virus from clinical specimens in a trial evaluating the use of ribavirin as an anti-influenza agent”. Ciba-Geigy S.P.A., Origgio (VA), Italy

## Health care activity

- Virus isolation, viral serology and molecular diagnostics in virology
- Set-up and lead of a dedicated HIV & Hepatitis service
- Emergency services in microbiology and virology
- ISO 9001 2008 and ISO 9001 215 certification activities

## Research interests

- Development of advanced molecular diagnostics applied to human viral infections
- Antiviral drug development
- Antiviral drug resistance
- Virus evolution
- HIV latency
- Application of statistical learning and mathematical modelling to antiviral therapy

## Teaching (see specific annex for detailed track record)

- Continuous teaching at the University of Siena since 1992 (1992-2002 as Adjunct Professor from the University Hospital of Siena; 2002-present as Associate Professor of the University of Siena) through lectures and laboratory practice
  - Medicine and Surgery (Microbiology, Laboratory Medicine)
  - Pharmacy (Microbiology)
  - Biomedical Laboratory Techniques (Microbiology, Applied Microbiology, Clinical Microbiology)
  - Medical Biotechnology (Nucleic Acids Diagnostics, HIV and AIDS, Clinical Virology and Antiviral Drug Resistance)
  - Postgraduate Schools in Microbiology and Virology, Dermatology, Internal Medicine, Pediatrics, Forensics Medicine
- Supervisor of more than 40 thesis for the degree in Biological Sciences, in Biotechnology and for the Specialty School in Microbiology and Virology, University of Siena
- Supervisor of more than 20 PhD students, University of Siena

### **Organizational skills and competences**

- Set-up, maintenance and updating of an HIV dedicated laboratory and research group at the Department of Molecular Biology, then Department of Biotechnology, then Department of Medical Biotechnology of the University of Siena since 1990.
- Continuous cooperation with infectious diseases clinics in Italy since 1990.
- Continuous cooperation with many HIV international experts from academy and industry through conferences, workshops and research projects since 1995.
- Invited speaker at 115 CME events, 38 national and international conferences and 11 roundtables and consensus meetings.

### ***Membership of national and international research consortia***

1. 2002-ongoing. President of the Scientific Board of the Antiretroviral Resistance Cohort Analysis (<https://db.dbarca.net/>), a curated collection of HIV treatments and HIV drug resistance data throughout Italy.
2. 2003-2007. Founding member and then consultant of the Resistance Response Database Initiative ([www.hivrdb.org](http://www.hivrdb.org)), an international consortium dedicated to the development of artificial intelligence systems for optimizing anti-HIV therapy.
3. 2009-2011. Member of the OSCAR and DIVA national network involving laboratories developing molecular systems for the analysis of HIV coreceptor tropism.
4. 2009-ongoing. Founding member and then permanent member of the Steering Committee of the EuResist Network ([www.euresist.org](http://www.euresist.org)), a European consortium (plus non-European partners) for research studies based on large datasets related to anti-HIV therapy.
5. 2010. Expert member in the European Centre for Disease Prevention and Control (ECDC) tender "Public Health Value of HIV ARV Resistance monitoring within the EU/EEA" (Publication Reference: OJ/2010/02/22-PROC/2010/008).
6. 2011-ongoing. Member of the Steering Committee of the European HIV coreceptor study group (<https://www.euresist.org/eucohiv>), a research consortium aimed at studying HIV coreceptor tropism and the use of coreceptor antagonists.
7. 2012-2016. Coordinator of the Italian HLA Virological-Clinical Network, a national network of laboratories involved in the development of HLA-related assays for optimization of antiviral therapy.
8. 2013-2019. Member of the collaborative group for the management of the INIMAGE (Integrase Inhibitors Management by Genotype) national study.
9. 2015-2020. Italian delegate for the European Society for Translational Antiviral Research (ESAR, [www.esar-society.eu](http://www.esar-society.eu)), a scientific society for the study of virus evolution and its pathogenetic implications.
10. 2016-ongoing. Member of the Scientific Board and Coordinator of the Virology Group in the VIRONET-C collaboration (<https://www.vironetc.org/>), a national network of laboratories and clinics studying anti-HCV treatment.
11. 2017-ongoing. Member of the Steering Committee of the INTEGRATE project

- (<https://www.euresist.org/integrate>), an activity coordinated by the EuResist consortium to optimize the use of HIV integrase inhibitors across Europe.
- 2018-ongoing. Member and Coordinator of the HIV DNA Network, a national initiative for setup and harmonization of quantitative HIV DNA assays.

### ***Congress and Conference chairmanship***

1. Aggiornamenti in tema di resistenze agli antiretrovirali: dal genotipo alla risposta virologica al trattamento. Firenze, Villa Le Rondini, 10 Aprile 2003.
2. Attualità in tema di interpretazione dei test di resistenza agli antiretrovirali. Roma, Università Cattolica del Sacro Cuore, 31 marzo - 1 aprile 2004.
3. HAART 10 anni dopo. Siena, Certosa di Pontignano, 6 Giugno 2006.
4. Biomedical informatics for optimised treatment of infectious diseases. Helsinki, November 22, 2006.
5. First Workshop on Italian HIV Cohorts. Siena, Certosa di Pontignano, October 9th, 2007.
6. EuResist Moscow Meeting. Moscow, Borodino Hotel, December 15-16, 2008.
7. EuResist Tallinn Meeting. Tallinn, Estonia, April 3, 2008.
8. HIV drug resistance genotyping. A practical course. Kenya Medical Research Institute, Nairobi, February 21-25, 2011.
9. HIV drug resistance genotyping. A practical course. Kenya Medical Research Institute, Nairobi, February 20-22, 2012.
10. ARCA Mentor School. Siena, 27-28 Maggio 2015.
11. Presente e futuro degli INSTI nella pratica clinica. Siena, 4 Ottobre 2016.
12. ARCA Mentor School. Siena, 6-7 Ottobre 2016.
13. 9th Italian Conference on AIDS and Antiviral Research (ICAR 2017). Siena, 12-14 Giugno 2017.
14. ARCA Mentor School. Siena, 20-21 settembre 2017.
15. Le terapie antiretrovirali a due farmaci. Un cambio di paradigma? Firenze, 5 Aprile 2018.
16. Scuola di Alta Formazione in Virologia Clinica – VIKT 2018. Siena 24-25 settembre 2018.
17. ARCA Mentor School. Sioena, 18-19 Settembre 2019.
18. ARCA Factory. Web, 28-29 Settembre 2020.

### ***Membership in the organizing/scientific committee of national and international congresses***

1. Congress of the Italian Society for Virology. 2010-2015. Secretary of the Society from 10/2012 to 11/2015.
2. National Congress of the Società Italiana di Virologia - Italian Society for Virology. Consultant Member and Member of the Scientific Committee since 2016.
3. ICAR, Italian Conference on AIDS and Antiviral Research. Member of the Scientific and/or Program Committee since 2015.
4. European Meeting on HIV and Hepatitis. Member of the Scientific Committee since 2012.

### ***Grants***

1. 1990-1995. VII, VIII and IX AIDS Project, Istituto Superiore di Sanità, Ministry of Health, Rome.
2. 1994-1996. I, II and III Project on Antiretroviral Therapy, Istituto Superiore di Sanità, Ministry of Health, Rome.
3. 1997-2006. I, II, III and IV National AIDS Programme, Istituto Superiore di Sanità, Ministry of Health, Rome.
4. 2004. INFOBIOMED (Network of Excellence of the European Community, IST-507585): "Biomedical Informatics to Support Individualised Healthcare".
5. 2005. PRIN 2005 (Ministry of University and Research, Italy): "Development and use of a dedicated database for the study of genotypic antiretroviral resistance in vivo: integrated management of the factors involved in antiretroviral resistance".
6. 2005. Targeted Research 2005 (Ministry of Health, Italy): "Management of HIV drug resistance in modeling novel antiretroviral therapy strategies".
7. 2005. University Research Plan 2005 (University of Siena): "Development of a surveillance system for the circulation of different human immunodeficiency virus type 1 (HIV-1) subtypes and recombinant forms".
8. 2006. EuResist (STREP of the European Community, IST-2004-027173), "Integration of viral genomics with

- clinical data to predict response to anti-HIV treatment”
9. 2008. PRIN 2008 (Ministry of University and Research, Italy): “Development of laboratory assays for advanced monitoring of HIV drug resistance”
  10. 2009. CHAIN (“Collaborative HIV and Anti-HIV Drug Resistance Network”, Large scale project of the European Community, Grant Agreement number 223131).
  11. 2009. EDCTP Joint Program Activities, “Integrated training activities and IT infrastructures to improve capacities in Eastern African area”
  12. 2009. AIDS Program 2009, Italy. “Implementation of an HIV drug resistance database as a platform for resistance related research proposals and for advanced HIV genotype interpretation” (grant 40h81).
  13. 2012. Fellowship Program Gilead. The role of the viral reservoir and residual viremia in patients switched to raltegravir plus 2 NRTIs after virological suppression.
  14. 2013. THINPAD (FP7-HEALTH-2013-INNOVATION-2): “Targeting the HIV-1 Nucleocapsid Protein to fight Antiretroviral Drug Resistance”.
  15. 2015. Fellowship Program Gilead. HBV DNA distribution in PBMC and plasma from HBV inactive carriers and patients with occult HBV infection (OBI).
  16. 2016. Tuscany Region FAS-Salute: “UNAVIR: a novel strategy to combat multiple viral infections with one antiviral”.
  17. 2017. Fellowship Program Gilead. Changes in total and integrated HIV-1 DNA following treatment deintensification.
  18. 2018. Tuscany Region POR-FESR 2014-2020 “PANVIR.NET: preclinical development of innovative PANVIRal antivirals in a specialized regional NETWORK”.
  19. 2019. CARE (H2020 Research and Innovation action: H2020-SC1-2018-Single-Stage-RTD - SC1-BHC-21-2018): “Common Action against HIV/TB/HCV across the Regions of Europe”. Grant agreement ID: 825673.
  20. 2019. PRIN 2017: “ORIGINALE CHEMIAE in Antiviral Strategy - Origin and Modernization of Multi-Component Chemistry as a Source of Innovative Broad Spectrum Antiviral Strategy”. Prot. 2017BMK8JR.
  21. 2019. AIFA 2017 Call for Independent Drug Research: “OPTIMA - Strategies to Contain HIV Drug-Resistance Emergence in Virologically Suppressed Patients Requiring Antiretroviral Therapy Optimization: Unraveling the Role of Mutational Burden in PBMCs”. AIFA Code TRS-2018-00001336.
  22. 2020. Tuscany Region Health Call 2018: TUSCAVIR (Tuscany Antiviral Research Network).
  23. 2020. Tuscany COVID19 Call 2020: APICE (Antibodies and Peptides Inhibiting Coronavirus Entry).
  24. 2020. Intesa San Paolo Bank COVID-19 Call: Blocking Coronavirus infection: developing inhibitors of SARS-CoV-2 protease and multifunctional compounds interfering with virus entry and replication.

### ***Invited speaker at Continuing Medical Education (CME) events***

1. Zazzi M: “PCR: principi teorici e metodologici”. In: Polymerase Chain Reaction (PCR): vantaggi nella diagnostica di laboratorio ed impiego clinico. Aggiornamento della Società Italiana di Medicina di Laboratorio. Arezzo, 1 ottobre 1992.
2. Zazzi M.: “Individuazione di sequenze a basso numero di copie: HIV”. In: Polymerase Chain Reaction (PCR): vantaggi nella diagnostica di laboratorio ed impiego clinico. Aggiornamento della Società Italiana di Medicina di Laboratorio. Arezzo, 1 ottobre 1992.
3. Zazzi M., Romano L., De Milito A., Valensin P.E.: “Sviluppo di una metodica di amplificazione degli acidi nucleici per la diagnosi e il monitoraggio dell'infezione da HIV”. Secondo Incontro Seminario del Comitato Etico-Deontologico, Siena, 1 giugno 1993.
4. Zazzi M. “Potenzialità di applicazione della reazione a catena della polimerasi (PCR) nella diagnostica microbiologica”. In: Diagnostica microbiologica: attualità e prospettive. Convegno Nazionale. Corso di aggiornamento ANTeL. Siena, 5-6 dicembre 1995.
5. Zazzi M. “Problemi aperti sull'impatto clinico delle chemioresistenze in HIV”. Tavola rotonda Glaxo-Wellcome. Firenze, 1 aprile 1998.
6. Zazzi M. “PCR quantitativa in Microbiologia”. Corso teorico-dimostrativo. Associazione Microbiologi Clinici Italiani. Firenze, 3-4 giugno 1999.
7. Zazzi M. “Patologie correlate alle farmacotossicodipendenze e connesse alle modalità d'uso delle sostanze: malattie da agenti patogeni esterni”. Corso di Perfezionamento in Medicina delle Farmacotossicodipendenze. Università di Siena. Siena, 11 giugno 1999.
8. Zazzi M. “Resistenze genotipiche: metodiche ed implicazioni nella pratica clinica.” Patogenesi, diagnosi e terapia dell'infezione-malattia da HIV. III Corso Avanzato. Vienna, 16-18 Aprile 2000.

9. Zazzi M. "L'esperienza dei centri virologici italiani sui test di resistenza". Breaking the resistance. Genotipizzazione: implicazioni cliniche del dato virologico nelle infezioni sostenute da HIV e HBV/HCV. Università degli Studi – Facoltà di Medicina e Chirurgia, Padova, 13 Ottobre 2000.
10. Zazzi M. "Quesiti aperti in tema di farmacoresistenza: alterazioni del potere patogeno in mutanti di HIV selezionati dalla terapia antiretrovirale". Meeting sul tema: Recenti acquisizioni nella patogenesi e terapia dell'infezione da HIV. Firenze, 14 Febbraio 2001.
11. Zazzi M. "Test genotipici e fenotipici". Meeting sul tema: Significato clinico delle resistenze in corso di terapia antiretrovirale. Firenze, 29 settembre 2001.
12. Zazzi M. "La diagnostica molecolare per le malattie infettive". Corso di Perfezionamento in Malattie Infettive Pediatriche 2001. Dipartimento di Pediatria, Università di Firenze. Firenze, 22 Ottobre 2001.
13. Zazzi M. "Resistenze agli inibitori di proteasi". In: Le resistenze alla terapia antiretrovirale nella pratica clinica. Azienda Ospedaliera 'Domenico Cotugno'. Napoli, 9-10 Novembre 2001.
14. Zazzi M. "La determinazione di HIV-1 RNA". In: Aggiornamento su epatiti virali e HIV: aspetti epidemiologici, diagnostici e clinici. Monsummano Terme (PT), 19 Aprile 2002.
15. Zazzi M. "Quantitative determination of HIV-1 RNA". In: Abbott: Molecular Diagnostics Roadshow. Grand Hotel Palace, Roma, 10 dicembre 2002.
16. Zazzi M. "La determinazione quantitativa di HIV RNA". In: La Biologia Molecolare nel Monitoraggio delle Infezioni da HIV e HCV. Residence Le Stelline, Milano, 30 settembre 2003.
17. Zazzi M. "Interpretazione dei test di resistenza e presentazione del database ARCA". In: Monitoraggio delle resistenze in HIV: esperienze a confronto nel Triveneto. Padova, Hotel Sheraton, 23 ottobre 2003.
18. Zazzi M. "Il razionale virologico delle strategie terapeutiche class-sparing". In: Strategie di sequenziamento nella terapia antiretrovirale: esperienze a confronto. Grand Hotel Sitea, Torino, 13 novembre 2003.
19. Zazzi M. "L'utilizzo di database esterni per l'interpretazione dei dati di sequenza". Viroseq User Meeting. Roma, Hotel Melià, 10 marzo 2004.
20. Zazzi M. Interactive session: "Case histories in HIV-1 ARV resistance testing". In: HIV-1 ARV Resistance Testing: Practical Tools and Case Histories in Therapy Management. Università Cattolica del Sacro Cuore, Rome, March 11, 2004.
21. Zazzi M. "Le basi virologiche della farmacoresistenza". In: Resistenze genotipiche: attualità e prospettive. Hotel Deco, Ponte S. Giovanni (PG), 7 maggio 2004.
22. Zazzi M. "L'uso dei test di resistenza nel sequencing terapeutico". In: Il futuro dell'infezione da HIV: una malattia "quasi normale". Hotel Palace, Bari, 7 giugno 2004.
23. Zazzi M. "Update su resistenza ai farmaci antiretrovirali". Conferenze Seminario della Scuola di Specializzazione in Malattie Infettive e della Scuola di Specializzazione in Medicina Tropicale. Università degli Studi di Milano. Polo Universitario L. Sacco. Milano, 14 giugno 2004.
24. Zazzi M. "Insorgenza e ruolo di mutanti farmacoresistenti in corso di terapia ARV". In: Infezione HIV/AIDS: le resistenze in corso di HAART. Primo corso di formazione. Aggiornamenti in infettivologia. SIMIT Lombardia. Jolly Hotel Pontevecchio, Lecco, 11 novembre 2004.
25. Zazzi M. "HIV resistance in clinical routine: what have we learned so far?" In: Münchner AIDS-Tage. Arabella Sheraton Grand Hotel, Munchen. November 26, 2004.
26. Zazzi M. "Interruzioni strutturate di terapia". I Upgrade Pluriregionale in HIV. Università Cattolica del Sacro Cuore. Roma, 13-14 dicembre 2004.
27. Zazzi M. "La gestione dei regimi di prima e seconda linea: aspetti virologici". In: Il sequenziamento della terapia antiretrovirale. Corso di Aggiornamento. Hotel Leon d'Oro, Verona, 16 maggio 2005.
28. Zazzi M. "HIV drug resistance". Invited seminary at the Institute of Virology, University of Cologne, Cologne, June 17, 2005.
29. Zazzi M. "Virus HIV e strategie di resistenza". In: Corso Nazionale sulla Terapia Antiretrovirale nella Malattia da HIV. Pesaro, 9-10 settembre 2005.
30. Zazzi M. "I test di resistenza agli antiretrovirali". In: Le resistenze farmacologiche al virus HIV. S. Angelo Lodigiano, Presidio Ospedaliero Delmati, 14 settembre 2005.
31. Zazzi M. "Interpretation of antiretroviral resistance tests". In: HIV: determinants of pathogenicity and clinical implications. 5th National Congress of the Italian Society of Virology. Orvieto, September 19-21, 2005.
32. Zazzi M. "Lo studio delle resistenze nel management del fallimento terapeutico". In: Lo stato dell'HAART: strategie per il successo terapeutico nel lungo termine. Pescara, 24 settembre 2005.
33. Zazzi M. "Patogenesi della multiresistenza di HIV, criteri virologici di definizione e sistemi interpretativi". In: Il Paziente con infezione da HIV multiresistente: strategie per uno scenario clinico emergente. Roma, 14-15

- ottobre 2005.
34. Zazzi M. "Resistenza a NRTI e sequencing: dalla virologia alle opzioni cliniche". In: Aggiornamento in tema di terapia antiretrovirale. Francavilla al Mare (CH), 18 ottobre 2005.
  35. Zazzi M. "Genotype interpretation systems for NRTI resistance: basis for clinical validity and applications". In: Nucleoside/nucleotide RT Inhibitors: a State-of-the-Art for the Backbone of Antiretroviral Therapy. Cannizzaro (CT), November 14-15, 2005.
  36. Zazzi M. "Resistenze: sequenziamento ottimale". In: Updated HAART. Terapia Antiretrovirale: i determinanti dell'Efficacia. Cesena, 24 novembre 2005.
  37. Zazzi M. "La sequenziazione ottimale degli NRTI's". In: La gestione della terapia antiretrovirale: ruolo degli NRTI. Perugia, 2 dicembre 2005.
  38. Zazzi M. "Interazione fra virus e farmaci". In: HAART 10 anni dopo. Siena, 6 giugno 2006.
  39. Zazzi M. "Resistenze e possibilità di sequenziamento". In: La terapia antiretrovirale: come iniziare, come proseguire. Ancona, 14 settembre 2006.
  40. Zazzi M. "Resistenze: ottimizzare il sequenziamento". In: Infezione da HIV: aspetti emergenti. San Patrignano, 4 ottobre 2006.
  41. Zazzi M. "Lack of major protease mutations as main feature of PI-boosted failure: mechanisms and clinical benefit". In: HIV Protease Inhibitors: A State-of-Art for Optimal Antiretroviral Combination. Taormina, 6 Novembre 2006.
  42. Zazzi M. "Challenges for optimization of treatment of infectious diseases". In: Biomedical informatics for optimised treatment of infectious diseases. IST 2006. Helsinki, November 22, 2006.
  43. Zazzi M. "From genotype to response". In: 1st Nordic HIV Clinical Front-line meeting – drug resistance. Stockholm, August 30, 2007.
  44. Zazzi M. "Algoritmi gestionali in env". In: Forum virologia: tropismo. Roma, 12 settembre 2007.
  45. Zazzi M. "The ARCA database: features and perspectives". In: First Workshop on Italian HIV Cohorts. Siena, October 9, 2007.
  46. Zazzi M. "La resistenza agli inibitori dell'entry: basi molecolari, conseguenze virologiche". In: Tropismo e immunità: la nuova frontiera della terapia antiretrovirale. Bolzano, 3-4 dicembre 2007.
  47. Zazzi M. "ARCA: gli inibitori delle proteasi e le resistenze". In: Gli inibitori della proteasi di terza generazione e le nuove sfide dell'HIV. Milano, 10-11 dicembre 2007.
  48. Zazzi M. "Diversità genetica di HIV e test per carica virale". In: Attualità e prospettive nella diagnostica delle malattie virali. Milano, 7 Aprile 2008 - Centro Congressi Palazzo delle Stelline.
  49. Zazzi M & Ceccherini-Silberstein F. "Le resistenze". Workshop in: Anti-infective Therapies: go beyond. Milano, Palazzo Mezzanotte, 6-7 giugno 2008.
  50. Zazzi M. "Progress towards prediction of response to antiretroviral therapy". In: Nuove strategie di terapia antiretrovirale. Padova, Villa Contarini, 18 settembre 2008.
  51. Zazzi M. "Raltegravir: profilo di resistenza". In: Nuove opportunità terapeutiche nelle infezioni da HIV. Roma, Jolly Hotel Carpegna, 4 ottobre 2008.
  52. Zazzi M. "Aspetti metodologici: le tecniche di laboratorio". In: Il buon uso clinico dei test di resistenza. Grottaferrata (RM), 22-23 ottobre 2008.
  53. Zazzi M. "Le resistenze nel paziente early experienced con elevato numero di opzioni terapeutiche". In: Il buon uso clinico dei test di resistenza. Grottaferrata (RM), 22-23 ottobre 2008.
  54. Zazzi M. "Biologia e clinica dell'infezione da HIV: dalla parte della ricerca di base". In: 3° Corso di perfezionamento in medicina della riproduzione. Università di Firenze, 10-12 novembre 2008.
  55. Zazzi M. "Ruolo delle Farmacoresistenze nella scelta del primo regime terapeutico". In: Le Farmacoresistenze nelle prime fasi della terapia ARV. Perugia, 2 dicembre 2008.
  56. Zazzi M. "Presupposti epidemiologici e virologici per un corretto approccio sequenziale alla terapia antiretrovirale". In: Infezioni da HIV – Nuovi pazienti, nuove opportunità terapeutiche, nuove strategie. Perugia, 4 dicembre 2008.
  57. Zazzi M. "From HIV genotype to treatment response". In: HIV: resistances and new treatment perspectives. Milano, December 9, 2008.
  58. Zazzi M. "Workshop Cinetica & Resistenze". In: Una nuova era nella terapia dell'HIV. Roma, 19-20 febbraio 2009.
  59. Zazzi M. "Implicazioni patogenetiche del tropismo corecettoriale". In: Gli inibitori del CCR5 nel management terapeutico dell'infezione da HIV: evidenze dalla pratica clinica. Roma, Palazzo Brancaccio. 3-4 Dicembre 2009.
  60. Zazzi M. "La resistenza agli inibitori di integrasi". in: I nuovi farmaci antiretrovirali e le nuove frontiere nel

- trattamento della infezione da HIV. Firenze, 15 gennaio 2010.
61. Zazzi M. "Aspetti metodologici: le tecniche di laboratorio". In: Il buon uso clinico del Test di Resistenza: disegnare terapie coerenti con il pattern mutazionale. Monastero S. Maria Colonna, Trani (BT), 3-4 Marzo 2010 - Castello Chiola, Loreto Aprutino (PE), 13-14 Aprile 2010.
  62. Zazzi M. "Le resistenze nel paziente early experienced con elevato numero di opzioni terapeutiche". In: Il buon uso clinico del Test di Resistenza: disegnare terapie coerenti con il pattern mutazionale. Monastero S. Maria Colonna, Trani (BT), 3-4 Marzo 2010 - Castello Chiola, Loreto Aprutino (PE), 13-14 Aprile 2010.
  63. Zazzi M. "HIV e apparato genitale". Corso di perfezionamento in Malattie Infettive e Gravidanza. Firenze, auditorium CTO, 21-22 marzo 2010.
  64. Zazzi M. "Razionali virologici di terapie di induzione a base di PI/r + INI / CCR5". In: Protect future saving treatment options and costs. Roma, Villa Mondragone, 14-15 giugno 2010.
  65. Zazzi M. "Razionale virologico del sequencing terapeutico stage-dependent". In: HIV: attualità diagnostiche e nuove offerte terapeutiche. Milano, Ospedale Sacco, 17 novembre 2010.
  66. Zazzi M. "Utilizzo di database di laboratorio a fini clinici". In: 9° Congresso Nazionale SIMIT, Hotel Ergife, Roma 24-27 Novembre 2010.
  67. Zazzi M. "Le nuove classi di antiretrovirali nelle strategie di semplificazione della terapia". In: Aggiornamenti degli aspetti microbiologici e diagnostico-terapeutici dell'infezione da HIV, di alcune malattie opportunistiche e di altre malattie infettive emergenti. Certosa di Pontignano, Siena, 19 gennaio e 9 marzo 2011.
  68. Zazzi M: "bHIVi - Percorsi decisionali interattivi nel trattamento del paziente HIV". Firenze, 25 maggio 2011; Bologna, 16 maggio 2011; Bari, 16 giugno 2011.
  69. Zazzi M: "PI/NNRTI mutations". In: Il futuro della terapia antiretrovirale disegnato dagli Studi di Coorte. Roma, Istituto Superiore di Sanità, 7 giugno 2011.
  70. Zazzi M: "Farmacoresistenze in HIV e in HCV". In: XII Giornata infettivologica toscana, "HIV-HCV: realtà a confronto". Arezzo, 22-23 marzo 2012.
  71. Zazzi M: "I test virologici nell'ottica della semplificazione". In: Dopo la soppressione virologica: ottimizzazione della terapia antiretrovirale. Firenze, 2-3 aprile 2012.
  72. Zazzi M: "DAA's, ruolo dei laboratori e resistenze". In: Epatite C: dimensioni del problema, trattamento e nuove prospettive terapeutiche. Firenze, 5 dicembre 2012.
  73. Zazzi M: "Il concetto di barriera di regime. Razionale virologico". In: Project START: Strategic barrier to resistance - Dalla barriera genetica del farmaco alla barriera di regime. Bologna, 28 settembre 2012; Torino, 3 dicembre 2012; Avellino, 26 febbraio 2013.
  74. Zazzi M: "Nex-gen sequencing nel management clinico di HCV". In: Corso di Perfezionamento in bioinformatica applicata all'evoluzione molecolare e filogenesi degli agenti infettivi. Milano, 10-14 Giugno 2013, Dipartimento di Scienze Cliniche L. Sacco.
  75. Zazzi M: "Le resistenze naturali e acquisite di HCV alle terapie antivirali nel contesto della variabilità genotipica: impatto clinico?". In: 3° Workshop del Gruppo di Studio Regionale sulle Epatiti Virali C: "Il progetto calabrese SINERGIE nel framework nazionale". Università Magna Grecia, Catanzaro, 04/10/2013.
  76. Zazzi M: "DNA di HIV e DNA genomico: HLA B\*5701 e HIV DNA quantificazione, resistenze e tropismo nella pratica clinica". In: Switch degli antiretrovirali nel paziente con soppressione virologica: seconda edizione. Firenze, 11-12 novembre 2013.
  77. Zazzi M: "HCV: aspetti virologici e resistenze". In: Il incontro SIMIT Toscana 2013: L'infettivologo tra innovazione e cambiamento. Prato, 25-26 novembre 2013.
  78. Zazzi M: "L'impiego di cartelle cliniche elettroniche e database relazionali". In: I Seminario SIMIT Toscana 2014: Cambiamenti paradigmatici nell'approccio terapeutico alle infezioni virali. Siena, 18 Settembre 2014.
  79. Zazzi M: "Efficacia virologica e barriera genetica dei nuovi schemi terapeutici I dati della coorte ARCA". In: HAART Evolution. Caserta, 2-3 Ottobre 2014.
  80. Zazzi M: "Virologia applicata alla pratica clinica con regimi PI based". In: Individualizzazione della terapia in HIV: percorsi terapeutici e ruolo dei regimi a minor numero di farmaci. Assisi, 14 Novembre 2014.
  81. Zazzi M: "HIV DNA nei pazienti virosoppressi, ruolo di diverse strategie terapeutiche". In: Switch degli antiretrovirali nel paziente con soppressione virologica: Terza edizione. Le strategie di switch, di semplificazione e di intensificazione nell'ottica dell'ottimizzazione della ART. Firenze, 9- 10 Febbraio 2015.
  82. Zazzi M: "Dolutegravir: la nuova generazione degli inibitori dell'integrasi". In: Dolutegravir Superiorità & Innovazione. Bologna, 25 Marzo 2015.
  83. Zazzi M: "ARCA". In: ARCA Mentor School. Siena, 27-28 Maggio 2015.
  84. Zazzi M: "Polimorfismi e mutazioni: il razionale della valutazione". In: HCV: terapia ottimale per il singolo paziente. Milano, 28 Ottobre 2015.



85. Zazzi M: "I PI nella terapia antiretrovirale: quando la virologia guida la clinica". In: Innovation that performs: focus on HIV. Genova, 3 Novembre 2015.
86. Zazzi M: "DTG/ABC/3TC first line therapy". In: Dolutegravir/Abacavir/Lamivudina: dall'Innovazione di Dolutegravir al al Single Pill Regimen. Torino, 11 Novembre 2015.
87. Zazzi M: "DNA quantitation and DNA genotyping: what do we offer to clinicians one year after?". In: SWITCH ART 2016: Quarta Edizione. Le strategie di switch, di semplificazione e di intensificazione nell'ottica dell'ottimizzazione della ART. Firenze, 8-9 Febbraio 2016.
88. Zazzi M: "Aspetti virologici degli INSTI". Presente e futuro degli INSTI nella pratica clinica. Siena, 4 Ottobre 2016.
89. Zazzi M: "HCV: le resistenze ai farmaci". Coinfezione HIV/HCV. Esperienze e riflessioni un anno dopo. Firenze, 10 Ottobre 2016.
90. Zazzi M: "La co-infezione HIV/HCV: lo scenario virologico". In: IDENTIFY: outline definite strategies in the co-infected patient therapy. Torino, 3 novembre 2016.
91. Zazzi M: "Il ruolo del virologo: dalla scoperta dell'epatite da HCV al tailoring della terapia". In: Infezioni da HIV e da HCV: le attuali problematiche. Firenze, 24 Novembre 2016.
92. Zazzi M: "Problemi di terapia antiretrovirale nel paziente experienced". In: Progetto BYKE, Società Italiana di Malattie Infettive e Tropicali. Milano, 12 Dicembre 2016.
93. Zazzi M: "L'importanza delle RAVs". In: Terapia dell'infezione da HCV CON I DAA: tra punti fermi e prospettive future. Firenze, 12 gennaio 2017.
94. Zazzi M: "Barriera genetica del farmaco o della combinazione?". In: Nuovi ingredienti e nuove ricette per mantenere l'efficacia e ridurre le comorbilità del paziente HIV. Roma, 4-5 Aprile 2017.
95. M Zazzi: "HCV: da bersaglio inafferrabile a specie a rischio di estinzione?". In: Trattamento delle infezioni da HIV e HCV: scenari presenti e futuri 2.0. Milano, 9 Maggio 2017.
96. M. Zazzi: "Varianti di resistenza e ritrattamento". In: SharePoint - Practical Challenges in HCV therapy. Firenze, 12 Maggio 2017.
97. M. Zazzi: "Focus on: efficacia virologica e barriera genetica". In: Nuove strategie di impiego degli inibitori delle proteasi. Siena, 24 Maggio 2017.
98. M. Zazzi: "Quale spazio per la ricerca delle RAVs alla luce dei futuri trattamenti". In: VIII Workshop Nazionale Innovazione e Ricerca per la Pratica Clinica. Terapie innovative delle epatiti croniche virali. Firenze, 17-18 Gennaio 2018.
99. M. Zazzi: "Why is lamivudine so relevant in the de-intensification strategy?". In: Switch ART 2018: Quinta Edizione. Le strategie di switch, di semplificazione e di intensificazione nell'ottica dell'ottimizzazione della ART - Centro Congressi Hotel Baglioni - Piazza Unità Italiana, 6 - Firenze 12-13 Febbraio 2018.
100. M. Zazzi: "Cosa oggi si intende per controllo virologico?". In: Convegno NAZIONALE impact. HIV, Epatiti e altri Virus: clinica, diagnostica e nuovi standard di gestione. Roma, 15-16 Marzo 2018 - NH Vittorio Veneto.
101. M. Zazzi: "Barriera genetica". In: HIV, il futuro è nella storia. Firenze, 8-9 Maggio 2018.
102. M. Zazzi: "Gestione multidisciplinare del paziente e governo clinico: valutazione del profilo di resistenza". In: Stronger against HIV: nuove sinergie di trattamento. Napoli, 17-18 Settembre 2018.
103. M. Zazzi: "GRT su DNA provirale: quando eseguirlo e come interpretarlo nella pratica clinica". In: Hot topics in Infettivologia. Napoli, 4-5 Ottobre 2018.
104. M. Zazzi: "Approcci diagnostici innovativi nella pratica clinica". In: Terapia a lungo termine e nuovi paradigmi in HIV: virologia e clinica. Firenze, 6-7 Novembre 2018.
105. M. Zazzi: "Le terapie di domani: nuovi paradigmi e nuove possibilità terapeutiche". In: VII Riunione Annuale SIMIT Toscana. Arezzo, 16/17 Novembre 2018.
106. M. Zazzi: "Do we need novel virological assays for optimising HIV therapy?". In: Percorsi in HIV. Perugia, 26 marzo 2019.
107. M. Zazzi: "Determinanti virologici di switch". In: How to improve HIV care. Roma, 14-15 Maggio 2019.
108. M. Zazzi: "L'aspetto virologico". In: Strategie terapeutiche 2DR in HIV. Modena: 18 Giugno 2019.
109. M. Zazzi: "ARCA". In: Evolving HIV, Caring for HIV. Bologna, 1 Ottobre 2019.
110. M. Zazzi: "Ruolo della barriera genetica nei regimi terapeutici 2DR". In: Update sui regimi a due farmaci. Napoli, 24 Ottobre 2019.
111. M. Zazzi: "Come cambia la diagnostica in caso di trattamento immediato". In: Covegno Nazionale IMPACT: HIV, Epatiti e altri Virus: clinica, diagnostica e nuovi standard di gestion. Web, 15 Luglio 2020.
112. M. Zazzi: "Nuove strategie per inizio e semplificazione della ARV: il punto di vista del Virologo". In: La gestione del PLWH nel lungo termine. Web, 21 Ottobre 2020.
113. M. Zazzi: "Diagnostica virologica: progressi e prospettive". Web, 23 ottobre 2020.

114. M. Zazzi: "Aspetti virologici da considerare nell'approccio ai 2DRs". In: Cura dell'infezione da HIV: nuove esigenze dei pazienti e nuove soluzioni terapeutiche. I regimi ARV a due farmaci. Web, 19 novembre 2020 e 2 Dicembre 2020.
115. M. Zazzi: "L'impatto delle mutazioni di resistenza nei pazienti in duplice terapia". In: L'importanza dei database clinici nella gestione dell'infezione da HIV. Web, 9 Dicembre 2020.

### ***Invited lectures at national and international conferences***

1. Zazzi M. "La biologia molecolare nella diagnostica microbiologica". Convegno nazionale dell'Associazione Microbiologi Clinici Italiani. Arezzo, 27 maggio 1999.
2. Zazzi M. "Can the M184V mutation confer clinical benefit?" XIII Convegno Nazionale AIDS e Sindromi Correlate. Simposio satellite Glaxo-Wellcome. Roma, 26-29 Novembre 1999.
3. Zazzi M. "Emergenza di resistenza agli inibitori della proteasi in corso di terapia tripla." XIV Convegno Nazionale AIDS e Sindromi Correlate. Milano, 26-28 Novembre 2000.
4. Zazzi M. "Trattamento virtuale". In: Convegno Nazionale: Infezione da HIV: presente e futuro. Villa Montalto, Firenze, 10-11 gennaio 2003.
5. Zazzi M. "Mutazioni, resistenza e fitness virale". Il Congresso Nazionale SIMIT. Bologna, 24-27 settembre 2003.
6. Zazzi M. "La determinazione quantitativa di HIV RNA e HCV RNA". In: 31° Congresso della Società Italiana di Microbiologia. Roma, 19-22 ottobre 2003.
7. Zazzi M. "The EuResist project". In: Third EuropeHIVResistance meeting. Cascais, March 27, 2007.
8. Zazzi M. "The ARCA database: features and perspectives". In: AREVIR Meeting. Bonn, 10-11 April 2008.
9. Zazzi M. "Il test di resistenza nella gestione del paziente con HIV". In: XXII Congresso Nazionale ANLAIDS, Palermo 6-7 novembre 2008.
10. Zazzi M. "The power and limitations of large database analysis". In: 7th European HIV Drug Resistance workshop. 25-27 March 2009, Stockholm, Sweden.
11. Zazzi M. "The EuResist Network". EDCTP Stakeholder Meeting on Optimisation of treatment of HIV and HIV-TB coinfection. 19 May 2009. Lisbon, Portugal.
12. Zazzi M. "Human versus machine: predicting virological responses to antiretroviral therapy". 14th UK Annual Meeting on HIV Resistance. London, September 22, 2010.
13. Zazzi M: "Clinical Medicine and Diagnosis I - Introduction". In: ICAR 2011 – III Italian Conference in AIDS and Retroviruses, Firenze, Palazzo dei Congressi, 27-29 Marzo 2011.
14. Zazzi M: "Aspetti critici della determinazione della viremia di HIV-1 nel monitoraggio della terapia antiretrovirale". In: Aggiornamenti nella diagnosi e nel monitoraggio delle infezioni virali. Workshop XL Congresso Nazionale AMCLI - Nuovo Palacongressi di Rimini, 8-11 novembre 2011.
15. Zazzi M: "Failure of HCV therapy: what is the value of drug resistance testing". In: ICAR 2012 IV Italian Conference in AIDS and Retroviruses, Napoli, Stazione Marittima, 10-12 Giugno 2012.
16. Zazzi M: "HCV Direct Acting Antivirals". In: 11th National Congress of the Italian Society for Virology. Orvieto, September 17-19, 2012.
17. Zazzi M: "Baseline HCV variability in relation to DAAs". In: 11th European Workshop on HIV & Hepatitis. 20 – 22 March 2013, Rome, Italy.
18. Zazzi M: "Hepatitis C and perspective for EuResist", In: AREVIR Meeting 2013. Cologne, 12/04/2013.
19. Zazzi M: "Evolution of HIV drug-resistance in Italy: a probing from the ARCA national database". In: ICAR 2013 - Italian Conference on AIDS and retrovirus. Centro Congressi Lingotto, Torino - 12-14 maggio 2013.
20. Zazzi M: "EuResist database: Current values". In: AREVIR Meeting 2014. Cologne, 05/04/2014.
21. Zazzi M: "HIV resistance: what is the role today?". In: ICAR 2014 VI Italian Conference in AIDS and Retroviruses. Roma, 25-27 Maggio 2014.
22. Zazzi M: "The role of HIV DNA in patient management". In: 6° Congresso Nazionale SIVIM, Roma 10-12 Dicembre 2014.
23. Zazzi M: "Il paziente «difficile - Il punto di vista del virologo". In: ICAR 2015 VII Italian Conference in AIDS and Retroviruses. Riccione, 17-19 Maggio 2015.
24. Zazzi M: "The evolution of the HIV laboratory as a fundamental support for patient management". In: 13th National Congress of the Italian Society for Virology (SIV). Orvieto (TR), Italy, 14-16 September 2015.
25. Zazzi M: "Patogenesi della coinfezione HIV/HCV". In: Convegno Nazionale IMPACT. Impatto clinico e nuovi standard nel monitoraggio di HIV. Roma, Villa Malta, 9-10 marzo 2016.
26. Zazzi M: "HIV DNA reservoir, how much defective or replication competent?". In: Lights and shadows in

- virology. ICAR 2016 VIII Italian Conference in AIDS and Retroviruses. Milano, 6-8 Giugno 2016.
27. Zazzi M: "Start and stay with high genetic barrier regimen". In: INSTI in continuum of care: from engagement to retention in care. ICAR 2016 VIII Italian Conference in AIDS and Retroviruses. Milano, 6-8 Giugno 2016.
  28. Zazzi M: "Significato della viremia residua di HIV". In: Impatto clinico e nuovi standard nel monitoraggio di HIV, della co-infezione con HCV e con altri virus. Convegno Nazionale IMPACT. Roma, Villa Malta 8-9 marzo 2017.
  29. Zazzi M: "Impact of the HIV-1 integrase natural polymorphism E157Q on susceptibility to integrase inhibitors". In: AREVIR Meeting. Colonia, 5 Maggio 2017.
  30. Zazzi M: "Clinical use of HIV-DNA quantity and resistance testing". In: 15th European Meeting on HIV & Hepatitis – Rome, 7-9 June 2017.
  31. Zazzi M: "Clinical use of HIV DNA quantification and genotyping". In: HIV and Hepatitis Nordic Conference. Stockholm, 27-29 September 2017.
  32. Zazzi M: "Clinical application of quantitative HIV-1 DNA". In: 48° Congresso della Società Italiana di Microbiologia. Genova 27-30 settembre 2017.
  33. Zazzi M: "HIV resistenze, dove, quando e perchè". In: XVI Congresso Nazionale SIMIT, Salerno, 16 ottobre 2017.
  34. Zazzi M: "Update sui test di resistenza ai farmaci antivirali: Cosa ci ha insegnato l'esperienza su HIV". In: XLVI Congresso Nazionale AMCLI. Rimini, 11 - 14 Novembre 2017.
  35. Zazzi M: "Future challenges in the long-term management of HIV infection – The virological vision". In: ICAR 2018. Roma, 22-24 maggio 2018.
  36. Zazzi M: "Le terapie di domani: nuovi paradigmi e nuove possibilità terapeutiche. In: XVII Congresso Nazionale SIMIT. Torino, 2-5 DICEMBRE 2018.
  37. Zazzi M: "Dolutegravir: the importance of the high barrier to resistance". In: ICAR 2019. Milano, 5-7 giugno 2019.
  38. M. Zazzi: "Resistance to long acting antivirals". In: ICAR 2020. Web, 13 ottobre 2020.


#### ***Invited speaker at roundtables and consensus meetings***

1. Brun-Vezinet F, Clotet B, Calvez V, Clavel F, Costagliola D, De Gruttola V, Haubrich R, Kempf D, King M, Kuritzkes D, Miller M, Miller V, Phillips A, Pillay D, Schapiro J, Shafer R, Zazzi M, Zolopa A. Roundtable on Analysis Standardization of Correlation between Genotypic Resistance and Virological Response. Hotel Alcora, Seville, Spain. July 1, 2002.
2. Zazzi M. "Resistance testing: Genotype and phenotype: alternative or complementary results?" In: Resistance to antiretroviral drugs and pharmacokinetics. Consensus Workshop. Grand Hotel Excelsior-Vesuvio, Napoli, 2-3 December 2002.
3. Boucher C, Camacho R, de Mendoza C, Descamps D, Masquelier B, Molina J-M, Moreno S, Perno CF, Perrin L., Schapiro J, Schmit JC, Staszewski S, Van Lunzen J, Zazzi M, European expert round on resistance: focusing on ddI. Paris, Sheraton Airport Hotel, October 16, 2003.
4. De Luca A, Boucher C, Braun P, Camacho R, Clotet B, Descamps D, Geretti AM, Korn K, Moreno S, Saracino A, Schmit JC, Sonnerborg A, Zazzi M. European expert round on HIV resistance. Hotel Windsor Royal, Bruxelles. June 17, 2004.
5. Boucher C, Blanco JL, Braun P, Camacho R, Clotet B, Danner S, Descamps D, Geretti AM, Kaiser R, Marcelin AG, Perno CF, Perrin L, Schapiro J, Soriano V, Zazzi M. European expert round on HIV resistance. Hotel Hilton, Paris. April 13, 2005.
6. Antonelli G, Balotta C, De Luca A, Zazzi M. Roundtable: HIV resistance and reservoirs. In: First CHIVAS – Conference on HIV and Antiretroviral Strategies. ES Hotel, Rome, 5-7 May, 2005.
7. Boucher C, Perrin L, Descamps D, Braun P, Walter H, Kaiser R, De Luca A, Zazzi M, Schmit JC, Wensing AM, Horban A, Camacho R, Soriano V, Geretti AM, Vandamme A, Mayers D, Clotet B, Keulen W, Posthumus A. APTIVUS Resistance Expert Meeting. Dublin, November 16, 2005.
8. Zazzi M. "Resistance testing in drug-naïve patients". Clinical application of HIV drug resistance testing: Italian Consensus Conference 2008. Rome (Italy), 21-22 February 2008.
9. Clementi M, Balotta C, De Luca A, Parisi S, Zazzi M. Roundtable "R5/X4/DM genotipo nella pratica clinica". In: Second Expert Panel Workshop. Gli inibitori CCR5: una rivoluzione copernicana dell'approccio terapeutico all'infezione da HIV. Firenze, 4-5 dicembre 2008.
10. Zazzi M. "Virological parameters in two drug regimen efficacy". Think tank - Consensus on Two Drug Regimens. Firenze, 19-20 ottobre 2018.

11. Zazzi M: "Fattibilità e modelli organizzativi virologici". In: Test and Treat: esperti a confronto. Bologna, 10-11 Maggio 2019.

### Scientific publications list


- Scientific peer-reviewed publications indexed in PubMed: 241 (224 as author, 17 as indexed member of the Working Group)
- Impact factor: 897.436
- Citations: 3954 (Scopus)
- H index: 32 (Scopus)



This author's *h*-index


32

The *h*-index is based upon the number of documents and number of citations.



Citations by year

3.954



**Articles indexed in PubMed (author only, articles as member of the Working Group are omitted)**

Public link: <https://www.ncbi.nlm.nih.gov/sites/myncbi/1LA5H90hBaj/collections/60857087/public/>

1. Vicenti I, Gatti F, Scaggiante R, Boccuto A, Zago D, Basso M, Dragoni F, Zazzi M, Parisi SG. Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection. *Int J Infect Dis.* 2021 May 19;S1201-9712(21)00435-5. doi: 10.1016/j.ijid.2021.05.033. Epub ahead of print. PMID: 34022329.
2. Boccuto A, Dragoni F, Picarazzi F, Lai A, Della Ventura C, Veo C, Giammarino F, Saladini F, Zehender G, Zazzi M, Mori M, Vicenti I. Sofosbuvir Selects for Drug-Resistant Amino Acid Variants in the Zika Virus RNA-Dependent RNA- Polymerase Complex In Vitro. *Int J Mol Sci.* 2021 Mar 6;22(5):2670. doi: 10.3390/ijms22052670. PMID: 33800884; PMCID: PMC7962015.
3. Vicenti I, Zazzi M, Saladini F. SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. *Expert Opin Ther Pat.* 2021 Apr;31(4):325-337. doi: 10.1080/13543776.2021.1880568. Epub 2021 Mar 3. PMID: 33475441; PMCID: PMC7938656.
4. Vicenti I, Dragoni F, Monti M, Trombetta CM, Giannini A, Boccuto A, Saladini F, Rossetti B, De Luca A, Ciabattini A, Pastore G, Medagliani D, Orofino G, Montomoli E, Zazzi M. Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and *in vivo* CD4 T cells. *J Gen Virol.* 2021 Jan;102(1). doi: 10.1099/jgv.0.001499. PMID: 33048041.
5. Saladini F, Giammarino F, Hosseini BA, Giannini A, Boccuto A, Dragoni F, Vicenti I, Shafer RW, Zazzi M. In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations. *J Antimicrob Chemother.* 2021 Jan 1;76(1):130-134. doi: 10.1093/jac/dkaa401. PMID: 32974670.
6. Picarazzi F, Vicenti I, Saladini F, Zazzi M, Mori M. Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge. *Molecules.* 2020 Dec 3;25(23):5695. doi: 10.3390/molecules25235695. PMID: 33287144; PMCID: PMC7730706.
7. Petkov S, Bekele Y, Lakshmikanth T, Hejdeman B, Zazzi M, Brodin P, Chiodi F. High CD45 expression of CD8+ and CD4+ T cells correlates with the size of HIV-1 reservoir in blood. *Sci Rep.* 2020 Nov 24;10(1):20425. doi: 10.1038/s41598-020-77433-z. PMID: 33235273; PMCID: PMC7686502.
8. Vergori A, Rossetti B, Vicenti I, Meini G, Lentini G, Valoriani B, Caudai C, Morandi M, Cusi MG, Zazzi M, De Luca A. Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection. *Infez Med.* 2020 Nov 1;28(4):576-586. PMID: 33257634.
9. Maggiolo F, Bandera A, Bonora S, Borderi M, Calcagno A, Cattelan A, Cingolani A, Gianotti N, Lichtner M, Lo Caputo S, Madeddu G, Maggi P, Marchetti GC, Maserati R, Nozza S, Rusconi S, Zazzi M, Di Biagio A. Enhancing care for people living with HIV: current and future monitoring approaches. *Expert Rev Anti Infect Ther.* 2021 Apr;19(4):443-456. doi: 10.1080/14787210.2021.1823217. Epub 2020 Oct 15. PMID: 33054479.
10. Galli L, Parisi MR, Poli A, Menozzi M, Fisco M, Garlassi E, Francisci D, Di Biagio A, Sterrantino G, Fornabaio C, Degli Antoni A, Angarano G, Fusco FM, D'Arminio Monforte A, Corbelli GM, Santoro MM, Zazzi M, Castagna A; PRESTIGIO Study Group. Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry. *Open Forum Infect Dis.* 2020 Sep 26;7(11):ofaa456. doi: 10.1093/ofid/ofaa456. PMID: 33241063; PMCID: PMC7673611.
11. Borghetti A, Ciccullo A, Lombardi F, Baldin G, Belmonti S, Prosperi M, Incardona F, Heger E, Borghi V, Sönnnerborg A, Zazzi M, De Luca A, Di Giambenedetto S. Transmitted drug resistance to NRTIs and risk of virological failure in naïve patients treated with integrase inhibitors. *HIV Med.* 2021 Jan;22(1):22-27. doi: 10.1111/hiv.12956. Epub 2020 Sep 23. PMID: 32964671.
12. Saladini F, Giannini A, Giammarino F, Maggiolo F, Vichi F, Corbelli GM, Galli A, Bigoloni A, Poli A, Santoro MM, Zazzi M, Castagna A. In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients. *J Antimicrob Chemother.* 2020 Sep 1;75(9):2547-2553. doi: 10.1093/jac/dkaa178. PMID: 32464638.
13. Riva V, Garbelli A, Brai A, Casiraghi F, Fazi R, Trivisani CI, Boccuto A, Saladini F, Vicenti I, Martelli F, Zazzi M, Gianneccchini S, Dreassi E, Botta M, Maga G. Unique Domain for a Unique Target: Selective Inhibitors of Host Cell DDX3X to Fight Emerging Viruses. *J Med Chem.* 2020 Sep 10;63(17):9876-9887. doi: 10.1021/acs.jmedchem.0c01039. Epub 2020 Aug 18. PMID: 32787106.
14. Canetti D, Galli L, Gianotti N, Celotti A, Calza L, Gagliardini R, Rusconi S, Modica S, Cenderello G, Ferrara M, Santoro MM, Zazzi M, Castagna A; PRESTIGIO Study Group. Simplification to High Genetic Barrier 2-Drug

- Regimens in People Living With HIV Harboring 4-Class Resistance Enrolled in the PRESTIGIO Registry. *J Acquir Immune Defic Syndr*. 2020 Aug 1;84(4):e24–e28. doi: 10.1097/QAI.0000000000002378. PMID: 32598119.
15. Lai A, Bergna A, Caucci S, Clementi N, Vicenti I, Dragoni F, Cattelan AM, Menzo S, Pan A, Callegaro A, Tagliabracci A, Caruso A, Caccuri F, Ronchiadin S, Balotta C, Zazzi M, Vaccher E, Clementi M, Galli M, Zehender G. Molecular Tracing of SARS-CoV-2 in Italy in the First Three Months of the Epidemic. *Viruses*. 2020 Jul 24;12(8):798. doi: 10.3390/v12080798. PMID: 32722343; PMCID: PMC7472216.
  16. Marchi S, Viviani S, Montomoli E, Tang Y, Boccuto A, Vicenti I, Zazzi M, Sow S, Diallo A, Idoko OT, Bhat N, Trombetta CM. Zika Virus in West Africa: A Seroepidemiological Study between 2007 and 2012. *Viruses*. 2020 Jun 13;12(6):641. doi: 10.3390/v12060641. PMID: 32545775; PMCID: PMC7354557.
  17. Santoro MM, Fornabaio C, Malena M, Galli L, Poli A, Menozzi M, Zazzi M, White KL, Castagna A; PRESTIGIO Study Group. Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen. *Int J Antimicrob Agents*. 2020 Jul;56(1):106027. doi: 10.1016/j.ijantimicag.2020.106027. Epub 2020 May 23. PMID: 32450199.
  18. Brai A, Riva V, Saladini F, Zamperini C, Trivisani CI, Garbelli A, Pennisi C, Giannini A, Boccuto A, Bugli F, Martini M, Sanguinetti M, Zazzi M, Dreassi E, Botta M, Maga G. DDX3X inhibitors, an effective way to overcome HIV-1 resistance targeting host proteins. *Eur J Med Chem*. 2020 Aug 15;200:112319. doi: 10.1016/j.ejmech.2020.112319. Epub 2020 May 7. PMID: 32446036.
  19. Schlösser M, Kartashev VV, Mikkola VH, Shemshura A, Saukhat S, Kolpakov D, Suladze A, Tverdokhlebova T, Hutt K, Heger E, Knops E, Böhm M, Di Cristanziano V, Kaiser R, Sönnnerborg A, Zazzi M, Bobkova M, Sierra S. HIV-1 Sub-Subtype A6: Settings for Normalised Identification and Molecular Epidemiology in the Southern Federal District, Russia. *Viruses*. 2020 Apr 22;12(4):475. doi: 10.3390/v12040475. PMID: 32331438; PMCID: PMC7232409.
  20. Brai A, Boccuto A, Monti M, Marchi S, Vicenti I, Saladini F, Trivisani CI, Pollutri A, Trombetta CM, Montomoli E, Riva V, Garbelli A, Nola EM, Zazzi M, Maga G, Dreassi E, Botta M. Exploring the Implication of DDX3X in DENV Infection: Discovery of the First-in-Class DDX3X Fluorescent Inhibitor. *ACS Med Chem Lett*. 2020 Apr 9;11(5):956–962. doi: 10.1021/acsmchemlett.9b00681. PMID: 32435411; PMCID: PMC7236276.
  21. Malancona S, Mori M, Fezzardi P, Santoriello M, Basta A, Nibbio M, Kovalenko L, Speziale R, Battista MR, Cellucci A, Gennari N, Monteagudo E, Di Marco A, Giannini A, Sharma R, Pires M, Real E, Zazzi M, Dasso Lang MC, De Forni D, Saladini F, Mely Y, Summa V, Harper S, Botta M. 5,6-Dihydroxypyrimidine Scaffold to Target HIV-1 Nucleocapsid Protein. *ACS Med Chem Lett*. 2020 Mar 19;11(5):766–772. doi: 10.1021/acsmchemlett.9b00608. PMID: 32435383; PMCID: PMC7236274.
  22. Vicenti I, Dragoni F, Giannini A, Giammarino F, Spinicci M, Saladini F, Boccuto A, Zazzi M. Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication. *SLAS Discov*. 2020 Jun;25(5):506–514. doi: 10.1177/2472555220911456. Epub 2020 Mar 18. PMID: 32186426.
  23. Humbert N, Kovalenko L, Saladini F, Giannini A, Pires M, Botzanowski T, Cherenok S, Boudier C, Sharma KK, Real E, Zaporozhets OA, Cianféroni S, Seguin-Devaux C, Poggialini F, Botta M, Zazzi M, Kalchenko VI, Mori M, Mély Y. (Thia)calixarene phosphonic Acids as Potent Inhibitors of the Nucleic Acid Chaperone Activity of the HIV-1 Nucleocapsid Protein with a New Binding Mode and Multitarget Antiviral Activity. *ACS Infect Dis*. 2020 Apr 10;6(4):687–702. doi: 10.1021/acsinfectdis.9b00290. Epub 2020 Feb 21. PMID: 32045204.
  24. Dragoni F, Boccuto A, Picarazzi F, Giannini A, Giammarino F, Saladini F, Mori M, Mastrangelo E, Zazzi M, Vicenti I. Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro. *Antiviral Res*. 2020 Mar;175:104708. doi: 10.1016/j.antiviral.2020.104708. Epub 2020 Jan 10. PMID: 31931104.
  25. Modica S, Redi D, Gagliardini R, Giombini E, Bezenchek A, Di Carlo D, Maggiolo F, Lombardi F, Borghetti A, Farinacci D, Callegaro A, Gismondo MR, Colafigli M, Sterrantino G, Costantini A, Ferrara SM, Rusconi S, Zazzi M, Rossetti B, De Luca A, Gianotti N. Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort study. *J Antimicrob Chemother*. 2020 Jan 1;75(1):194–199. doi: 10.1093/jac/dkz424. PMID: 31605107.
  26. Caudai C, Papalini C, Francisci D, Baldelli F, Zazzi M. Very late relapse in an HCV genotype 3-infected patient treated with direct-acting antivirals (DAA). *J Antimicrob Chemother*. 2020 Jan 1;75(1):252–253. doi: 10.1093/jac/dkz402. PMID: 31535150.
  27. Saladini F, Giannini A, Boccuto A, Dragoni F, Appendino A, Albanesi E, Vicenti I, Zazzi M. Comparable *In Vitro* Activities of Second-Generation HIV-1 Integrase Strand Transfer Inhibitors (INSTIs) on HIV-1 Clinical Isolates with INSTI Resistance Mutations. *Antimicrob Agents Chemother*. 2019 Dec 20;64(1):e01717–19. doi: 10.1128/AAC.01717–19. PMID: 31611362; PMCID: PMC7187585.

28. Olearo F, Nguyen H, Bonnet F, Yerly S, Wandeler G, Stoeckle M, Cavassini M, Scherrer A, Costagliola D, Schmid P, Günthard HF, Bernasconi E, Boeni J, D'arminio Monforte A, Zazzi M, Rossetti B, Neau D, Bellecave P, Rijnders B, Reiss P, Wit F, Kouyos R, Calmy A. Corrigendum to: Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients. *Open Forum Infect Dis.* 2019 Dec 8;6(12):ofz500. doi: 10.1093/ofid/ofz500. Erratum for: *Open Forum Infect Dis.* 2019 Jul 12;6(10):ofz330. PMID: 31832485; PMCID: PMC6899347.
29. De Luca A, Pezzotti P, Boucher C, Döring M, Incardona F, Kaiser R, Lengauer T, Pfeifer N, Schülter E, Vandamme AM, Zazzi M, Geretti AM; EucoHIV Study Group. Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey. *PLoS One.* 2019 Nov 21;14(11):e0225381. doi: 10.1371/journal.pone.0225381. PMID: 31751385; PMCID: PMC6874206.
30. Brai A, Ronzini S, Riva V, Botta L, Zamperini C, Borgini M, Trivisani CI, Garbelli A, Pennisi C, Boccuto A, Saladini F, Zazzi M, Maga G, Botta M. Synthesis and Antiviral Activity of Novel 1,3,4-Thiadiazole Inhibitors of DDX3X. *Molecules.* 2019 Nov 4;24(21):3988. doi: 10.3390/molecules24213988. PMID: 31690062; PMCID: PMC6864647.
31. Scutari R, Alteri C, Vicenti I, Di Carlo D, Zuccaro V, Incardona F, Borghi V, Bezenchek A, Andreoni M, Antinori A, Perno CF, Cascio A, De Luca A, Zazzi M, Santoro MM; ARCA (Antiviral Response Cohort Analysis) Study Group. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors. *J Glob Antimicrob Resist.* 2020 Mar;20:163-169. doi: 10.1016/j.jgar.2019.07.015. Epub 2019 Jul 19. PMID: 31330378.
32. Olearo F, Nguyen H, Bonnet F, Yerly S, Wandeler G, Stoeckle M, Cavassini M, Scherrer A, Costagliola D, Schmid P, Günthard HF, Bernasconi E, Boeni J, D'arminio Monforte A, Zazzi M, Rossetti B, Neau D, Bellecave P, Rijnders B, Reiss P, Wit F, Kouyos R, Calmy A. Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment- Experienced Patients. *Open Forum Infect Dis.* 2019 Jul 12;6(10):ofz330. doi: 10.1093/ofid/ofz330. Erratum in: *Open Forum Infect Dis.* 2019 Dec 08;6(12):ofz500. PMID: 31660328; PMCID: PMC6778427.
33. Del Puente F, Riccardi N, Taramasso L, Borghetti A, D'Avino A, Irene Bonelli S, De Luca A, Zazzi M, Di Biagio A. Is it time to re-think the use of etravirine in patients with available genotypic resistance test? *Infect Dis (Lond).* 2019 Jun;51(6):452-455. doi: 10.1080/23744235.2019.1569257. Epub 2019 Apr 30. PMID: 31035844.
34. Lai A, Simonetti FR, Brindicci G, Bergna A, Di Giambenedetto S, Sterrantino G, Mussini C, Menzo S, Bagnarelli P, Zazzi M, Angarano G, Galli M, Monno L, Balotta C. Local Epidemics Gone Viral: Evolution and Diffusion of the Italian HIV-1 Recombinant Form CRF60\_BC. *Front Microbiol.* 2019 Apr 12;10:769. doi: 10.3389/fmicb.2019.00769. PMID: 31031735; PMCID: PMC6474184.
35. Serranti D, Indolfi G, Caudai C, Bartolini E, Trapani S, Zazzi M, Resti M. Hepatitis C Genotype 4 Virus Nonstructural 3 and Nonstructural 5A Resistance- associated Substitutions in a 16-year-old Adolescent Failing Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin. *Pediatr Infect Dis J.* 2019 Apr;38(4):e72-e74. doi: 10.1097/INF.0000000000002137. PMID: 30882744.
36. Sarfo FS, Castelnuovo B, Fanti I, Feldt T, Incardona F, Kaiser R, Lwanga I, Marrone G, Sonnerborg A, Tufa TB, Zazzi M, De Luca A. Longer-term effectiveness of protease-inhibitor-based second line antiretroviral therapy in four large sub-Saharan African clinics. *J Infect.* 2019 May;78(5):402-408. doi: 10.1016/j.jinf.2019.03.003. Epub 2019 Mar 6. PMID: 30849438.
37. Soulie C, Santoro MM, Charpentier C, Storto A, Paraskevis D, Di Carlo D, Gennari W, Sterrantino G, Zazzi M, Perno CF, Calvez V, Descamps D, Ceccherini-Silberstein F, Marcelin AG. Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients. *J Antimicrob Chemother.* 2019 Mar 1;74(3):614-617. doi: 10.1093/jac/dky464. PMID: 30476106.
38. Giannini A, Vicenti I, Materazzi A, Boccuto A, Dragoni F, Zazzi M, Saladini F. The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro. *J Antimicrob Chemother.* 2019 Mar 1;74(3):607-613. doi: 10.1093/jac/dky479. PMID: 30462235.
39. Alteri C, Scutari R, Bertoli A, Armenia D, Gori C, Fabbri G, Mastroianni CM, Cerva C, Cristaudo A, Vicenti I, Bruzzone B, Zazzi M, Andreoni M, Antinori A, Svicher V, Ceccherini-Silberstein F, Perno CF, Santoro MM. Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice. *Virus Genes.* 2019 Jun;55(3):290-297. doi: 10.1007/s11262-019-01649-z. Epub 2019 Feb 22. PMID: 30796743.
40. Sterrantino G, Borghi V, Callegaro AP, Bruzzone B, Saladini F, Maggiolo F, Maffongelli G, Andreoni M, De Gennaro M, Gianotti N, Bagnarelli P, Vergori A, Antinori A, Zazzi M, Zaccarelli M; ARCA Study Group. Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non- nucleoside

- reverse transcriptase inhibitors. *Int J Antimicrob Agents*. 2019 Apr;53(4):515-519. doi: 10.1016/j.ijantimicag.2019.02.007. Epub 2019 Feb 12. PMID: 30769200.
41. Schultze A, Torti C, Cozzi-Lepri A, Vandamme AM, Zazzi M, Sambatakou H, De Luca A, Geretti AM, Sonnerborg A, Ruiz L, Monno L, Di Giambenedetto S, Gori A, Lapadula G; European Transmitted Drug Resistance collaboration (EU-TDR). The effect of primary drug resistance on CD4+ cell decline and the viral load set-point in HIV-positive individuals before the start of antiretroviral therapy. *AIDS*. 2019 Feb 1;33(2):315-326. doi: 10.1097/QAD.0000000000002046. PMID: 30325769.
  42. Bavaro DF, Di Carlo D, Zuccalà P, Bai F, Incardona F, Battisti A, Giachè S, Salomoni E, Gagliardini R, Di Giambenedetto S, Pecorari M, Zazzi M, De Luca A, Bezenchek A, Lo Caputo S. Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV- infected patients - evidence from a large observational cohort. *Infect Dis (Lond)*. 2019 Mar;51(3):234-239. doi: 10.1080/23744235.2018.1544423. Epub 2019 Jan 21. PMID: 30663927.
  43. Vicenti I, Lai A, Giannini A, Boccutto A, Dragoni F, Saladini F, Zazzi M. Performance of Geno2Pheno[coreceptor] to infer coreceptor use in human immunodeficiency virus type 1 (HIV-1) subtype A. *J Clin Virol*. 2019 Feb;111:12-18. doi: 10.1016/j.jcv.2018.12.007. Epub 2018 Dec 19. PMID: 30594700.
  44. Mori M, Dasso Lang MC, Saladini F, Palombi N, Kovalenko L, De Forni D, Poddesu B, Friggeri L, Giannini A, Malancona S, Summa V, Zazzi M, Mely Y, Botta M. Synthesis and Evaluation of Bifunctional Aminothiazoles as Antiretrovirals Targeting the HIV-1 Nucleocapsid Protein. *ACS Med Chem Lett*. 2018 Dec 7;10(4):463-468. doi: 10.1021/acsmchemlett.8b00506. PMID: 30996780; PMCID: PMC6466545.
  45. Modica S, Rossetti B, Lombardi F, Lagi F, Maffeo M, D'Autilia R, Pecorari M, Vicenti I, Bruzzone B, Magnani G, Paolucci S, Francisci D, Penco G, Sacchini D, Zazzi M, De Luca A, Di Biagio A. Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort. *HIV Med*. 2019 Feb;20(2):137-146. doi: 10.1111/hiv.12692. Epub 2018 Nov 21. PMID: 30461149.
  46. Vicenti I, Rossetti B, Mariano S, Saladini F, Montagnani F, Zazzi M, De Luca A. Distribution of different HBV DNA forms in plasma and peripheral blood mononuclear cells (PBMCs) of chronically infected patients with low or undetectable HBV plasma viremia. *New Microbiol*. 2018 Oct;41(4):302-305. Epub 2018 Sep 25. PMID: 30252927.
  47. Spertilli Raffaelli C, Rossetti B, Paglicci L, Colafigli M, Punzi G, Borghi V, Pecorari M, Santoro MM, Penco G, Antinori A, Zazzi M, De Luca A, Zanelli G. Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor. *J Antimicrob Chemother*. 2018 Sep 1;73(9):2480-2484. doi: 10.1093/jac/dky211. PMID: 29945251.
  48. Rossetti B, Di Giambenedetto S, Torti C, Postorino MC, Punzi G, Saladini F, Gennari W, Borghi V, Monno L, Pignataro AR, Polilli E, Colafigli M, Poggi A, Tini S, Zazzi M, De Luca A; Antiviral Response Cohort Analysis (ARCA) Collaborative Group. Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016. *HIV Med*. 2018 Oct;19(9):619-628. doi: 10.1111/hiv.12640. Epub 2018 Jun 22. PMID: 29932313.
  49. Rusconi S, Adorni F, Tau P, Borghi V, Pecorari M, Maserati R, Francisci D, Monno L, Punzi G, Meraviglia P, Paolucci S, Di Biagio A, Bruzzone B, Mancon A, Micheli V, Zazzi M; ARCA (Antiviral Response Cohort Analysis). Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA). *J Clin Virol*. 2018 Aug;105:112-117. doi: 10.1016/j.jcv.2018.06.012. Epub 2018 Jun 21. PMID: 29957545.
  50. Zazzi M, Hu H, Prosperi M. The global burden of HIV-1 drug resistance in the past 20 years. *PeerJ*. 2018 May 25;6:e4848. doi: 10.7717/peerj.4848. PMID: 29844989; PMCID: PMC5971836.
  51. Gagliardini R, Ciccullo A, Borghetti A, Maggiolo F, Bartolozzi D, Borghi V, Pecorari M, Di Biagio A, Callegaro AP, Bruzzone B, Saladini F, Paolucci S, Maserati R, Zazzi M, Di Giambenedetto S, De Luca A; ARCA Study Group. Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study. *Open Forum Infect Dis*. 2018 May 15;5(6):ofy113. doi: 10.1093/ofid/ofy113. PMID: 29977967; PMCID: PMC6016422.
  52. Ripamonti D, Zazzi M. Rethinking recycling nucleoside reverse transcriptase inhibitors in HIV treatment: learning from dual therapy studies. *AIDS*. 2018 Apr 24;32(7):835-840. doi: 10.1097/QAD.0000000000001776. PMID: 29424781.
  53. Vicenti I, Meini G, Saladini F, Giannini A, Boccutto A, Schiaroli E, Zazzi M. Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood. *Clin Chem Lab Med*. 2018 Feb 23;56(3):e75-e77. doi: 10.1515/cclm-2017-0587. PMID: 28915108.



54. Bekele Y, Graham RL, Soeria-Atmadja S, Nasi A, Zazzi M, Vicenti I, Naver L, Nilsson A, Chiodi F. Hepatitis B Virus Vaccination in HIV-1-Infected Young Adults: A Tool to Reduce the Size of HIV-1 Reservoirs? *Front Immunol.* 2018 Jan 10;8:1966. doi: 10.3389/fimmu.2017.01966. PMID: 29375579; PMCID: PMC5767726.
55. Mori M, Kovalenko L, Malancona S, Saladini F, De Forni D, Pires M, Humbert N, Real E, Botzanowski T, Cianférani S, Giannini A, Dasso Lang MC, Cugia G, Poddesu B, Lori F, Zazzi M, Harper S, Summa V, Mely Y, Botta M. Structure-Based Identification of HIV-1 Nucleocapsid Protein Inhibitors Active against Wild-Type and Drug-Resistant HIV-1 Strains. *ACS Chem Biol.* 2018 Jan 19;13(1):253-266. doi: 10.1021/acscchembio.7b00907. Epub 2017 Dec 28. PMID: 29235845.
56. Rossetti B, Gagliardini R, Meini G, Sterrantino G, Colangeli V, Re MC, Latini A, Colafigli M, Vignale F, Rusconi S, Micheli V, Di Biagio A, Orofino G, Ghisetti V, Fantauzzi A, Vullo V, Grima P, Francisci D, Mastroianni C, Antinori A, Trezzi M, Lisi L, Navarra P, Canovari B, D'Arminio Monforte A, Lamonica S, D'Avino A, Zazzi M, Di Giambenedetto S, De Luca A; for GUSTA trial study group. Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. *PLoS One.* 2017 Nov 21;12(11):e0187393. doi: 10.1371/journal.pone.0187393. PMID: 29161288; PMCID: PMC5697828.
57. Vicenti I, Boccutto A, Giannini A, Dragoni F, Saladini F, Zazzi M. Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro. *Virus Res.* 2018 Jan 15;244:64-70. doi: 10.1016/j.virusres.2017.11.003. Epub 2017 Nov 4. PMID: 29113824.
58. Saladini F, Giannini A, Boccutto A, Tiezzi D, Vicenti I, Zazzi M. The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro. *AIDS.* 2017 Oct 23;31(16):2307-2309. doi: 10.1097/QAD.0000000000001616. PMID: 28832412.
59. Di Maio VC, Cento V, Aragri M, Paolucci S, Pollicino T, Coppola N, Bruzzone B, Ghisetti V, Zazzi M, Brunetto M, Bertoli A, Barbaliscia S, Galli S, Gennari W, Baldanti F, Raimondo G, Perno CF, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network (VIRONET-C). Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? *J Hepatol.* 2018 Mar;68(3):597-600. doi: 10.1016/j.jhep.2017.09.008. Epub 2017 Sep 20. PMID: 28939133.
60. Caudai C, Materazzi A, Saladini F, Di Giambenedetto S, Torti C, Ricciardi B, Rossetti B, Almi P, De Luca A, Zazzi M. Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy. *Clin Microbiol Infect.* 2018 Mar;24(3):308.e5-308.e8. doi: 10.1016/j.cmi.2017.08.003. Epub 2017 Aug 12. PMID: 28811242.
61. Parbhoo S, Bogojeska J, Zazzi M, Roth V, Doshi-Velez F. Combining Kernel and Model Based Learning for HIV Therapy Selection. *AMIA Jt Summits Transl Sci Proc.* 2017 Jul 26;2017:239-248. PMID: 28815137; PMCID: PMC5543338.
62. Svärd J, Mugusi S, Mloka D, Neogi U, Meini G, Mugusi F, Incardona F, Zazzi M, Sönnernborg A. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy. *PLoS One.* 2017 Jun 5;12(6):e0178942. doi: 10.1371/journal.pone.0178942. PMID: 28582463; PMCID: PMC5459473.
63. Pironti A, Pfeifer N, Walter H, Jensen BO, Zazzi M, Gomes P, Kaiser R, Lengauer T. Using drug exposure for predicting drug resistance - A data-driven genotypic interpretation tool. *PLoS One.* 2017 Apr 10;12(4):e0174992. doi: 10.1371/journal.pone.0174992. PMID: 28394945; PMCID: PMC5386274.
64. Rossetti B, Meini G, Bianco C, Lamonica S, Mondini A, Belmonti S, Fanti I, Ciccarelli N, Di Giambenedetto S, Zazzi M, De Luca A. Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA. *J Clin Virol.* 2017 Jun;91:18-24. doi: 10.1016/j.jcv.2017.03.018. Epub 2017 Mar 23. PMID: 28395180.
65. Saladini F, Giannini A, Boccutto A, Vicenti I, Zazzi M. Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors. *J Clin Lab Anal.* 2018 Jan;32(1):e22206. doi: 10.1002/jcla.22206. Epub 2017 Mar 17. PMID: 28303602; PMCID: PMC6816933.
66. Rossotti R, Borghi V, Callegaro AP, Micheli V, Bruzzone B, Colao G, Gismondo MR, Vicenti I, Penco G, Zazzi M, Rusconi S. Impact of circulating resistance-associated mutations on HIV pre-exposure prophylaxis (PrEP) efficacy: Modeling from antiretroviral resistance cohort analysis (ARCA) national database. *J Clin Virol.* 2016 Oct;83:48-53. doi: 10.1016/j.jcv.2016.08.293. Epub 2016 Aug 23. PMID: 27591555.
67. Magiorkinis G, Angelis K, Mamais I, Katzourakis A, Hatzakis A, Albert J, Lawyer G, Hamouda O, Struck D, Vercauteren J, Wensing A, Alexiev I, Åsjö B, Balotta C, Gomes P, Camacho RJ, Coughlan S, Griskevicius A, Grossman Z, Horban A, Kostrikis LG, Lepej SJ, Liitsola K, Linka M, Nielsen C, Otelea D, Paredes R, Poljak M, Puchhammer-Stöckl E, Schmit JC, Sönnernborg A, Staneková D, Stanojevic M, Stylianou DC, Boucher CAB;

- SPREAD program, Nikolopoulos G, Vasylyeva T, Friedman SR, van de Vijver D, Angarano G, Chaix ML, de Luca A, Korn K, Loveday C, Soriano V, Yerly S, Zazzi M, Vandamme AM, Paraskevis D. The global spread of HIV-1 subtype B epidemic. *Infect Genet Evol.* 2016 Dec;46:169-179. doi: 10.1016/j.meegid.2016.05.041. Epub 2016 Jun 2. PMID: 27262355; PMCID: PMC5157885.
68. Amu S, Lantto Graham R, Bekele Y, Nasi A, Bengtsson C, Rethi B, Sorial S, Meini G, Zazzi M, Hejdeman B, Chiodi F. Dysfunctional phenotypes of CD4+ and CD8+ T cells are comparable in patients initiating ART during early or chronic HIV-1 infection. *Medicine (Baltimore).* 2016 Jun;95(23):e3738. doi: 10.1097/MD.0000000000003738. Erratum in: *Medicine (Baltimore).* 2016 Jul 18;95(28):e0916. PMID: 27281071; PMCID: PMC4907649.
  69. Brai A, Fazi R, Tintori C, Zamperini C, Bugli F, Sanguinetti M, Stigliano E, Esté J, Badia R, Franco S, Martinez MA, Martinez JP, Meyerhans A, Saladini F, Zazzi M, Garbelli A, Maga G, Botta M. Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents. *Proc Natl Acad Sci U S A.* 2016 May 10;113(19):5388-93. doi: 10.1073/pnas.1522987113. Epub 2016 Apr 26. PMID: 27118832; PMCID: PMC4868442.
  70. Williams EA, Lewis DJ, Bertholet S, Zazzi M. Anticipating policy considerations for a future HIV vaccine: a preliminary study. *Vaccine.* 2016 Jul 12;34(32):3697-701. doi: 10.1016/j.vaccine.2016.03.086. Epub 2016 Apr 4. PMID: 27055022.
  71. Meini G, Dello Russo C, Alice T, Barresi R, D'Arrigo R, Falasca F, Lipsi MR, Paolucci S, Zanussi S, Antonetti R, Baldanti F, Basaglia G, Bruzzone B, Polilli E, Ghisetti V, Pucillo LP, Turriziani O, Pirazzoli A, Navarra P, Zazzi M. First external quality assurance program of the Italian HLA-B\*57:01 Network assessing the performance of clinical virology laboratories in HLA-B\*57:01 testing. *J Clin Virol.* 2016 May;78:1-3. doi: 10.1016/j.jcv.2016.02.020. Epub 2016 Feb 23. PMID: 26946153.
  72. De Luca A, Flandre P, Dunn D, Zazzi M, Wensing A, Santoro MM, Günthard HF, Wittkop L, Kordossis T, Garcia F, Castagna A, Cozzi-Lepri A, Churchill D, De Wit S, Brockmeyer NH, Imaz A, Mussini C, Obel N, Perno CF, Roca B, Reiss P, Schülter E, Torti C, van Sighem A, Zangerle R, Descamps D; CHAIN and COHERE in EuroCoord. Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. *J Antimicrob Chemother.* 2016 May;71(5):1352-60. doi: 10.1093/jac/dkv465. Epub 2016 Jan 28. PMID: 26825119; PMCID: PMC5808835.
  73. Vicenti I, Falasca F, Sticchi L, Bruzzone B, Turriziani O, Zazzi M. Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients. *J Clin Virol.* 2016 Mar;76:20-3. doi: 10.1016/j.jcv.2016.01.006. Epub 2016 Jan 12. PMID: 26802683.
  74. Lai A, Bozzi G, Franzetti M, Binda F, Simonetti FR, De Luca A, Micheli V, Meraviglia P, Bagnarelli P, Di Biagio A, Monno L, Saladini F, Zazzi M, Zehender G, Ciccozzi M, Balotta C. HIV-1 A1 Subtype Epidemic in Italy Originated from Africa and Eastern Europe and Shows a High Frequency of Transmission Chains Involving Intravenous Drug Users. *PLoS One.* 2016 Jan 11;11(1):e0146097. doi: 10.1371/journal.pone.0146097. PMID: 26752062; PMCID: PMC4709132.
  75. Zazzi M, Cozzi-Lepri A, Prosperi MC. Computer-Aided Optimization of Combined Anti-Retroviral Therapy for HIV: New Drugs, New Drug Targets and Drug Resistance. *Curr HIV Res.* 2016;14(2):101-9. doi: 10.2174/1570162x13666151029102254. PMID: 26511342.
  76. Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, Van de Vijver DAMC, Åsjö B, Beshkov D, Coughlan S, Descamps D, Griskevicius A, Hamouda O, Horban A, Van Kasteren M, Kolupajeva T, Kostrikis LG, Liitsola K, Linka M, Mor O, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnnerborg A, Staneková D, Stanojevic M, Van Laethem K, Zazzi M, Zidovec Lepej S, Boucher CAB, Schmit JC, Wensing AMJ; SPREAD Program. Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe. *Clin Infect Dis.* 2016 Mar 1;62(5):655-663. doi: 10.1093/cid/civ963. Epub 2015 Nov 29. PMID: 26620652; PMCID: PMC4741360.
  77. Neogi U, Häggblom A, Singh K, Rogers LC, Rao SD, Amogne W, Schülter E, Zazzi M, Arnold E, Sarafianos SG, Sönnnerborg A. Factors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- and middle-income countries. *J Antimicrob Chemother.* 2016 Feb;71(2):367-71. doi: 10.1093/jac/dkv359. Epub 2015 Oct 30. PMID: 26518047; PMCID: PMC4710214.
  78. Rosi A, Meini G, Materazzi A, Vicenti I, Saladini F, Zazzi M. Low-cost simultaneous detection of CCR5-delta32 and HLA-B\*5701 alleles in human immunodeficiency virus type 1 infected patients by selective multiplex endpoint PCR. *J Virol Methods.* 2015 Nov;224:102-4. doi: 10.1016/j.jviromet.2015.08.020. Epub 2015 Sep 2. PMID: 26341061.
  79. Bruzzone B, Saladini F, Sticchi L, Mayinda Mboundou FA, Barresi R, Caligiuri P, Calzi A, Zazzi M, Icardi G, Viscoli C, Bisio F. Prevalence of HIV-1 Subtypes and Drug Resistance-Associated Mutations in HIV-1-Positive

- Treatment-Naive Pregnant Women in Pointe Noire, Republic of the Congo (Kento-Mwana Project). *AIDS Res Hum Retroviruses*. 2015 Aug;31(8):837-40. doi: 10.1089/AID.2015.0105. Epub 2015 Jun 2. PMID: 25970260.
80. De Luca A, Di Giambenedetto S, Lo Presti A, Sierra S, Prosperi M, Cella E, Giovanetti M, Torti C, Caudai C, Vicenti I, Saladini F, Almi P, Grima P, Blanc P, Fabbiani M, Rossetti B, Gagliardini R, Kaiser R, Ciccozzi M, Zazzi M. Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors. *Open Forum Infect Dis*. 2015 Mar 31;2(2):ofv043. doi: 10.1093/ofid/ofv043. PMID: 26213689; PMCID: PMC4511743.
  81. De Luca A, Zazzi M. Interplay Between Transmitted and Acquired HIV Type 1 Drug Resistance: Reasons for a Disconnect. *J Infect Dis*. 2015 Jul 1;212(1):5-7. doi: 10.1093/infdis/jiv008. Epub 2015 Jan 9. PMID: 25576598; PMCID: PMC4462716.
  82. Swartz JE, Vandekerckhove L, Ammerlaan H, de Vries AC, Begovac J, Bierman WF, Boucher CA, van der Ende ME, Grossman Z, Kaiser R, Levy I, Mudrikova T, Paredes R, Perez-Bercoff D, Pronk M, Richter C, Schmit JC, Vercauteren J, Zazzi M, Židovec Lepej S, De Luca A, Wensing AM; European Society for translational Antiviral Research (ESAR). Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naïve patients in Europe. *J Antimicrob Chemother*. 2015;70(6):1850-7. doi: 10.1093/jac/dkv033. Epub 2015 Mar 3. PMID: 25740950.
  83. Meini G, Balestrieri M, Cianchino S, Tacconi D, Rossi de Gasperis M, Concato C, Vicenti I, Rosi A, Saladini F, Callea F, Zazzi M. Frequent detection of antiretroviral drug resistance in HIV-1-infected orphaned children followed at a donor-funded rural pediatric clinic in Dodoma, Tanzania. *AIDS Res Hum Retroviruses*. 2015 Apr;31(4):448-51. doi: 10.1089/AID.2014.0251. Epub 2014 Dec 31. PMID: 25492218.
  84. Bianco C, Meini G, Rossetti B, Lamonica S, Mondì A, Belmonti S, Fanti L, Ciccarelli N, Di Giambenedetto S, Zazzi M, De Luca A. Switch to raltegravir- based regimens and HIV DNA decrease in patients with suppressed HIV RNA. *J Int AIDS Soc*. 2014 Nov 2;17(4 Suppl 3):19791. doi: 10.7448/IAS.17.4.19791. PMID: 25397535; PMCID: PMC4225325.
  85. Schülter E, Kaiser R, Zazzi M, Sönnnerborg A, Camacho R, Verheyen J. Time on drug analysis based on real life data. *J Int AIDS Soc*. 2014 Nov 2;17(4 Suppl 3):19790. doi: 10.7448/IAS.17.4.19790. PMID: 25397534; PMCID: PMC4225363.
  86. Franzetti M, Violin M, Antinori A, De Luca A, Ceccherini-Silberstein F, Gianotti N, Torti C, Bonora S, Zazzi M, Balotta C. Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy. *BMC Infect Dis*. 2014 Jul 18;14:398. doi: 10.1186/1471-2334-14-398. PMID: 25037229; PMCID: PMC4223427.
  87. Di Biagio A, Rusconi S, Marzocchetti A, Signori A, Schiavetti I, Bruzzone B, Monno L, Punzi G, Colao MG, Penco G, Zazzi M, De Luca A; ARCA Collaborative Group. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy. *J Med Virol*. 2014 Oct;86(10):1648-55. doi: 10.1002/jmv.24017. Epub 2014 Jul 11. PMID: 25042976.
  88. Rossotti R, Fonte L, Meini G, Maggiolo F, Zazzi M, Rusconi S; ARCA Collaborative Group. Rilpivirine resistance and the dangerous liaisons with substitutions at position 184 among patients infected with HIV-1: analysis from a national drug-resistance database (ARCA). *J Med Virol*. 2014 Sep;86(9):1459-66. doi: 10.1002/jmv.23978. Epub 2014 May 17. PMID: 24838991.
  89. Bruzzone B, Bisio F, Caligiuri P, Mboungou FA, Nigro N, Sticchi L, Ventura A, Saladini F, Zazzi M, Icardi G, Viscoli C. Discordances with HIV-1 RNA quantitative determinations by three commercial assays in Pointe Noire, Republic of Congo. *J Virol Methods*. 2014 Jul;203:102-6. doi: 10.1016/j.jviromet.2014.02.030. Epub 2014 Mar 30. PMID: 24694776.
  90. Simonetti FR, Lai A, Monno L, Binda F, Brindicci G, Punzi G, Bozzi G, Violin M, Galli M, Zazzi M, Angarano G, Balotta C. Identification of a new HIV-1 BC circulating recombinant form (CRF60\_BC) in Italian young men having sex with men. *Infect Genet Evol*. 2014 Apr;23:176-81. doi: 10.1016/j.meegid.2014.02.007. Epub 2014 Mar 3. PMID: 24602697.
  91. Lai A, Bozzi G, Franzetti M, Binda F, Simonetti FR, Micheli V, Meraviglia P, Corsi P, Bagnarelli P, De Luca A, Ciccozzi M, Zehender G, Zazzi M, Balotta C. Phylogenetic analysis provides evidence of interactions between Italian heterosexual and South American homosexual males as the main source of national HIV-1 subtype C epidemics. *J Med Virol*. 2014 May;86(5):729-36. doi: 10.1002/jmv.23891. Epub 2014 Jan 31. PMID: 24482324.
  92. Bartha I, Assel M, Sloot PM, Zazzi M, Torti C, Schülter E, De Luca A, Sönnnerborg A, Abecasis AB, Van Laethem K, Rosi A, Svärd J, Paredes R, van de Vijver DA, Vandamme AM, Müller V. Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort. *BMC Infect Dis*. 2013 Nov 12;13:537. doi: 10.1186/1471-2334-13-537. PMID: 24219163; PMCID: PMC3879221.

93. Meini G, Materazzi A, Saladini F, Rosi A, Vicenti I, Mancini M, Pirazzoli A, Caudai C, Zazzi M. Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism. *BMC Infect Dis.* 2013 Oct 30;13:508. doi: 10.1186/1471-2334-13-508. PMID: 24172636; PMCID: PMC3819463.
94. Meini G, Rossetti B, Bianco C, Ceccherini-Silberstein F, Di Giambenedetto S, Sighinolfi L, Monno L, Castagna A, Rozera G, D'Arminio Monforte A, Zazzi M, De Luca A; ICONA Foundation Group. Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy. *J Antimicrob Chemother.* 2014 Mar;69(3):735-41. doi: 10.1093/jac/dkt426. Epub 2013 Oct 23. PMID: 24155059; PMCID: PMC3954119.
95. Svicher V, Alteri C, Montano M, Nori A, D'Arrigo R, Andreoni M, Angarano G, Antinori A, Antonelli G, Alice T, Bagnarelli P, Baldanti F, Bertoli A, Borderi M, Boeri E, Bon I, Bruzzone B, Barresi R, Calderisi S, Callegaro AP, Capobianchi MR, Gargiulo F, Castelli F, Cauda R, Ceccherini-Silberstein F, Clementi M, Chirianni A, Colafigli M, D'Arminio Monforte A, De Luca A, Di Biagio A, Di Nicuolo G, Di Perri G, Di Santo F, Fadda G, Galli M, Gennari W, Ghisetti V, Costantini A, Gori A, Gulminetti R, Leoncini F, Maffongelli G, Maggiolo F, Maserati R, Mazzotta F, Meini G, Micheli V, Monno L, Mussini C, Nozza S, Paolucci S, Palù G, Parisi S, Parruti G, Pignataro AR, Quirino T, Re MC, Rizzardini G, Sanguinetti M, Santangelo R, Scaggiante R, Sterrantino G, Turriziani O, Vatteroni ML, Viscoli C, Vullo V, Zazzi M, Lazzarin A, Perno CF. Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group. *Infection.* 2014 Feb;42(1):61-71. doi: 10.1007/s15010-013-0510-3. Epub 2013 Oct 22. PMID: 24146352; PMCID: PMC3906530.
96. Rossetti B, Bianco C, Bellazzi LI, Bruzzone B, Colao G, Corsi P, Monno L, Pagano G, Paolucci S, Punzi G, Setti M, Zazzi M, De Luca A. Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice: role of different tropism testing results and of concomitant treatments. *AIDS Res Hum Retroviruses.* 2014 Jan;30(1):17-24. doi: 10.1089/AID.2012.0235. Epub 2013 Sep 17. PMID: 23971941; PMCID: PMC3887413.
97. Santoro MM, Sabin C, Forbici F, Bansi L, Dunn D, Fearnhill E, Boumis E, Nicastrì E, Antinori A, Palamara G, Callegaro A, Francisci D, Zoncada A, Maggiolo F, Zazzi M, Perno CF, Ceccherini-Silberstein F, Mussini C. Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. *HIV Med.* 2013 Oct;14(9):571-7. doi: 10.1111/hiv.12044. Epub 2013 May 13. PMID: 23668660.
98. Libin P, Beheydt G, Deforche K, Imbrechts S, Ferreira F, Van Laethem K, Theys K, Carvalho AP, Cavaco-Silva J, Lapadula G, Torti C, Assel M, Wesner S, Snoeck J, Ruelle J, De Bel A, Lacor P, De Munter P, Van Wijngaerden E, Zazzi M, Kaiser R, Ayoub A, Peeters M, de Oliveira T, Alcantara LC, Grossman Z, Sloot P, Otelea D, Paraschiv S, Boucher C, Camacho RJ, Vandamme AM. RegaDB: community-driven data management and analysis for infectious diseases. *Bioinformatics.* 2013 Jun 1;29(11):1477-80. doi: 10.1093/bioinformatics/btt162. Epub 2013 May 2. PMID: 23645815; PMCID: PMC3661054.
99. Sangeda RZ, Theys K, Beheydt G, Rhee SY, Deforche K, Vercauteren J, Libin P, Imbrechts S, Grossman Z, Camacho RJ, Van Laethem K, Pironti A, Zazzi M, Sönnnerborg A, Incardona F, De Luca A, Torti C, Ruiz L, Van de Vijver DA, Shafer RW, Bruzzone B, Van Wijngaerden E, Vandamme AM; Virolab and EuResist Projects. HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure. *Infect Genet Evol.* 2013 Oct;19:349-60. doi: 10.1016/j.meegid.2013.03.014. Epub 2013 Mar 21. PMID: 23523594.
100. De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, Fanti I, Kaiser R, Sönnnerborg A, Codoñer FM, Van Laethem K, Vandamme AM, Bansi L, Ghisetti V, van de Vijver DA, Asboe D, Prospero MC, Di Giambenedetto S; SEHERE collaboration in Chain. Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. *J Infect Dis.* 2013 Apr 15;207(8):1216-20. doi: 10.1093/infdis/jit017. Epub 2013 Jan 11. PMID: 23315324.
101. Rusconi S, Vitiello P, Adorni F, Bruzzone B, De Luca A, Micheli V, Meraviglia P, Maserati R, Di Pietro M, Colao G, Penco G, Di Biagio A, Punzi G, Monno L, Zazzi M; Antiretroviral Resistance Cohort Analysis Collaborative Group. Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database. *Clin Microbiol Infect.* 2013 Oct;19(10):936-42. doi: 10.1111/1469-0691.12100. Epub 2013 Jan 4. PMID: 23289841.
102. Vercauteren J, Beheydt G, Prospero M, Libin P, Imbrechts S, Camacho R, Clotet B, De Luca A, Grossman Z, Kaiser R, Sönnnerborg A, Torti C, Van Wijngaerden E, Schmit JC, Zazzi M, Geretti AM, Vandamme AM, Van Laethem K. Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response. *PLoS One.* 2013 Apr 17;8(4):e61436. doi: 10.1371/journal.pone.0061436. PMID: 23613852; PMCID: PMC3629176.

103. Zazzi M. Dried blood spot testing: filling the gap between antiretroviral treatment & monitoring in India. *Indian J Med Res.* 2012 Dec;136(6):903-5. PMID: 23391786; PMCID: PMC3612320.
104. Theys K, Vercauteren J, Snoeck J, Zazzi M, Camacho RJ, Torti C, Schülter E, Clotet B, Sönnnerborg A, De Luca A, Grossman Z, Struck D, Vandamme AM, Abecasis AB. HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. *Antimicrob Agents Chemother.* 2013 Feb;57(2):1053-6. doi: 10.1128/AAC.01668-12. Epub 2012 Nov 26. PMID: 23183438; PMCID: PMC3553726.
105. Saladini F, Meini G, Bianco C, Monno L, Punzi G, Pecorari M, Borghi V, Di Pietro M, Filice G, Gismondo MR, Micheli V, Penco G, Carli T, De Luca A, Zazzi M; ARCA Collaborative Group. Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients. *Clin Microbiol Infect.* 2012 Oct;18(10):E428-30. doi: 10.1111/j.1469-0691.2012.03917.x. Epub 2012 Jun 21. PMID: 22716970.
106. Rhee SY, Blanco JL, Liu TF, Pere I, Kaiser R, Zazzi M, Incardona F, Towner W, Gatell JM, De Luca A, Fessel WJ, Shafer RW. Standardized representation, visualization and searchable repository of antiretroviral treatment-change episodes. *AIDS Res Ther.* 2012 May 3;9(1):13. doi: 10.1186/1742-6405-9-13. PMID: 22554313; PMCID: PMC3439255.
107. Sterrantino G, Zaccarelli M, Trotta M, De Luca A, Borghi V, Meraviglia P, Corsi P, Bonora S, Leoncini F, Zazzi M; ARCA Database Study Group. Interpretation of genotypic resistance to predict darunavir/ritonavir failure in antiretroviral experienced patients. *J Acquir Immune Defic Syndr.* 2012 Feb 1;59(2):170-2. doi: 10.1097/QAI.0b013e31823e6518. PMID: 22067663.
108. Vicenti I, Rosi A, Saladini F, Meini G, Pippi F, Rossetti B, Sidella L, Di Giambenedetto S, Almi P, De Luca A, Caudai C, Zazzi M. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy. *J Antimicrob Chemother.* 2012 Apr;67(4):984-7. doi: 10.1093/jac/dkr581. Epub 2012 Jan 18. PMID: 22258932.
109. Sterrantino G, Zaccarelli M, Colao G, Baldanti F, Di Giambenedetto S, Carli T, Maggiolo F, Zazzi M; ARCA Database Study Group. Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis. *Infection.* 2012 Jun;40(3):311-8. doi: 10.1007/s15010-011-0237-y. Epub 2012 Jan 12. PMID: 22237471.
110. Torti C, Zazzi M, Abenavoli L, Trapasso F, Cesario F, Corigliano D, Cosco L, Costa C, Curia RL, De Rosa M, Foti G, Giraldi C, Leone R, Liberto MC, Lucchino D, Marascio N, Masciari R, Matera G, Pisani V, Serrao N, Surace L, Zicca E, Castelli F, Ciccozzi M, Puoti M, Focà A; SINERGIE Study Group. Future research and collaboration: the "SINERGIE" project on HCV (South Italian Network for Rational Guidelines and International Epidemiology). *BMC Infect Dis.* 2012;12 Suppl 2(Suppl 2):S9. doi: 10.1186/1471-2334-12-S2-S9. Epub 2012 Nov 12. PMID: 23173812; PMCID: PMC3495626.
111. Lai A, Simonetti FR, Zehender G, De Luca A, Micheli V, Meraviglia P, Corsi P, Bagnarelli P, Almi P, Zoncada A, Paolucci S, Gonnelli A, Colao G, Tacconi D, Franzetti M, Ciccozzi M, Zazzi M, Balotta C. HIV-1 subtype F1 epidemiological networks among Italian heterosexual males are associated with introduction events from South America. *PLoS One.* 2012;7(8):e42223. doi: 10.1371/journal.pone.0042223. Epub 2012 Aug 2. PMID: 22876310; PMCID: PMC3410915.
112. Svicher V, Alteri C, Montano M, D'Arrigo R, Andreoni M, Angarano G, Antinori A, Antonelli G, Alice T, Bagnarelli P, Baldanti F, Bertoli A, Borderi M, Boeri E, Bon I, Bruzzone B, Callegaro AP, Capobianchi MR, Carosi G, Cauda R, Ceccherini-Silberstein F, Clementi M, Chirrianni A, Colafigli M, D'Arminio Monforte A, De Luca A, Di Biagio A, Di Nicuolo G, Di Perri G, Di Pietro M, Di Santo F, Fabeni L, Fadda G, Galli M, Gennari W, Ghesetti V, Giacometti A, Gori C, Gori A, Gulminetti R, Leoncini F, Maffongelli G, Maggiolo F, Manca G, Gargiulo F, Martinelli C, Maserati R, Mazzotta F, Meini G, Micheli V, Monno L, Mussini C, Narciso P, Nozza S, Paolucci S, Pal G, Parisi S, Parruti G, Pignataro AR, Pollicita M, Quirino T, Re MC, Rizzardini G, Santangelo R, Scaggiante R, Sterrantino G, Turriziani O, Vatteroni ML, Vecchi L, Viscoli C, Vullo V, Zazzi M, Lazzarini A, Perno CF; DIVA group. Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. *New Microbiol.* 2012 Jan;35(1):17-25. Epub 2012 Jan 10. PMID: 22378549.
113. Oette M, Schülter E, Rosen-Zvi M, Peres Y, Zazzi M, Sönnnerborg A, Struck D, Altmann A, Kaiser R; EuResist Network Study Group. Efficacy of antiretroviral therapy switch in HIV-infected patients: a 10-year analysis of the EuResist Cohort. *Intervirology.* 2012;55(2):160-6. doi: 10.1159/000332018. Epub 2012 Jan 24. PMID: 22286887.
114. Zazzi M, Incardona F, Rosen-Zvi M, Prosperi M, Lengauer T, Altmann A, Sonnerborg A, Lavee T, Schülter E, Kaiser R. Predicting response to antiretroviral treatment by machine learning: the EuResist project. *Intervirology.* 2012;55(2):123-7. doi: 10.1159/000332008. Epub 2012 Jan 24. PMID: 22286881.

115. Franzetti M, Violin M, Casazza G, Meini G, Callegaro A, Corsi P, Maggiolo F, Pignataro AR, Paolucci S, Gianotti N, Francisci D, Rossotti R, Filice G, Carli T, Zazzi M, Balotta C. Human immunodeficiency virus-1 B and non-B subtypes with the same drug resistance pattern respond similarly to antiretroviral therapy. *Clin Microbiol Infect.* 2012 Mar;18(3):E66-70. doi: 10.1111/j.1469-0691.2011.03740.x. Epub 2011 Dec 22. PMID: 22192680.
116. Lawyer G, Altmann A, Thielen A, Zazzi M, Sönnnerborg A, Lengauer T. HIV-1 mutational pathways under multidrug therapy. *AIDS Res Ther.* 2011 Jul 27;8:26. doi: 10.1186/1742-6405-8-26. PMID: 21794106; PMCID: PMC3162516.
117. Saladini F, Foley BT, Rosi A, Vicenti I, Nannetti G, Meini G, Razzolini F, Zazzi M. Near full-length sequence analysis of HIV type 1 BF recombinants from Italy. *AIDS Res Hum Retroviruses.* 2012 Mar;28(3):299-303. doi: 10.1089/aid.2011.0002. Epub 2011 Jul 8. PMID: 21740272; PMCID: PMC3292755.
118. Prosperi MC, Di Giambenedetto S, Fanti I, Meini G, Bruzzone B, Callegaro A, Penco G, Bagnarelli P, Micheli V, Paolini E, Di Biagio A, Ghisetti V, Di Pietro M, Zazzi M, De Luca A; ARCA cohort. A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen. *BMC Med Inform Decis Mak.* 2011 Jun 14;11:40. doi: 10.1186/1472-6947-11-40. PMID: 21672248; PMCID: PMC3144446.
119. Di Giambenedetto S, Prosperi M, Fanti I, Bruzzone B, Paolucci S, Penco G, Meini G, Di Biagio A, Paolini E, Micheli V, Meraviglia P, Castelli P, Corsi P, Gonnelli A, Fabbiani M, Zazzi M, De Luca A; ARCA Collaborative Group. Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009. *Clin Microbiol Infect.* 2011 Sep;17(9):1352-5. doi: 10.1111/j.1469-0691.2011.03563.x. Epub 2011 Jun 2. PMID: 21635664.
120. Prosperi MC, Mackie N, Di Giambenedetto S, Zazzi M, Camacho R, Fanti I, Torti C, Sönnnerborg A, Kaiser R, Codoñer FM, Van Laethem K, Bansi L, van de Vijver DA, Geretti AM, De Luca A; SEHERE consortium. Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. *J Antimicrob Chemother.* 2011 Aug;66(8):1886-96. doi: 10.1093/jac/dkr171. Epub 2011 May 30. PMID: 21624929.
121. Vandekerckhove LP, Wensing AM, Kaiser R, Brun-Vézinet F, Clotet B, De Luca A, Dressler S, Garcia F, Geretti AM, Klimkait T, Korn K, Masquelier B, Perno CF, Schapiro JM, Soriano V, Sönnnerborg A, Vandamme AM, Verhofstede C, Walter H, Zazzi M, Boucher CA; European Consensus Group on clinical management of tropism testing. European guidelines on the clinical management of HIV-1 tropism testing. *Lancet Infect Dis.* 2011 May;11(5):394-407. doi: 10.1016/S1473-3099(10)70319-4. Epub 2011 Mar 21. PMID: 21429803.
122. Gianotti N, Galli L, Zazzi M, Ghisetti V, Bonora S, Micheli V, Meraviglia P, Corsi P, Bruzzone B, Menzo S, Di Giambenedetto S, De Luca A, Filice G, Penco G, Castagna A; ARCA database initiative. No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy. *J Med Virol.* 2011 Mar;83(3):391-8. doi: 10.1002/jmv.21989. PMID: 21264858.
123. Svicher V, Alteri C, Artese A, Zhang JM, Costa G, Mercurio F, D'Arrigo R, Alcaro S, Palù G, Clementi M, Zazzi M, Andreoni M, Antinori A, Lazzarin A, Ceccherini-Silberstein F, Perno CF; OSCAR study group. Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage. *Antivir Ther.* 2011;16(7):1035-45. doi: 10.3851/IMP1862. PMID: 22024519.
124. De Luca A, Di Giambenedetto S, Maserati R, Gianotti N, Narciso P, Antinori A, Di Perri G, Prosperi MC, Baldanti F, Micheli V, Zazzi M, Perno CF, Santoro MM; TMC114-C226 study group; ARCA study group. Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score. *Antivir Ther.* 2011;16(4):489-97. doi: 10.3851/IMP1799. PMID: 21685536.
125. Prosperi MC, Ciccozzi M, Fanti I, Saladini F, Pecorari M, Borghi V, Di Giambenedetto S, Bruzzone B, Capetti A, Vivarelli A, Rusconi S, Re MC, Gismondo MR, Sighinolfi L, Gray RR, Salemi M, Zazzi M, De Luca A; ARCA collaborative group. A novel methodology for large-scale phylogeny partition. *Nat Commun.* 2011;2:321. doi: 10.1038/ncomms1325. Epub 2011 May 24. PMID: 21610724; PMCID: PMC6045912.
126. Francisci D, Martinelli L, Weimer LE, Zazzi M, Florida M, Masini G, Baldelli F. HIV-2 infection, end-stage renal disease and protease inhibitor intolerance: which salvage regimen? *Clin Drug Investig.* 2011;31(5):345-9. doi: 10.1007/BF03256933. PMID: 21344955.
127. van de Vijver DA, Wensing AM, Åsjö B, Bruckova M, Jorgensen LB, Camacho R, Horban A, Linka M, Lazanas M, Loveday C, MacRae E, Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Ruiz L, Schmit JC, Stanczak G, Stanojevic M, Vandamme AM, Vercauteren J, Zazzi M, Bachelier L, Lecocq P, Villacian J, Boucher CA. HIV-1 drug-resistance patterns among patients on failing treatment in a large number of European countries. *Acta Dermatovenerol Alp Pannonica Adriat.* 2010 Dec;19(4):3-9. PMID: 21390473.
128. Prosperi MC, Zazzi M, Punzi G, Monno L, Colao G, Corsi P, Di Giambenedetto S, Meini G, Ghisetti V, Bonora S, Pecorari M, Gismondo MR, Bagnarelli P, Carli T, De Luca A; ARCA Collaborative Group. Low rate of virological

- failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice. *J Med Virol.* 2010 Dec;82(12):1996-2003. doi: 10.1002/jmv.21927. PMID: 20981785.
129. Prosperi MC, Rosen-Zvi M, Altmann A, Zazzi M, Di Giambenedetto S, Kaiser R, Schülter E, Struck D, Sloot P, van de Vijver DA, Vandamme AM, Sönnnerborg A; EuResist study group; Virolab study group. Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models. *PLoS One.* 2010 Oct 29;5(10):e13753. doi: 10.1371/journal.pone.0013753. Erratum in: *PLoS One.* 2011;6(4). doi:10.1371/annotation/d0254103-21b9-4078-836b-57ba5bd1c26a. PMID: 21060792; PMCID: PMC2966424.
  130. Zazzi M, Kaiser R, Sönnnerborg A, Struck D, Altmann A, Prosperi M, Rosen-Zvi M, Petroczi A, Peres Y, Schülter E, Boucher CA, Brun-Vezinet F, Harrigan PR, Morris L, Obermeier M, Perno CF, Phanuphak P, Pillay D, Shafer RW, Vandamme AM, van Laethem K, Wensing AM, Lengauer T, Incardona F. Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study). *HIV Med.* 2011 Apr;12(4):211-8. doi: 10.1111/j.1468-1293.2010.00871.x. Epub 2010 Aug 19. Erratum in: *HIV Med.* 2012 Apr;13(4):253. PMID: 20731728.
  131. Frentz D, Boucher CA, Assel M, De Luca A, Fabbiani M, Incardona F, Libin P, Manca N, Müller V, O Nualláin B, Paredes R, Prosperi M, Quiros-Roldan E, Ruiz L, Sloot PM, Torti C, Vandamme AM, Van Laethem K, Zazzi M, van de Vijver DA. Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. *PLoS One.* 2010 Jul 9;5(7):e11505. doi: 10.1371/journal.pone.0011505. PMID: 20634893; PMCID: PMC2901338.
  132. Prosperi MC, Bracciale L, Fabbiani M, Di Giambenedetto S, Razzolini F, Meini G, Colafigli M, Marzocchetti A, Cauda R, Zazzi M, De Luca A. Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping. *Retrovirology.* 2010 Jun 30;7:56. doi: 10.1186/1742-4690-7-56. PMID: 20591141; PMCID: PMC2907304.
  133. Lai A, Riva C, Marconi A, Balestrieri M, Razzolini F, Meini G, Vicenti I, Rosi A, Saladini F, Caramma I, Franzetti M, Rossini V, Galli A, Galli M, Violin M, Zazzi M, Balotta C. Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades. *HIV Med.* 2010 Oct 1;11(9):593-602. doi: 10.1111/j.1468-1293.2010.00832.x. Epub 2010 Jun 28. PMID: 20408891.
  134. Maserati R, De Silvestri A, Uglietti A, Colao G, Di Biagio A, Bruzzone B, Di Pietro M, Re MC, Tinelli C, Zazzi M; ARCA Collaborative Group. Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine. *AIDS.* 2010 Apr 24;24(7):1013-8. doi: 10.1097/QAD.0b013e328336e962. PMID: 20124969.
  135. Balestrieri M, Marconi A, Meini G, Rosi A, Saladini F, Vicenti I, Razzolini F, Zazzi M. Impact of remote versus local sampling on sensitivity of genotypic antiretroviral resistance testing. *J Clin Microbiol.* 2010 Jun;48(6):2321-2. doi: 10.1128/JCM.02394-09. Epub 2010 Apr 21. PMID: 20410346; PMCID: PMC2884515.
  136. Zazzi M. High genetic barrier antiretroviral drugs in human immunodeficiency virus-positive pregnancy. *Clin Infect Dis.* 2010 Mar 15;50(6):895-7. doi: 10.1086/650748. PMID: 20166822.
  137. Di Vincenzo P, Rusconi S, Adorni F, Vitiello P, Maggiolo F, Francisci D, Di Biagio A, Monno L, Antinori A, Boeri E, Punzi G, Perno CF, Callegaro A, Bruzzone B, Zazzi M; Antiretroviral Resistance Cohort Analysis (ARCA) Collaborative Group. Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA). *HIV Med.* 2010 Sep;11(8):530-4. doi: 10.1111/j.1468-1293.2009.00819.x. Epub 2010 Mar 8. PMID: 20236364.
  138. Bruzzone B, Ventura A, Bisio F, Mboundou FA, Miguel LM, Saladini F, Zazzi M, Icardi G, De Maria A, Viscoli C. Impact of extensive HIV-1 variability on molecular diagnosis in the Congo basin. *J Clin Virol.* 2010 Apr;47(4):372-5. doi: 10.1016/j.jcv.2010.01.014. Epub 2010 Feb 20. PMID: 20172759.
  139. Weisser H, Altmann A, Sierra S, Incardona F, Struck D, Sönnnerborg A, Kaiser R, Zazzi M, Tschochner M, Walter H, Lengauer T. Only slight impact of predicted replicative capacity for therapy response prediction. *PLoS One.* 2010 Feb 3;5(2):e9044. doi: 10.1371/journal.pone.0009044. PMID: 20140263; PMCID: PMC2815793.
  140. Di Giambenedetto S, Torti C, Prosperi M, Manca N, Lapadula G, Parainfo G, Ladisa N, Zazzi M, Trezzi M, Cicconi P, Corsi P, Nasta P, Cauda R, De Luca A; UCSC cohort; MASTER cohort; ARCA cohort. Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study. *Infection.* 2009 Oct;37(5):438-44. doi: 10.1007/s15010-009-8237-x. Epub 2009 Aug 7. PMID: 19669091.
  141. Saladini F, Vicenti I, Razzolini F, Zazzi M. Detection of residual human immunodeficiency virus type 1 reverse transcriptase K103N minority species in plasma RNA and peripheral blood mononuclear cell DNA following discontinuation of non-nucleoside therapy. *Clin Microbiol Infect.* 2010 Jul;16(7):848-51. doi: 10.1111/j.1469-0691.2009.03005.x. Epub 2009 Jul 21. PMID: 19681953.

142. Zazzi M, Prosperi M, Vicenti I, Di Giambenedetto S, Callegaro A, Bruzzone B, Baldanti F, Gonnelli A, Boeri E, Paolini E, Rusconi S, Giacometti A, Maggiolo F, Menzo S, De Luca A; ARCA Collaborative Group. Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting. *J Antimicrob Chemother.* 2009 Sep;64(3):616-24. doi: 10.1093/jac/dkp252. Epub 2009 Jul 19. PMID: 19620134.
143. Bracciale L, Colafigli M, Zazzi M, Corsi P, Meraviglia P, Micheli V, Maserati R, Gianotti N, Penco G, Setti M, Di Giambenedetto S, Butini L, Vivarelli A, Trezzi M, De Luca A. Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors. *J Antimicrob Chemother.* 2009 Sep;64(3):607-15. doi: 10.1093/jac/dkp246. Epub 2009 Jul 16. PMID: 19608581.
144. Wang D, Larder B, Revell A, Montaner J, Harrigan R, De Wolf F, Lange J, Wegner S, Ruiz L, Pérez-Elías MJ, Emery S, Gatell J, D'Arminio Monforte A, Torti C, Zazzi M, Lane C. A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy. *Artif Intell Med.* 2009 Sep;47(1):63-74. doi: 10.1016/j.artmed.2009.05.002. Epub 2009 Jun 12. PMID: 19524413.
145. Paraskevis D, Pybus O, Magiorkinis G, Hatzakis A, Wensing AM, van de Vijver DA, Albert J, Angarano G, Asjö B, Balotta C, Boeri E, Camacho R, Chaix ML, Coughlan S, Costagliola D, De Luca A, de Mendoza C, Derdelinckx I, Grossman Z, Hamouda O, Hoepelman I, Horban A, Korn K, Kücherer C, Leitner T, Loveday C, Macrae E, Maljkovic-Berry I, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Perrin L, Puchhammer-Stöckl E, Ruiz L, Salminen MO, Schmit JC, Schuurman R, Soriano V, Stanczak J, Stanojevic M, Struck D, Van Laethem K, Violin M, Yerly S, Zazzi M, Boucher CA, Vandamme AM; SPREAD Programme. Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. *Retrovirology.* 2009 May 20;6:49. doi: 10.1186/1742-4690-6-49. PMID: 19457244; PMCID: PMC2717046.
146. Altmann A, Däumer M, Beerenwinkel N, Peres Y, Schülter E, Büch J, Rhee SY, Sönnnerborg A, Fessel WJ, Shafer RW, Zazzi M, Kaiser R, Lengauer T. Predicting the response to combination antiretroviral therapy: retrospective validation of geno2pheno-THEO on a large clinical database. *J Infect Dis.* 2009 Apr 1;199(7):999-1006. doi: 10.1086/597305. PMID: 19239365.
147. Prosperi MC, Fanti I, Ulivi G, Micarelli A, De Luca A, Zazzi M. Robust supervised and unsupervised statistical learning for HIV type 1 coreceptor usage analysis. *AIDS Res Hum Retroviruses.* 2009 Mar;25(3):305-14. doi: 10.1089/aid.2008.0039. PMID: 19327050.
148. Prosperi MC, Altmann A, Rosen-Zvi M, Aharoni E, Borgulya G, Bazso F, Sönnnerborg A, Schülter E, Struck D, Ulivi G, Vandamme AM, Vercauteren J, Zazzi M; EuResist and Virolab study groups. Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment. *Antivir Ther.* 2009;14(3):433-42. PMID: 19474477.
149. Di Giambenedetto S, Zazzi M, Corsi P, Gonnelli A, Di Pietro M, Giacometti A, Almi P, Trezzi M, Boeri E, Gianotti N, Menzo S, Del Gobbo R, Francisci D, Nerli A, Galli L, De Luca A; Antiretroviral Resistance Cohort Analysis Study Group. Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy. *Antivir Ther.* 2009;14(3):359-69. PMID: 19474470.
150. Altmann A, Sing T, Vermeiren H, Winters B, Van Craenenbroeck E, Van der Borght K, Rhee SY, Shafer RW, Schülter E, Kaiser R, Peres Y, Sönnnerborg A, Fessel WJ, Incardona F, Zazzi M, Bachelier L, Van Vlijmen H, Lengauer T. Advantages of predicted phenotypes and statistical learning models in inferring virological response to antiretroviral therapy from HIV genotype. *Antivir Ther.* 2009;14(2):273-83. PMID: 19430102.
151. Marconi A, Balestrieri M, Comastri G, Pulvirenti FR, Gennari W, Tagliazucchi S, Pecorari M, Borghi V, Marri D, Zazzi M. Evaluation of the Abbott Real-Time HIV-1 quantitative assay with dried blood spot specimens. *Clin Microbiol Infect.* 2009 Jan;15(1):93-7. doi: 10.1111/j.1469-0691.2008.02116.x. PMID: 19220340.
152. Galli A, Lai A, Corvasce S, Saladini F, Riva C, Dehò L, Caramma I, Franzetti M, Romano L, Galli M, Zazzi M, Balotta C. Recombination analysis and structure prediction show correlation between breakpoint clusters and RNA hairpins in the pol gene of human immunodeficiency virus type 1 unique recombinant forms. *J Gen Virol.* 2008 Dec;89(Pt 12):3119-3125. doi: 10.1099/vir.0.2008/003418-0. PMID: 19008401.
153. Prosperi MC, D'Autilia R, Incardona F, De Luca A, Zazzi M, Ulivi G. Stochastic modelling of genotypic drug-resistance for human immunodeficiency virus towards long-term combination therapy optimization. *Bioinformatics.* 2009 Apr 15;25(8):1040-7. doi: 10.1093/bioinformatics/btn568. Epub 2008 Oct 31. PMID: 18977781.
154. Riva C, Romano L, Saladini F, Lai A, Carr JK, Francisci D, Balotta C, Zazzi M. Identification of a possible ancestor of the subtype A1 HIV Type 1 variant circulating in the former Soviet Union. *AIDS Res Hum Retroviruses.* 2008 Oct;24(10):1319-25. doi: 10.1089/aid.2008.0119. Erratum in: *AIDS Res Hum Retroviruses.* 2008 Nov;24(11):1475. PMID: 18851681.



155. Razzolini F, Saladini F, Malincarne L, Vicenti I, Palladino N, Romano L, Francisci D, Zazzi M. Three-class-resistant human immunodeficiency virus type 1 variant in a drug-naive heterosexual couple. *J Clin Microbiol*. 2008 Nov;46(11):3856-9. doi: 10.1128/JCM.01122-08. Epub 2008 Sep 24. PMID: 18845824; PMCID: PMC2576576.
156. Rosen-Zvi M, Altmann A, Prosperi M, Aharoni E, Neuvirth H, Sönnnerborg A, Schülter E, Struck D, Peres Y, Incardona F, Kaiser R, Zazzi M, Lengauer T. Selecting anti-HIV therapies based on a variety of genomic and clinical factors. *Bioinformatics*. 2008 Jul 1;24(13):i399-406. doi: 10.1093/bioinformatics/btn141. PMID: 18586740; PMCID: PMC2718619.
157. De Socio GV, Martinelli L, Zazzi M, Baldelli F. Acute meningoencephalitis in chronic HIV infection: clinical resolution with lopinavir-ritonavir-containing therapy. *Clin Infect Dis*. 2008 Jun 15;46(12):1938. doi: 10.1086/588554. PMID: 18540815.
158. Altmann A, Rosen-Zvi M, Prosperi M, Aharoni E, Neuvirth H, Schülter E, Büch J, Struck D, Peres Y, Incardona F, Sönnnerborg A, Kaiser R, Zazzi M, Lengauer T. Comparison of classifier fusion methods for predicting response to anti HIV-1 therapy. *PLoS One*. 2008;3(10):e3470. doi: 10.1371/journal.pone.0003470. Epub 2008 Oct 21. PMID: 18941628; PMCID: PMC2565127.
159. Tordini G, Giaccherini R, Pacenti L, Miracco C, Zazzi M, Zanelli G. Cutaneous leishmaniasis: usefulness of PCR on paraffin-embedded skin biopsies as part of routine investigation. *Ann Trop Med Parasitol*. 2007 Dec;101(8):745-9. doi: 10.1179/136485907X229059. PMID: 18028736.
160. Rusconi S, Gianotti N, Adorni F, Boeri E, Menzo S, Gonnelli A, Micheli V, Meraviglia P, Trezzi M, Paolini E, Giacometti A, Corsi P, Di Pietro M, Monno L, Punzi G, Zazzi M; ARCA Collaborative Group. Determinants of HIV-1 genotypic resistance to darunavir (TMC114) in a large Italian resistance database (Antiretroviral Resistance Cohort Analysis). *J Acquir Immune Defic Syndr*. 2007 Nov 1;46(3):373-5. doi: 10.1097/QAI.0b013e3181378f73. PMID: 18090302.
161. Vicenti I, Razzolini F, Saladini F, Romano L, Zazzi M. Use of peripheral blood DNA for genotype antiretroviral resistance testing in drug-naive HIV-1 infected subjects. *Clin Infect Dis*. 2007 Jun 15;44(12):1657-61. doi: 10.1086/518287. Epub 2007 May 8. PMID: 17516412.
162. Parisi SG, Boldrin C, Cruciani M, Nicolini G, Cerbaro I, Manfrin V, Dal Bello F, Franchin E, Franzetti M, Rossi MC, Cattelan AM, Romano L, Zazzi M, Andreoni M, Palù G. Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients. *J Clin Microbiol*. 2007 Jun;45(6):1783-8. doi: 10.1128/JCM.00056-07. Epub 2007 Apr 18. Erratum in: *J Clin Microbiol*. 2007 Oct;45(10):3484. PMID: 17442799; PMCID: PMC1933075.
163. Razzolini F, Vicenti I, Saladini F, Micheli V, Romano L, Cargnel A, Zazzi M. Natural variability in the HR-1 and HR-2 domains of HIV type 1 gp41 from different clades circulating in Italy. *AIDS Res Hum Retroviruses*. 2007 Apr;23(4):558-63. doi: 10.1089/aid.2006.0273. PMID: 17451345.
164. Larder B, Wang D, Revell A, Montaner J, Harrigan R, De Wolf F, Lange J, Wegner S, Ruiz L, Pérez-Elías MJ, Emery S, Gatell J, Monforte AD, Torti C, Zazzi M, Lane C. The development of artificial neural networks to predict virological response to combination HIV therapy. *Antivir Ther*. 2007;12(1):15-24. PMID: 17503743.
165. De Luca A, Di Giambenedetto S, Romano L, Gonnelli A, Corsi P, Baldari M, Di Pietro M, Menzo S, Francisci D, Almi P, Zazzi M; Antiretroviral Resistance Cohort Analysis Study Group. Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy. *J Infect Dis*. 2006 May 1;193(9):1219-22. doi: 10.1086/502976. Epub 2006 Mar 28. PMID: 16586357.
166. Pianigiani E, Risulo M, Ierardi F, Sbanò P, Andreassi L, Fimiani M, Caudai C, Valensin PE, Zazzi M. Prevalence of skin allograft discards as a result of serological and molecular microbiological screening in a regional skin bank in Italy. *Burns*. 2006 May;32(3):348-51. doi: 10.1016/j.burns.2005.10.005. Epub 2006 Mar 9. PMID: 16529868.
167. van de Vijver DA, Wensing AM, Angarano G, Asjö B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kücherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stöckl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CA. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. *J Acquir Immune Defic Syndr*. 2006 Mar;41(3):352-60. doi: 10.1097/01.qai.0000209899.05126.e4. PMID: 16540937.

168. Zannolli R, Zazzi M, Muraca MC, Macucci F, Buoni S, Nuti D. A child with vestibular neuritis. Is adenovirus implicated? *Brain Dev.* 2006 Jul;28(6):410-2. doi: 10.1016/j.braindev.2005.12.001. Epub 2006 Feb 28. PMID: 16504444.
169. Corvasce S, Violin M, Romano L, Razzolini F, Vicenti I, Galli A, Duca P, Caramma I, Balotta C, Zazzi M. Evidence of differential selection of HIV-1 variants carrying drug-resistant mutations in seroconverters. *Antivir Ther.* 2006;11(3):329-34. PMID: 16759049.
170. Wensing AM, van de Vijver DA, Angarano G, Asjö B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kücherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stöckl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CA; SPREAD Programme. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. *J Infect Dis.* 2005 Sep 15;192(6):958-66. doi: 10.1086/432916. Epub 2005 Aug 15. Erratum in: *J Infect Dis.* 2005 Oct 15;192(8):1501. PMID: 16107947.
171. Caudai C, Pianese M, Zacchini F, Toti M, Zazzi M, Valensin PE. Longitudinal study in HIV/HCV-coinfected HAART-naïve patients and role of HCV genotype. *J Clin Virol.* 2005 Feb;32(2):151-5. doi: 10.1016/j.jcv.2004.05.005. PMID: 15653418.
172. Paolucci S, Baldanti F, Maga G, Cancio R, Zazzi M, Zavattoni M, Chiesa A, Spadari S, Gerna G. Gln145Met/Leu changes in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nucleoside and nonnucleoside analogs and impair virus replication. *Antimicrob Agents Chemother.* 2004 Dec;48(12):4611-7. doi: 10.1128/AAC.48.12.4611-4617.2004. PMID: 15561833; PMCID: PMC529209.
173. Brun-Vézinet F, Costagliola D, Khaled MA, Calvez V, Clavel F, Clotet B, Haubrich R, Kempf D, King M, Kuritzkes D, Lanier R, Miller M, Miller V, Phillips A, Pillay D, Schapiro J, Scott J, Shafer R, Zazzi M, Zolopa A, DeGruttola V. Clinically validated genotype analysis: guiding principles and statistical concerns. *Antivir Ther.* 2004 Aug;9(4):465-78. PMID: 15456077.
174. Zazzi M, Romano L, Venturi G, Shafer RW, Reid C, Dal Bello F, Parolin C, Palù G, Valensin PE. Comparative evaluation of three computerized algorithms for prediction of antiretroviral susceptibility from HIV type 1 genotype. *J Antimicrob Chemother.* 2004 Feb;53(2):356-60. doi: 10.1093/jac/dkh021. Epub 2003 Dec 19. PMID: 14688053.
175. Chiappini E, Galli L, Zazzi M, de Martino M. Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active antiretroviral therapy. *J Med Virol.* 2003 Aug;70(4):506-12. doi: 10.1002/jmv.10424. PMID: 12794711.
176. Titanji K, Nilsson A, Mörch C, Samuelsson A, Sönnnerborg A, Grutzmeier S, Zazzi M, De Milito A. Low frequency of plasma nerve-growth factor detection is associated with death of memory B lymphocytes in HIV-1 infection. *Clin Exp Immunol.* 2003 May;132(2):297-303. doi: 10.1046/j.1365-2249.2003.02145.x. PMID: 12699420; PMCID: PMC1808715.
177. De Milito A, Titanji K, Zazzi M. Surrogate markers as a guide to evaluate response to antiretroviral therapy. *Curr Med Chem.* 2003 Mar;10(5):349-65. doi: 10.2174/0929867033368240. PMID: 12570696.
178. Dionisio D, Vivarelli A, Zazzi M, Esperti F, Fabbri C, Giorgi M, Menichini B. Long-term CD4+ T-cell response in HIV-1-infected patients continuing combination antiretroviral therapy despite high-level viremia and drug resistance. *Eur J Clin Microbiol Infect Dis.* 2003 Jan;22(1):69-71. doi: 10.1007/s10096-002-0845-7. Epub 2003 Jan 28. PMID: 12582750.
179. Venturi G, Romano L, Carli T, Corsi P, Pippi L, Valensin PE, Zazzi M. Divergent distribution of HIV-1 drug-resistant variants on and off antiretroviral therapy. *Antivir Ther.* 2002 Dec;7(4):245-50. PMID: 12553478.
180. Romano L, Peduzzi C, Venturi G, Di Pietro M, Carli T, Corsi P, Gonnelli A, Valensin PE, Zazzi M. Treatment with lopinavir/ritonavir in heavily pretreated subjects failing multiple antiretroviral regimens in clinical practice. *J Acquir Immune Defic Syndr.* 2002 Aug 15;30(5):533-5. doi: 10.1097/00126334-200208150-00010. PMID: 12154345.
181. Peduzzi C, Pierotti P, Venturi G, Romano L, Mazzotta F, Zazzi M. Performance of an in-house genotypic antiretroviral resistance assay in patients pretreated with multiple human immunodeficiency virus type 1 protease and reverse transcriptase inhibitors. *J Clin Virol.* 2002 Jul;25(1):57-62. doi: 10.1016/s1386-6532(01)00252-9. PMID: 12126722.
182. Romano L, Venturi G, Bloor S, Harrigan R, Larder BA, Major JC, Zazzi M. Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118. *J Infect Dis.* 2002 Apr 1;185(7):898-904. doi: 10.1086/339706. Epub 2002 Mar 11. PMID: 11920313.

183. De Milito A, Aleman S, Marenzi R, Sonnerborg A, Fuchs D, Zazzi M, Chiodi F. Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-1-infected subjects. *Clin Exp Immunol*. 2002 Mar;127(3):486-94. doi: 10.1046/j.1365-2249.2002.01786.x. Erratum in: *Clin Exp Immunol*. 2003 Oct;134(1):167. D Fuchs [corrected to Fuchs D]. PMID: 11966765; PMCID: PMC1906306.
184. Bellan C, Lazzi S, Zazzi M, Lalinga AV, Palumbo N, Galieni P, Marafioti T, Tonini T, Cinti C, Leoncini L, Pileri SA, Tosi P. Immunoglobulin gene rearrangement analysis in composite Hodgkin disease and large B-cell lymphoma: evidence for receptor revision of immunoglobulin heavy chain variable region genes in Hodgkin-Reed-Sternberg cells? *Diagn Mol Pathol*. 2002 Mar;11(1):2-8. doi: 10.1097/00019606-200203000-00002. PMID: 11854595.
185. Romano L, Venturi G, Giomi S, Pippi L, Valensin PE, Zazzi M. Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice. *J Med Virol*. 2002 Feb;66(2):143-50. doi: 10.1002/jmv.2123. PMID: 11782921.
186. Romano L, Venturi G, Vivarelli A, Galli L, Zazzi M. Detection of a drug-resistant human immunodeficiency virus variant in a newly infected heterosexual couple. *Clin Infect Dis*. 2002 Jan 1;34(1):116-7. doi: 10.1086/322521. PMID: 11731954.
187. Dionisio D, Vivarelli A, Zazzi M, Esperti F, Uberti M, Polidori M. Extent of human immunodeficiency virus type 1 drug resistance as a predictor of virological failure after genotype-guided treatment switch. *Clin Infect Dis*. 2001 Sep 1;33(5):706-9. doi: 10.1086/322660. Epub 2001 Jul 30. PMID: 11486293.
188. de Martino M, Galli L, Moriondo M, Zazzi M, Azzari C, Peruzzi M, Vierucci A. Dissociation of responses to highly active antiretroviral therapy: Notwithstanding virologic failure and virus drug resistance, both CD4+ and CD8+ T lymphocytes recover in HIV-1 perinatally infected children. *J Acquir Immune Defic Syndr*. 2001 Feb 1;26(2):196-7. doi: 10.1097/00042560-200102010-00018. PMID: 11242191.
189. Romano L, Venturi G, Ferruzzi R, Riccio ML, Corsi P, Leoncini F, Vinattieri A, Incandela L, Valensin PE, Zazzi M. Detection of genotypically drug-resistant HIV-1 variants and non-B subtypes in recently infected antiretroviral-naïve adults in Italy. *AIDS*. 2000 Sep 29;14(14):2204-6. doi: 10.1097/00002030-200009290-00019. PMID: 11061664.
190. De Milito A, Hejdeman B, Albert J, Aleman S, Sönnnerborg A, Zazzi M, Chiodi F. High plasma levels of soluble fas in HIV type 1-infected subjects are not normalized during highly active antiretroviral therapy. *AIDS Res Hum Retroviruses*. 2000 Sep 20;16(14):1379-84. doi: 10.1089/08892220050140928. PMID: 11018857.
191. Venturi G, Ferruzzi R, Romano L, Catucci M, Valensin PE, Zazzi M. Ultrasensitive in-house reverse transcription-competitive PCR for quantitation of HIV-1 RNA in plasma. *J Virol Methods*. 2000 Jun;87(1-2):91-7. doi: 10.1016/s0166-0934(00)00151-8. PMID: 10856756.
192. Catucci M, Venturi G, Romano L, Valensin PE, Zazzi M. Analysis of the HIV-1 nef gene in five intravenous drug users with long-term nonprogressive HIV-1 infection in Italy. *J Med Virol*. 2000 Mar;60(3):294-9. PMID: 10630962.
193. Venturi G, Catucci M, Romano L, Corsi P, Leoncini F, Valensin PE, Zazzi M. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples. *J Infect Dis*. 2000 Feb;181(2):740-5. doi: 10.1086/315249. PMID: 10669367.
194. Catucci M, Venturi G, Romano L, Riccio ML, De Milito A, Valensin PE, Zazzi M. Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine, and protease inhibitors. *J Acquir Immune Defic Syndr*. 1999 Jul 1;21(3):203-8. doi: 10.1097/00126334-199907010-00004. PMID: 10421243.
195. Venturi G, Romano L, Catucci M, Riccio ML, De Milito A, Gonnelli A, Rubino M, Valensin PE, Zazzi M. Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type-1 nucleoside reverse-transcriptase inhibitors. *Eur J Clin Microbiol Infect Dis*. 1999 Apr;18(4):274-82. doi: 10.1007/s100960050276. PMID: 10385016.
196. Oggioni MR, Medagliani D, Romano L, Peruzzi F, Maggi T, Lozzi L, Bracci L, Zazzi M, Manca F, Valensin PE, Pozzi G. Antigenicity and immunogenicity of the V3 domain of HIV type 1 glycoprotein 120 expressed on the surface of *Streptococcus gordonii*. *AIDS Res Hum Retroviruses*. 1999 Mar 20;15(5):451-9. doi: 10.1089/088922299311204. PMID: 10195755.
197. De Milito A, Catucci M, Venturi G, Romano L, Incandela L, Valensin PE, Zazzi M. Antiretroviral therapy with protease inhibitors in human immunodeficiency virus type 1- and human herpesvirus 8-coinfected patients. *J Med Virol*. 1999 Feb;57(2):140-4. doi: 10.1002/(sici)1096-9071(199902)57:2<140::aid-jmv9>3.0.co;2-y. PMID: 9892398.

198. Zazzi M, Romano L, Catucci M, Venturi G, De Milito A, Valensin PE. Clinical evaluation of an in-house reverse transcription-competitive PCR for quantitation of human immunodeficiency virus type 1 RNA in plasma. *J Clin Microbiol*. 1999 Feb;37(2):333-8. doi: 10.1128/JCM.37.2.333-338.1999. PMID: 9889213; PMCID: PMC84299.
199. Romano L, Venturi G, Catucci M, De Milito A, Valensin PE, Zazzi M. Evaluation of cell-free and cell-associated peripheral blood human immunodeficiency virus type 1 RNA response to antiretroviral therapy. *J Infect Dis*. 1999 Feb;179(2):361-6. doi: 10.1086/314583. PMID: 9878019.
200. Lazzi S, Ferrari F, Nyong'o A, Palumbo N, de Milito A, Zazzi M, Leoncini L, Luzi P, Tosi P. HIV-associated malignant lymphomas in Kenya (Equatorial Africa). *Hum Pathol*. 1998 Nov;29(11):1285-9. doi: 10.1016/s0046-8177(98)90258-1. PMID: 9824108.
201. Martinelli C, Zazzi M, Ambu S, Bartolozzi D, Corsi P, Leoncini F. Complete regression of AIDS-related Kaposi's sarcoma-associated human herpesvirus-8 during therapy with indinavir. *AIDS*. 1998 Sep 10;12(13):1717-9. PMID: 9764794.
202. Nyong'o A, Leoncini L, Lazzi S, Kioko E, Zazzi M, Luzi P. Fatal cytomegalovirus infection in a patient without evidence of prior immunodeficiency. *Clin Infect Dis*. 1998 Sep;27(3):659-60. doi: 10.1086/517150. PMID: 9770181.
203. Zazzi M, Riccio ML, Venturi G, Catucci M, Romano L, De Milito A, Valensin PE. Long-read direct infrared sequencing of crude PCR products for prediction of resistance to HIV-1 reverse transcriptase and protease inhibitors. *Mol Biotechnol*. 1998 Aug;10(1):1-8. doi: 10.1007/BF02745858. PMID: 9779418.
204. Bosi A, Zazzi M, Amantini A, Cellerini M, Vannucchi AM, De Milito A, Guidi S, Saccardi R, Lombardini L, Laszlo D, Rossi Ferrini P. Fatal herpesvirus 6 encephalitis after unrelated bone marrow transplant. *Bone Marrow Transplant*. 1998 Aug;22(3):285-8. doi: 10.1038/sj.bmt.1701326. PMID: 9720744.
205. Bocci V, Venturi G, Catucci M, Valensin PE, Zazzi M. Lack of efficacy of ozone therapy in HIV infection. *Clin Microbiol Infect*. 1998 Jan;4(11):667-669. doi: 10.1111/j.1469-0691.1998.tb00355.x. PMID: 11864271.
206. Zazzi M, Romano L, Catucci M, Venturi G, De Milito A, Almi P, Gonnelli A, Rubino M, Occhini U, Valensin PE. Evaluation of the presence of 2-LTR HIV-1 unintegrated DNA as a simple molecular predictor of disease progression. *J Med Virol*. 1997 May;52(1):20-5. doi: 10.1002/(sici)1096-9071(199705)52:1<20::aid-jmv4>3.0.co;2-t. PMID: 9131453.
207. De Milito A, Venturi G, Catucci M, Romano L, Bianchi Bandinelli ML, Zazzi M. Lack of evidence of HHV-8 DNA in blood cells from heart transplant recipients. *Blood*. 1997 Mar 1;89(5):1837-8. PMID: 9057673.
208. Toti P, Romano L, Villanova M, Zazzi M, Luzi P. Focal myositis: a polymerase chain reaction analysis for a viral etiology. *Hum Pathol*. 1997 Jan;28(1):111-3. doi: 10.1016/s0046-8177(97)90290-2. PMID: 9013843.
209. Zazzi M, Catucci M, De Milito A, Romano L, Venturi G, Almi P, Gonnelli A, Rubino M, Valensin PE. Zidovudine resistance mutations and human immunodeficiency virus type 1 DNA burden: longitudinal evaluation of six patients under treatment. *Infection*. 1996 Nov-Dec;24(6):419-25. doi: 10.1007/BF01713041. PMID: 9007588.
210. De Milito A, Catucci M, Venturi G, Romano L, Valensin PE, Zazzi M, Almi P. Human immunodeficiency virus-1 infection, homosexuality, and Kaposi-associated herpes-like DNA in peripheral blood mononuclear cells. *Blood*. 1996 Apr 15;87(8):3521-2. PMID: 8605374.
211. Malandrini A, Fabrizi GM, Cavallaro T, Zazzi M, Parrotta E, Romano L, Berti G, Villanova M, Guazzi GC. Neuronal intranuclear inclusion disease: polymerase chain reaction and ultrastructural study of rectal biopsy specimen in a new case. *Acta Neuropathol*. 1996;91(2):215-8. doi: 10.1007/s004010050417. PMID: 8787158.
212. Romano L, Catucci M, De Milito A, Venturi G, Zazzi M, Almi P, Gonnelli A, Rubino M, Maestrini R, Valensin PE. Concordance between polymerase chain reaction and antibody detection in the diagnosis of human immunodeficiency virus type 1 infection. *Eur J Clin Microbiol Infect Dis*. 1995 Nov;14(11):1011-14. doi: 10.1007/BF01691386. PMID: 8654439.
213. Oggioni MR, Fattorini L, Li B, De Milito A, Zazzi M, Pozzi G, Orefici G, Valensin PE. Identification of *Mycobacterium tuberculosis* complex, *Mycobacterium avium* and *Mycobacterium intracellulare* by selective nested polymerase chain reaction. *Mol Cell Probes*. 1995 Oct;9(5):321-6. doi: 10.1016/s0890-8508(95)91604-0. PMID: 8569772.
214. Manganelli R, Romano L, Ricci S, Zazzi M, Pozzi G. Dosage of Tn916 circular intermediates in *Enterococcus faecalis*. *Plasmid*. 1995 Jul;34(1):48-57. doi: 10.1006/plas.1995.1032. PMID: 7480170.
215. De Milito A, Catucci M, Iannelli F, Romano L, Zazzi M, Valensin PE. Increased reliability of selective PCR by using additionally mutated primers and a commercial Taq DNA polymerase enhancer. *Mol Biotechnol*. 1995 Apr;3(2):166-9. doi: 10.1007/BF02789112. PMID: 7620977.
216. Zazzi M, Romano L, Catucci M, De Milito A, Almi P, Gonnelli A, Rubino M, Valensin PE. Low human immunodeficiency virus type 1 (HIV-1) DNA burden as a major cause for failure to detect HIV-1 DNA in clinical

- specimens by PCR. *J Clin Microbiol.* 1995 Jan;33(1):205-8. doi: 10.1128/JCM.33.1.205-208.1995. PMID: 7699043; PMCID: PMC227909.
217. Zazzi M, Romano L, Peruzzi F, Toneatto S, De Milito A, Botta G, Valensin PE. Optimal conditions for detection of human immunodeficiency virus type 1 DNA by polymerase chain reaction with nested primers. *Mol Cell Probes.* 1993 Dec;7(6):431-7. doi: 10.1006/mcpr.1993.1064. PMID: 8145774.
218. Zazzi M, Romano L, Brasini A, Valensin PE. Simultaneous amplification of multiple HIV-1 DNA sequences from clinical specimens by using nested-primer polymerase chain reaction. *AIDS Res Hum Retroviruses.* 1993 Apr;9(4):315-20. doi: 10.1089/aid.1993.9.315. PMID: 8512746.
219. Zazzi M, Romano L, Brasini A, Valensin PE. Nested polymerase chain reaction for detection of human immunodeficiency virus type 1 DNA in clinical specimens. *J Med Virol.* 1992 Nov;38(3):172-4. doi: 10.1002/jmv.1890380304. PMID: 1287130.
220. Zazzi M, Romano L, Brasini A, Valensin PE. Low human immunodeficiency virus titer and polymerase chain reaction false-negatives. *J Infect Dis.* 1992 Apr;165(4):779-80. doi: 10.1093/infdis/165.4.779. PMID: 1552213.
221. Rottoli P, Bianchi Bandinelli ML, Rottoli L, Zazzi M, Panzardi G, Valensin PE. Sarcoidosis and infections by human lymphotropic viruses. *Sarcoidosis.* 1990 Mar;7(1):31-3. PMID: 2161122.
222. Valensin PE, Bianchi Bandinelli ML, Zazzi M, Gaggelli E, Valensin G. NMR investigation of cell cultures: early detection of infection by Herpes simplex virus type 2 and transformation. *Microbiologica.* 1990 Jan;13(1):11-9. PMID: 2155373.
223. Valensin PE, Zazzi M, Valassina M, Bianchi Bandinelli ML, Toti M, Almi P, Rubino M, Caruso A. Live-cell immunofluorescence for detection of human immunodeficiency virus type 1 (HIV-1)-related antigens in peripheral blood mononuclear cells from HIV-1 seropositive individuals. *Microbiologica.* 1989 Oct;12(4):281-9. PMID: 2685514.
224. Valensin PE, Bianchi Bandinelli ML, Cusi MG, Rossolini GM, Zazzi M. Biotechnology for virus vaccine design, production, and control. *J Chemother.* 1989 Jul;1(4 Suppl):1069-71. PMID: 16312775.

***Papers presented at national and international conferences based on the selection by the scientific committee (Speaker/First author)***

1. Zazzi M, Rossolini GM, Valassina M, Romano L, Valensin PE. Individuazione di sequenze HIV-1-specifiche mediante reazione a catena della polimerasi. Cinquantunesimo Convegno della sezione TUEMA della Società Italiana di Microbiologia. Ferrara, 18-19 maggio 1990.
2. Zazzi M, Romano L, Caudai C, Valensin PE. Impiego della reazione a catena della polimerasi per il rilevamento di DNA di HIV-1 in campioni clinici. Ventitreesimo Congresso Nazionale della Società Italiana di Microbiologia. Palermo, 26-30 novembre 1990.
3. Zazzi M, Romano L, Bianchi Bandinelli ML, Valensin PE. Diagnosi tramite PCR delle infezioni da HIV. Istituto Superiore di Sanità, progress report sul terzo progetto di ricerche sull'AIDS. Orbetello, 18-23 maggio 1991.
4. Zazzi M, Romano L, Brasini A, Valensin PE. Two-step polymerase chain reaction assay for detection of human immunodeficiency virus type 1 (HIV-1) DNA. Fifth International Symposium on Clinical and Environmental Microbiology. Brescia, October 9-13, 1991.
5. Zazzi M, Romano L, Brasini A, Valensin PE. Analysis of human immunodeficiency virus type 1 (HIV-1)-seropositive and seronegative individuals by nested polymerase chain reaction. Fifth International Symposium on Clinical and Environmental Microbiology. Brescia, October 9-13, 1991.
6. Zazzi M, Romano L, Brasini A, Valensin PE. Identificazione di sequenze HIV-1-specifiche mediante 'nested' PCR. Cinquantaduesimo Convegno della sezione TUEMA della Società Italiana di Microbiologia. Pisa, 12-13 dicembre 1991.
7. Zazzi M, Romano L, Brasini A, Valensin PE. Analisi di soggetti HIV-1-seropositivi e sieronegativi mediante 'nested' PCR. Cinquantaduesimo Convegno della sezione TUEMA della Società Italiana di Microbiologia. Pisa, 12-13 dicembre 1991.
8. Zazzi M, Romano L, Brasini A, Toneatto S, Peruzzi F, Valensin PE. 'Nested' PCR nella diagnosi e nel monitoraggio dell'evoluzione dell'infezione da HIV1. Convegno di studi 'AIDS: una sfida possibile?' promosso dalla Società Italiana di Malattie Infettive e Parassitarie, Sezione Lombardia. Brescia, 27-28 Marzo 1992.
9. Zazzi M, Rubino M, Romano L, Gonnelli A, Valensin PE, Almi P. Valutazione di marcatori molecolari nell'andamento dell'infezione da HIV-1. Dodicesimo simposio 'Epatite e AIDS'. Rimini, 4-6 maggio 1993. Relazione premiata dal Coordinamento Scientifico e dalla Segreteria Scientifica.
10. Zazzi M, De Milito A, Romano L, Valensin PE. Monitoraggio dell'insorgenza di mutazioni correlate alla chemioresistenza in vitro in soggetti HIV-1-infetti in trattamento con AZT. Attuali metodi in genetica

- molecolare. Verona (Incontri Genenco). 14 maggio 1993.
11. Zazzi M, Romano L, De Milito A, Almi P, Gonnelli A, Rubino M, Valensin PE. Nested PCR per la diagnosi e il monitoraggio dell'infezione da HIV-1. I Congresso Nazionale SIMMOC, Pisa 18-19 giugno 1993.
  12. Zazzi M, Romano L, De Milito A, Catucci M, Almi P, Gonnelli A, Rubino M, Valensin PE. Monitoring HIV-1 DNA burden and development of AZT resistance mutations in AZT-treated patients. Fourth European Conference on Clinical Aspects and Treatment of HIV infection. Milan, March 16-18, 1994.
  13. Zazzi M, Romano L, De Milito A, Catucci M, Iannelli F, Gonnelli A, Almi P, Rubino M, Valensin PE. Valutazione longitudinale di parametri molecolari in corso di infezione da HIV-1. Secondo Congresso Nazionale della Società Italiana di Microbiologia Medica, Odontoiatrica e Clinica. Novara, 27-28 maggio 1994.
  14. Zazzi M, Romano L, De Milito A, Catucci M, Gonnelli A, Almi P, Rubino M, Valensin PE. Molecular monitoring of HIV-1 infection in zidovudine-treated subjects. Seventh research project on AIDS. Progress report. Roma, July 4-8, 1994.
  15. Zazzi M, Romano L, De Milito A, Catucci M, Gonnelli A, Almi P, Rubino M, Valensin PE. Longitudinal analysis of HIV-1 DNA burden and predicted level of zidovudine resistance during treatment of HIV-1-infected subjects. Eighth research project on AIDS. Progress report. Roma, May 29-June 2, 1995.
  16. Zazzi M, Catucci M, De Milito A, Romano L, Venturi G, Valensin PE. Insorgenza di mutanti di HIV-1 chemioresistenti in corso di trattamento con inibitori della trascrittasi inversa. Convegno congiunto dell'Associazione di Biologia Cellulare e del Differenziamento, Associazione Genetica Italiana, Società Italiana di Biofisica e Biologia Molecolare, Società Italiana di Microbiologia Generale e Biotecnologie Microbiche. Montesilvano Lido (PE), 2-6 ottobre 1995.
  17. Zazzi M, Romano L, De Milito A, Catucci M, Venturi G, Almi P, Gonnelli A, Rubino M, Valensin PE. Molecular monitoring of HIV-1 infection in subjects under different treatments. Ninth research project on AIDS. Progress report. Rome, January 13-17, 1997.
  18. Zazzi M, Romano L, Venturi G, Riccio ML, Ferruzzi R, Corsi P, Leoncini F, Incandela L, Gonnelli A, Valensin PE. Development of genotypic resistance to HIV-1 protease inhibitors during triple-drug therapy. 12th World AIDS Conference, Durban, July 9-14, 2000.
  19. Zazzi M, Romano L, Venturi G, Giomi S, Gonnelli A, Valensin PE. Insorgenza e significato della resistenza agli inibitori di proteasi in pazienti HIV infetti sotto terapia tripla nella pratica clinica. Cortonavirus 2000. Cortona, 15-16 settembre 2000.
  20. Zazzi M, Venturi G, Romano L, Valensin PE. Sviluppo di un sistema esperto per l'analisi e lo studio delle mutazioni di farmacoresistenza in HIV1. Primo Congresso Nazionale della Società Italiana di Virologia. Cortona, 14-15 settembre 2001.
  21. Zazzi M, Romano L, Venturi G, Valensin PE. Use of an integrated HIV resistance mutation database for uncovering associations between mutants and treatments: RT mutations at codons 44 and 118 are preferentially selected by stavudine and didanosine. Third National program on AIDS. Progress Report. Rome, February 26-March 2, 2001.
  22. Zazzi M, Romano L, Venturi G, Valensin PE. Evoluzione dei sistemi interpretativi del genotipo per l'ottimizzazione della terapia antiretrovirale in presenza di ceppi di HIV1 farmacoresistenti. Secondo Congresso Nazionale della Società Italiana di Virologia. Cortona, 17-19 settembre 2002
  23. Zazzi M, Romano L, Razzolini F, Vicenti I, Macchiesi C, Machetti S, Marconi A and Valensin PE. Prevalence and time trends of primary and secondary antiretroviral drug resistance in a large sequence database maintained at the University of Siena, Italy. 2nd European HIV Drug Resistance Workshop: From Basic Science to Clinical Implications. Rome, March 11-13, 2004.
  24. Zazzi M, Romano L, Razzolini F, Vicenti I, Macchiesi C, Machetti S, Marconi A and Valensin PE. Prevalence and transmission of HIV-1 variants resistant to antiretroviral drugs: a 1995-2003 survey based on the analysis of >12,000 reverse transcriptase and protease sequences obtained at the University of Siena, Italy. Gesellschaft für Virologie, joint meeting with the Società Italiana di Virologia. Tubingen, March 17-20, 2004.
  25. Zazzi M, Romano L, Razzolini F, Vicenti I, Macchiesi C, Machetti S, Marconi A, Valensin PE. Natural polymorphisms associated with differential pathways to multi-nucleoside analog resistance in HIV-1. 4th National Congress of the Italian Society of Virology. Orvieto, Italy, September 20-22, 2004.
  26. Zazzi M, Parisi SG, Razzolini F, Romano L, Dal Bello F, Franchin E, Manfrin V, Nicolini G, Palù G, Valensin PE. Comparative evaluation of plasma RNA and peripheral blood mononuclear cell DNA for detection of antiretroviral drug resistance mutations in HIV from antiretroviral-naive subjects. Third European HIV Drug Resistance Workshop. Athens, March 30 – April 1, 2005. Abstract 4.
  27. Zazzi M, Romano L, De Luca A, Gianotti N, Prosperi M, Torti C, Valensin PE. Allestimento e utilizzazione di un database multicentrico on-line come base per lo studio delle farmacoresistenze agli antiretrovirali. Progress

- Report Meeting - V Programma Nazionale di Ricerca sull'AIDS. Roma, 2-6 maggio 2005.
28. Zazzi M, Corsi P, Gonnelli A, Di Pietro M, Giacometti A, Almi P, Trezzi M, Boeri E, Gianotti N, Menzo S, del Gobbo R, Francisci D, Nerli A, Galli L, De Luca A for the ARCA Collaborative Group. Evolution of the prevalence of HIV drug resistance patterns over 9 years of HAART and its relation with changes in the failing treatment regimens: an analysis of a large Italian database. XV International HIV Drug Resistance Workshop. Sitges (Spain), June 13-17, 2006.
  29. Zazzi M, Aharoni E, Altmann A, Bazsó F, Bidgood P, Borgulya G, Denholm-Price J, Fielder M, Kaiser R, Kent C, Lengauer T, Nepusz T, Neuvirth H, Peres Y, Petroczi A, Prospero M, Romano L, Rosen-Zvi M, Schuelter E, Sing T, Sonnerborg A, Thompson R, Ulivi G, Zalányi L, Incardina F. EuResist: exploration of multiple modeling techniques for prediction of response to treatment. Fifth European HIV Drug Resistance Workshop. Cascais, March 28-30, 2007.
  30. Zazzi M, Marconi A, Comastri G, Pulvirenti FR, Gennari W, Tagliazucchi S, Pecorari M. Evaluation of use of dried blood spot specimens with the Abbott Real-Time HIV-1 Quantitative Assay. 1st Interest Workshop - International Workshop on HIV Treatment, Pathogenesis and Prevention Research in Resource-poor Settings. Kampala, Uganda, May 30 - June 2, 2007.
  31. Zazzi M, Prospero M, Vicenti I, Di Giambenedetto S, Callegaro A, Bruzzone B, Baldanti F, Gonnelli A, Boeri E, Paolini E, Rusconi S, Giacometti A, Maggiolo F, Menzo S, De Luca A on behalf of the ARCA Collaborative Group. Rules-Based HIV-1 Genotypic Resistance Interpretation Systems Predict 8-week and 24-week Virological Antiretroviral Treatment Outcome and Benefit from Drug Potency Weighting. 7th European HIV Drug Resistance workshop. 25-27 March 2009, Stockholm, Sweden.
  32. Zazzi M, Kaiser R, Sonnerborg A, Struck D, Altmann A, Prospero M, Rosen-Zvi M, Petroczi A, Peres Y, Schülter E, Boucher CAB, Brun-Vezinet F, Harrigan PR, Morris L, Obermeier M, Perno CF, Phanuphak P, Pillay D, Shafer RW, Vandamme AM, Van Laethem K, Wensing AM, Lengauer T, Incardona F. Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study). Eighth European HIV Drug Resistance Workshop. 17-19 March 2010. Sorrento, Italy.
  33. Zazzi M, Meini G, Emary A, Fikrie N, Kadima S, Marandu E, Mloka D, Mugusi S, Mutuku S, Njogu W, Worku A, Bakari M, Fekade D, Mugusi F, Mwau M, Toti M, Incardona F, Sonnerborg A. Training and strategy for HIV drug resistance testing in Eastern Africa. Sixth EDCTP Forum. October 9-12, 2011. Addis Ababa, Ethiopia.
  34. Zazzi M, Di Giambenedetto S, Torti C, Lo Presti A, Caudai C, Vicenti I, Saladini F, Almi P, Grima P, Blanc P, Fabbiani M, Rossetti B, Gagliardini R, Ciccozzi M, De Luca A. Characterization of two distinct HCV genotype 1a clades: association with primary resistance mutations to HCV protease inhibitor. 11th European Workshop on HIV & Hepatitis. 20 – 22 March 2013, Rome, Italy.
  35. Zazzi M, Abecasis A, Bobkova M, Devaux C, Fanti I, Incardona F, Kaiser R, Marrone G, Paredes R, Rusconi S, Sayan M, De Luca A, INTEGRATE Study Group. Integrating EuResist Database with Integrase Resistance Data for Optimized Antiretroviral Treatment (the INTEGRATE Project). 16th European AIDS Conference October 25-27, 2017 - Milan, Italy.

***Papers presented at national and international conferences based on the selection by the scientific committee (non-Speaker/non-First author)***

1. Valensin PE, Rottoli P, Bianchi Bandinelli ML, Cusi MG, Rossolini GM, Rottoli L, Zazzi M. Sarcoidosi ed infezioni da virus linfotropici umani. Sedicesimo Congresso Nazionale Associazione Microbiologi Clinici. Genova, 12-15 novembre 1987.
2. Valensin PE, Valassina M, Zazzi M, Cusi MG. Isolamento di virus influenzali di tipo B in pazienti geriatriche della provincia di Siena. Ventiduesimo Congresso Nazionale della Società Italiana di Microbiologia. Salsomaggiore Terme, 1-4 maggio 1988.
3. Valensin PE, Zazzi M, Valassina M, Bianchi Bandinelli ML, Cusi MG, Caruso A, Toti M, Almi P, Rubino M. Immunofluorescenza con anticorpi monoclonali per la ricerca di antigeni HIV-specifici in linfociti di soggetti HIV-sieropositivi. Ventiduesimo Congresso Nazionale della Società Italiana di Microbiologia. Salsomaggiore Terme, 1-4 maggio 1988.
4. Valensin PE, Bianchi Bandinelli ML, Cusi MG, Rossolini GM, Zazzi M. Biotechnology for virus vaccine design, production, and control. Proceedings of the Sixth Mediterranean Congress of Chemotherapy. Taormina, 22-27 May 1988 (Published in: J Chemother 1989;S4:1069-1071).
5. Rottoli P, Valensin PE, Bianchi Bandinelli ML, Cusi MG, Rossolini GM, Rottoli L, Sparnacci F, Zazzi M. Sarcoidosi e infezioni da virus linfotropici umani. Secondo Congresso Italiano su: Sarcoidosi ed altre malattie granulomatose. Salsomaggiore Terme, 10-11 giugno 1988.

6. Valensin PE, Zazzi M, Bianchi Bandinelli ML, Caudai C, Moschettini D, Valassina M. Diagnosi precoce e monitoraggio dell'infezione da HIV: individuazione di DNA ed antigeni virus-specifici. Istituto Superiore di Sanità, progress report sul secondo progetto di ricerche sull'AIDS. Orbetello, 28 maggio - 1 giugno 1990.
7. Cusi MG, Soldani P, Zazzi M, Valensin PE. Cross-reazione tra emoagglutinina del virus influenzale e proteina basica della mielina. Ventitreesimo Congresso Nazionale della Società Italiana di Microbiologia. Palermo, 26-30 novembre 1990.
8. Bianchi Bandinelli ML, Guglielmetti P, Rossolini A, Valassina M, Zazzi M, Valensin PE. Controllo su campo della vaccinazione anti-morbillosa in un gruppo di bambini boliviani. Ventitreesimo Congresso Nazionale della Società Italiana di Microbiologia. Palermo, 26-30 novembre 1990.
9. Santucci A, Bracci L, Orlandini M, Zazzi M, Neri P. Anti-human central nervous system monoclonal antibodies cross-react with HIV-1. Proteine '92. Settimo Convegno Nazionale del Gruppo Struttura e Funzione delle Proteine della Società Italiana di Biochimica. Pavia, 26-28 Maggio 1992.
10. Annunziata P, Maimone D, Guazzi GC, Bracci L, Santucci A, Orlandini M, Zazzi M, Neri P. Relazioni antigeniche e strutturali tra HIV e proteine della mielina umana. Istituto Superiore di Sanità. Quinto progetto di ricerche sull'AIDS. Progress report. Orbetello, 13-17 Giugno 1992.
11. Oggioni MR, Zazzi M, Valensin PE, Pozzi G. Non-pathogenic Streptococci as live vectors for vaccine delivery. Fifth Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS. Chantilly, Virginia, 30 August-3 September 1992.
12. Valensin PE, Zazzi M, Romano L, Brasini A, Peruzzi F, Toneatto S. Ottimizzazione di un sistema di 'nested PCR' per il rilevamento di sequenze HIV1-specifiche in campioni clinici. Ventiquattresimo Congresso Nazionale della Società Italiana di Microbiologia. Genova, 14-18 settembre 1992.
13. Valensin PE, Zazzi M, Romano L, Brasini A, Peruzzi F, Toneatto S. Individuazione e quantizzazione del DNA virale in corso di infezione da HIV-1. Ventiquattresimo Congresso Nazionale della Società Italiana di Microbiologia. Genova, 14-18 settembre 1992.
14. Gonnelli A, Rubino M, Valensin PE, Zazzi M, Toscano L, Nencioni C, Incandela L, Almi P. Determinazione con PCR di HIV1 DNA in linfociti periferici: risultati in soggetti ad alto rischio di infezione da HIV. Ventitreesimo Congresso Nazionale dell'Associazione Medici Ospedalieri Infettivologi. Pugnochiuso (FG), 19-22 maggio 1993. Pubblicato su: Giornale di Malattie Infettive e Parassitarie 1994;46:580.
15. Pozzi G, Oggioni MR., Nicoletti C, Zazzi M, Romano L, Valensin PE. Streptococchi ricombinanti come vettori vivi di vaccini. Sesto progetto di ricerche sull'AIDS. Progress report. Orbetello, 19-23 giugno 1993.
16. Manganelli R, Romano L, Zazzi M, Valensin PE, Pozzi G. Dimostrazione e dosaggio degli intermedi circolari del trasposone coniugativo Tn916 in *Enterococcus faecalis*. Dodicesimo convegno scientifico della Società Italiana di Microniologia Generale e Biotecnologie Microbiche. Camerino (MC), 26-29 settembre 1993.
17. Manganelli R, Romano L, Ricci S, Zazzi M, Valensin PE, Pozzi G. Circular intermediates of Tn916. Fourth International Conference on Streptococcal Genetics. Santa Fe, New Mexico, May 15-18, 1994.
18. Oggioni MR, Fattorini L, Zazzi M, Pozzi G, Orefici G, Valensin PE. Identificazione di specie micobatteriche tramite nested PCR selettiva sul gene del 16S rRNA. Secondo Congresso Nazionale della Società Italiana di Microbiologia Medica, Odontoiatrica e Clinica. Novara, 27-28 maggio 1994.
19. Manganelli R, Romano L, Ricci S, Proveddi R, Zazzi M, Valensin PE, Pozzi G. Gli Intermedi Circolari del Trasposone Coniugativo Tn916. Convegno congiunto dell'Associazione di Biologia Cellulare e del Differenziamento, Associazione Genetica Italiana, Società Italiana di Biofisica e Biologia Molecolare, Società Italiana di Microbiologia Generale e Biotecnologie Microbiche. Montesilvano Lido (PE), 26-30 settembre 1994.
20. Oggioni MR, Fattorini L, Bo L, De Milito A, Zazzi M, Pozzi G, Orefici G, Valensin PE. Identificazione di specie micobatteriche tramite nested PCR selettiva sul gene del 16S rRNA. Convegno congiunto dell'Associazione di Biologia Cellulare e del Differenziamento, Associazione Genetica Italiana, Società Italiana di Biofisica e Biologia Molecolare, Società Italiana di Microbiologia Generale e Biotecnologie Microbiche. Montesilvano Lido (PE), 2-6 ottobre 1995.
21. Bilenchi R, Zazzi M, Valensin PE, Marcolongo RF. Sarcoma di Kaposi HHV-8 positivo associato ad artrite psoriasica in paziente HIV negativa. 71° Congresso Nazionale della Società Italiana di Dermatologia e Venereologia. Rimini, 11-15 giugno 1996.
22. Nencioni C, Carli T, Madonna R, Allegri MP, Giomi S, Riccardi MP, Incandela L, Zazzi M, Fischetti M, Rosso R, Toti M. Descrizione di una caso fatale di mononucleosi infettiva. XXVI Congresso Nazionale Associazione Medici Ospedalieri Infettivologi. Castiglione della Pescaia (GR), 18-20 settembre 1996.
23. Rubino M, De Milito A, Carnicelli N, Pippi L, Toscano L, Catucci M, Venturi G, Romano L, Valensin PE, Zazzi M. Determinazione mediante PCR di DNA di herpesvirus umano tipo 8 (HHV8) in leucociti mononucleati



- periferici: correlazione con infezione da HIV, omosessualità e sarcoma di Kaposi. XXVI Congresso Nazionale Associazione Medici Ospedalieri Infettivologi. Castiglione della Pescaia (GR), 18-20 settembre 1996.
24. Traversi C, Speri EA, Franceschini R, Zazzi M, Romano L, Almi P. Esame con PCR sul vitreo per la diagnosi di retinite da CMV. 76° Congresso della Società Oftalmologica Italiana. Roma, 21-23 novembre 1996.
  25. De Milito A, Catucci M, Venturi G, Romano L, Marconi A, Bianchi-Bandinelli ML, Valensin PE, Zazzi M. Prevalence of human herpesvirus type 8 DNA in blood cells from different groups at risk for Kaposi's sarcoma in Italy. IX Symposium on HIV infection. Toulon, March 7-8, 1997.
  26. Catucci M, Romano L, De Milito A, Venturi G, Zazzi M, Almi P, Gonnelli A, Rubino M, Bocci V, Valensin PE. Evaluation of molecular markers of HIV1 infection during different therapeutical treatments. IX Symposium on HIV infection. Toulon, March 7-8, 1997.
  27. De Milito A, Catucci M, Venturi G, Romano L, Marconi A, Bianchi Bandinelli ML, Leoncini L, Zazzi M, Valensin PE. Detection of KSV/HHV8 in groups at risk for Kaposi's sarcoma in Italy. Second International Conference on Human Herpesviruses 6, 7, and 8. Pisa, May 8-11, 1997.
  28. Almi P, Rubino M, Gonnelli A, Carnicelli N, Toscano L, Zazzi M, Romano L, De Milito A, Catucci M, Venturi G, Valensin PE, Pippi L. Monitoraggio molecolare dell'infezione da H)V-1 in pazienti con diversi regimi terapeutici. Ventinovesimo Congresso Nazionale della Società Italiana di Malattie Infettive. Alghero, 10-14 giugno 1997. Pubblicato su: *Giornale Italiano di Malattie Infettive* 1997;3:s172-s173.
  29. Bosi A, Zazzi M, Amantini A, Cellerini M, Vannucchi AM, De Milito A, Guidi S, Saccardi R, Lombardini L, Laszlo D, Rossi Ferrini P. Herpesvirus 6 fatal encephalitis after unrelated bone marrow transplantation. Congresso EBMT 1998. Pubblicato su: *Bone Marrow Transplant* 1998;21:s149 (abstract 316).
  30. Corsi P, Pozzi M, Zazzi M, Buffini G, Incandela L, Savalli E, Leoncini F. Pattern of drug resistance in HIV population. 12th World AIDS Conference, Geneva, June 28-July 3, 1998.
  31. Corsi P, Zazzi M, Buffini G, Farese A, Viganò S, Ambu S, Bartolozzi D. Opportunistic infections in AIDS patients during antiretroviral therapy: 12 months follow up. 12th World AIDS Conference, Geneva, June 28-July 3, 1998.
  32. De Milito A, Sönnnerborg A, Zazzi M, Chiodi F, Samuelsson A. Blocked nerve growth factor activity enhances IgG secretion during polyclonal B cell activation. 10th International Congress of Immunology. New Delhi, November 1-6, 1998.
  33. Leoncini F, Corsi P, Pozzi M, Zazzi M, Farese A, Viganò S, Ambu S, Bartolozzi D. Prevalence of resistance to drugs in HIV-naive patients. Fourth International Congress on Drug Therapy in HIV Infection. Glasgow, November 8-12, 1998. Pubblicato su: *AIDS* 1998;12:s26.
  34. Romano L, Venturi G, Catucci M, Riccio ML, De Milito A, Zazzi M, Valensin PE. Development of resistance to protease inhibitors in HIV-1-infected adults under three-drug therapy. Second National program on AIDS. Progress Report. Rome, July 12-16, 1999.
  35. Corsi P, Ambu S, Bartolozzi D, Pozzi M, Zazzi M, Leoncini F. Genotypic pattern of HIV-1 naive patients and clinical use of HIV-1 drug susceptibility testing. Seventh European Conference on Clinical Aspects and Treatment of HIV-Infection. Lisbon, Portugal. October 23-27, 1999.
  36. Blè C, Lo Caputo S, Peduzzi C, Meacci F, Di Pietro M, Mecocci L, Marino N, Blanc P, Vichi F, Gabbuti A, Zazzi M, Mazzotta F. Genotypic and phenotypic resistance assays in therapeutical options in pluri-experienced patients. Seventh European Conference on Clinical Aspects and Treatment of HIV-Infection. Lisbon, Portugal. October 23-27, 1999.
  37. Vivarelli A, Benvenuti M, Catalani C, Esperti F, Giorgi M, Uberti M, Dionisio D, Zazzi M, Frati E. Una riflessione sull'utilità dello studio delle resistenze farmacologiche. XIII Congresso ANLAIDS sull'AIDS e sindromi correlate. Roma, Palazzo dei Congressi, 26 - 29 Novembre 1999.
  38. Vivarelli A, Breschi R, Giorgi M, Uberti M, Zazzi M, Dionisio D. HIV e farmaco-resistenza: peculiarità di un caso clinico. XIII Congresso ANLAIDS sull'AIDS e sindromi correlate. Roma, Palazzo dei Congressi, 26 - 29 Novembre 1999.
  39. Lo Caputo S, Peduzzi C, Meacci F, Ble' C, Di Pietro M, Gabbuti A, Marino N, Mecocci L, Pierotti P, Zazzi M, Maserati R, Mazzotta F. Performance of genotypic and phenotypic antiretroviral resistance assays in patients pretreated with multiple protease and reverse transcriptase inhibitors 2nd Frankfurt Symposium on the Clinical Implications of HIV Drug Resistance, Frankfurt, Germany, February 25-27, 2000.
  40. Corsi P, Farese A, Pozzi M, Zazzi M, Ambu S, Bartolozzi D, Leoncini F. Utility of HIV genotypic resistance in antiretroviral therapy assessment. 12th World AIDS Conference, Durban, July 9-14, 2000.
  41. Romano L, Venturi G, Incandela L, Valensin PE, Zazzi M. Colonizzazione tardiva dei linfociti da parte di mutanti di HIV resistenti agli inibitori di proteasi. Cortonavirus 2000. Cortona, 15-16 settembre 2000.
  42. Dionisio D, Vivarelli A, Zazzi M, Esperti F, Uberti M. Fattori predittivi di successo terapeutico dopo switches

- genotipo-guidati in pazienti con fallimento di HAART. XIV Convegno Nazionale AIDS e Sindromi Correlate. Milano, 26-28 Novembre 2000.
43. Bocci V, Venturi G, Catucci M, Valensin PE, Zazzi M. A few comments in regard to the use of ozonated autohaemotherapy (O3-AHT) in HIV infection. First Congress of the International Medical Ozone Society. Siena, November 2-4, 2000.
  44. Romano L, Venturi G, Bloor S, Harrigan R, Major JC, Larder BA, Valensin PE, Zazzi M. Ruolo delle mutazioni ai codoni 44 e 118 della RT di HIV1 nella resistenza agli inibitori nucleosidici di RT. Primo Congresso Nazionale della Società Italiana di Virologia. Cortona, 14-15 settembre 2001.
  45. Romano L, Venturi G, Carli T, Corsi P, Pippi L, Valensin PE, Zazzi M. Distribution of drug-resistant HIV-1 variants in plasma RNA and PBMC DNA in patients on therapy and after treatment interruption. XI International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications. Seville, Spain, July 2-5, 2002.
  46. Larder BA, DeGruttola V, Hammer S, Harrigan R, Wegner S, Winslow D, Zazzi M, on behalf of the HIV Resistance Response Database Initiative (RDI). The International HIV Resistance Response Database Initiative: a new global collaborative approach to relating viral genotype and treatment to clinical outcome. XI International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications. Seville, Spain, July 2-5, 2002.
  47. Wang D, DeGruttola V, Hammer S, Harrigan R, Larder B, Wegner S, Winslow D, Zazzi M, on Behalf of The HIV Resistance Response Database Initiative (RDI). A Collaborative HIV Resistance Response Database Initiative: Predicting Virological Response Using Neural Network Models. XI International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications. Seville, Spain, July 2-5, 2002.
  48. De Milito A, Aleman S, Marenzi R, Sönnnerborg A, Fuchs D, Zazzi M, Chiodi F. Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-1-infected subjects. XIV International AIDS Conference. Barcelona, July 7-12, 2002.
  49. Dionisio D, Vivarelli A, Zazzi M, Esperti F, Fabbri C, Giorni M, Menichini B. Sustained immunologic response while continuing on antiretroviral therapy despite virological failure. XIV International AIDS Conference. Barcelona, July 7-12, 2002.
  50. Romano L, Venturi G, Carli T, Corsi P, Pippi L, Valensin PE, Zazzi M. Divergent distribution of HIV-1 drug-resistant variants on and off antiretroviral therapy. Secondo Congresso Nazionale della Società Italiana di Virologia. Cortona, 17-19 settembre 2002.
  51. Pianese M, Zacchini F, Toti M, Zazzi M, Mannino R, Valensin PE, Caudai C. Ruolo del genotipo di HCV nella coinfezione HIV/HCV in soggetti sottoposti ad HAART. Secondo Congresso Nazionale della Società Italiana di Virologia. Cortona, 17-19 settembre 2002.
  52. Zazzi M, Romano L, Venturi G, Valensin PE. Use of an in-house Windows-based desktop program for prediction of drug susceptibility from HIV genotype. First European HIV Drug Resistance Workshop. Luxembourg, March 6-8, 2003.
  53. Torti C, de Luca A, Gianotti N, Zazzi M, Balotta C, Regazzi-Bonora M, Carosi G. Setting-up guidelines for clinical application of HIV drug resistance testing and therapeutic drug monitoring: an Italian experience. First European HIV Drug Resistance Workshop. Luxembourg, March 6-8, 2003.
  54. Wensing AMJ, van de Vijver DAMC, Asjo B, Balotta C, Camacho R, de Mendoza C, Deroo S, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hoepelman A, Horban A, Korn K, Kuecherer C, Nielsen C, Ormaasen V, Perrin L, Paraskevis D, Puchhammer E, Roman F, Salminen M, Schmit JCC, Soriano V, Stanczak G, Stanojevic M, Vandamme A-M, Van Laethem K, Violin M, Yerly S, Zazzi M, Boucher CAB on behalf of the SPREAD Programme. Prevalence of transmitted drug resistance in Europe is largely influenced by the presence of non-B sequences: analysis of 1400 patients from 16 countries: the CATCH-Study. XII International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications. Cabo del Sol, Los Cabos, Mexico, June 10-14, 2003.
  55. Wensing AMJ, van de Vijver DAMC, Asjo B, Balotta C, Camacho R, de Mendoza C, Deroo S, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hoepelman A, Horban A, Korn K, Kuecherer C, Nielsen C, Ormaasen V, Perrin L, Paraskevis D, Puchhammer E, Roman F, Salminen M, Schmit JCC, Soriano V, Stanczak G, Stanojevic M, Vandamme A-M, Van Laethem K, Violin M, Yerly S, Zazzi M, Boucher CAB on behalf of the SPREAD Programme. Analysis from more than 1600 newly diagnosed patients with HIV from 17 European countries shows that 10% of the patients carry primary drug-resistance: the CATCH study. 2nd IAS Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris, France. Abstract LB1.
  56. Romano L, Razzolini F, Venturi G, Valensin PE, Zazzi M. Circulation and clinical significance of HIV-1 non-B subtypes. 3rd National Congress of the Italian Society of Virology. Cortona, Italy, September 22-24, 2003.

57. Valente M, Zazzi M, Francisci D, Luccheto ML, Baldelli F, Stagni G. Epidemiologia delle resistenze genotipiche e dei sottotipi di HIV-1 in Umbria. II Congresso Nazionale SIMIT. Bologna, 24-27 settembre 2003.
58. Corsi P, Prieto M, Pozzi M, Bartolozzi D, Farese A, Mazzetti M, Zazzi M. Farmacoresistenza di HIV: considerazioni cliniche e farmaco-economiche. II Congresso Nazionale SIMIT. Bologna, 24-27 settembre 2003.
59. Wensing AMJ, van de Vijver DAMC, Angarano G, Asjo B, Balotta C, Boeri E, Camacho R, de Luca A, Maljkovic I, de Mendoza C, Deroo S, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hoepelman AIM, Horban A, Korn K, Kuecherer C, Leitner T, Loveday C, Macrae E, Nielsen C, Ormaasen V, Perrin L, Paraskevis D, Puchhammer E, Roman F, Ruiz L, Salminen M, Schmit JCC, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme A, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M and Boucher CAB on behalf of the SPREAD Programme. Drug susceptibility patterns in 196 European patients de novo infected with drug resistant virus: implications for Post-Exposure Prophylaxis. 9th European AIDS Conference. Warsaw, October 25-29, 2003.
60. Balotta C, Riva C, Romano L, Deho L, Venturi G, Galli M, Valensin PE, Zazzi M. Female gender and heterosexual mode of infection are associated with high level of HIV-1 subtypes diversity in Italy. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, February 8-11, 2004.
61. Balotta C, Riva C, Romano L, Razzolini F, Deho L, Corvasce S, Venturi G and Zazzi M. High prevalence and high heterogeneity of HIV-1 non-B subtypes in Italian females and heterosexuals with known seroconversion date. 2nd European HIV Drug Resistance Workshop: From Basic Science to Clinical Implications. Rome, March 11-13, 2004.
62. Paolucci S, Baldanti F, Zazzi M, Zavattoni M, Maga G, Gerna G. Q145M/L mutations in HIV-1 RT cause high levels of resistance to NRTI and NNRTI and impaired virus replication. 2nd European HIV Drug Resistance Workshop: From Basic Science to Clinical Implications. Rome, March 11-13, 2004.
63. Riva C, Dehò L, Romano L, Razzolini F, Galli M, Valensin PE, Zazzi M and Balotta C. Increasing prevalence and high heterogeneity of HIV-1 strains in an Italian clade-B previously restricted area by phylogenetic analysis of pol gene. 11th International Workshop on HIV Dynamics and Evolution, Stockholm, April 29-May 2, 2004.
64. Balotta C, Corvasce S, Romano L, Violin M, Razzolini F, Vicenti I, Marconi A, Macchiesi C, Machetti S, Galli A, Duca P and Zazzi M. Evidence of differential selection of HIV-1 variants carrying drug-resistant mutations in seroconverters. XIII International HIV Drug Resistance Workshop: Basic Principles et Clinical Implications, Tenerife, Canary Islands, Spain, June 8-12 2004.
65. van de Vijver DAMC, Wensing AMJ, Angarano G, Asjo B, Balotta C, Boeri E, Camacho R, Chaix M-L, Costagliola D, Op de Coul E, de Luca A, Maljkovic I, de Mendoza C, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hoepelman AIM, Hemmer R, Horban A, Korn K, Kuecherer C, Leitner T, Loveday C, Macrae E, Nielsen C, Ormaasen V, Perrin L, Paraskevis D, Puchhammer E, Ruiz L, Salminen M, Schmit JCC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme A, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M and Boucher CAB on behalf of the SPREAD Programme. The calculated genetic barrier for drug resistance mutations in six different non-B subtypes and two different CRFs in a large European dataset is largely similar to subtype B. XIII International HIV Drug Resistance Workshop: Basic Principles et Clinical Implications, Tenerife, Canary Islands, Spain, June 8-12 2004.
66. Tordini G, Giaccherini R, Trezzi M, Barberi A, Zazzi M. Contributo della Polymerase Chain Reaction alla diagnosi di Leishmaniosi. Terzo Congresso Nazionale SIMIT. Firenze, 11-14 ottobre 2004.
67. Corsi P, Giuntini R, Zazzi M, Bartolozzi D, Ambu S, Leoncini F. Ceppi non-B di HIV-1 nel territorio fiorentino: primi dati di prevalenza. XVIII Convegno Nazionale AIDS e Sindromi Correlate. Milano, 28-30 Novembre 2004.
68. Corvasce S, Violin M, Romano L, Razzolini F, Vicenti I, Marconi A, Macchiesi C, Machetti S, Galli A, Duca P, Balotta C, Zazzi M. Studio delle forze selettive coinvolte nella trasmissione delle mutazioni di HIV-1 associate a farmaco-resistenza in soggetti recentemente sierconvertiti. XVIII Convegno Nazionale AIDS e Sindromi Correlate. Milano, 28-30 Novembre 2004.
69. Riva C, Galli A, Corvasce S, Romano L, Razzolini F, Dehò L, Venturi G, Zazzi M, Balotta C. Elevato incremento ed eterogeneità dei ceppi di HIV-1 di sottotipo non-B, delle forme ricombinanti circolanti (CRF) e uniche (URF) in una casistica di soggetti a sier conversione nota. XVIII Convegno Nazionale AIDS e Sindromi Correlate. Milano, 28-30 Novembre 2004.
70. De Luca A, Di Gianbenedetto S, Romano L, Gonnelli A, Corsi P, Baldari M, Di Pietro M, Menzo S, Francisci D, Almi P, Zazzi M. Prevalence and predictors of thymidine analog mutations (TAM) patterns in HIV-1 from patients failing antiretroviral therapy: finding from the ARCA cohort study. Third European HIV Drug Resistance Workshop. Athens, March 30 – April 1, 2005. Abstract 59.
71. Gianotti N, Almi P, Trezzi M, Butini L, Corsi P, Di Pietro M, Giacometti A, Gonnelli A, Menzo S, Romano L, Pezzotti P, Zazzi M. Prevalence and pharmacological determinants of genotypic resistance to atazanavir (ATV) in protease inhibitor-experienced, ATV-naive, HIV-infected patients in a large Italian database (ARCA). Third

- European HIV Drug Resistance Workshop. Athens, March 30 – April 1, 2005. Abstract 74.
72. Riva C, Dehò L, Galli A, Corvasce S, Colombo M, Rossi C, Rezza G, Romano L, Zazzi M, Balotta C. High prevalence and heterogeneity of HIV-1 non B subtypes and recombinant forms in Italy. Third European HIV Drug Resistance Workshop. Athens, March 30 – April 1, 2005. Abstract 29.
  73. van de Vijver DAMC, Wensing AMJ, Angarano G, Asjo B, Balotta C, Boeri E, Camacho R, Chaix M-L, Costagliola D, Op de Coul E, de Luca A, Maljkovic I, de Mendoza C, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hoepelman AIM, Hemmer R, Horban A, Korn K, Kuecherer C, Leitner T, Loveday C, Macrae E, Nielsen C, Ormaasen V, Perrin L, Paraskevis D, Puchhammer E, Ruiz L, Salminen M, Schmit JCC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme A, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M and Boucher CAB on behalf of the SPREAD Programme. Potential impact of differences in frequency of minor substitutions between HIV-1 subtypes on the genetic barrier for resistance to protease inhibitors. Third European HIV Drug Resistance Workshop. Athens, March 30 – April 1, 2005. Abstract 27.
  74. Parisi SG, Zazzi M, Dal Bello F, Manfrin V, Carolo G, Nicolini G, Gatti F, Boldrin C, Franchin E, Palù G. HIV-proviral DNA and plasma-RNA sequencing for detection of drug resistance mutations in antiretroviral naive patients. 15th European Congress of Clinical Microbiology and Infectious Diseases. Copenhagen, Denmark, April 2-5, 2005.
  75. Prospero M, Zazzi M, Perno CF, Di Giambenedetto S, Baxter J, Ruiz L, Clevenbergh P, Ulivi G, Antinori A, De Luca A for the ARCA cohort, INMI cohort, Argenta, Gart, Havana and Viradapt Study Groups. 'Common law' applied to treatment decisions for drug resistant HIV. XVI HIV Drug Resistance Workshop. Quebec City, Canada, June 7-11, 2005.
  76. van de Vijver DAMC, Wensing AMJ, Angarano G, Åsjö B, Balotta C, Boeri E, Camacho R, Chaix M-L, Costagliola D, Op de Coul ELM, de Luca A, Maljkovic I, de Mendoza C, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hoepelman IM, Hemmer R, Horban A, Korn K, Kücherer C, Leitner T, Loveday C, MacRae E, Meyer L, Nielsen C, Ormaasen V, Perrin L, Paraskevis D, Puchhammer-Stöckl E, Ruiz L, Salminen M, Schmit JCC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme A-M, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CAB on behalf of the SPREAD Programme. Differences in the frequency of minor substitutions between HIV-1 subtypes and their potential impact on the genetic barrier for resistance to protease inhibitors. XVI HIV Drug Resistance Workshop. Quebec City, Canada, June 7-11, 2005.
  77. Parisi SG, Mazzi R, Zazzi M, Manfrin V, Nicolini G, Carolo G, Boldrin C, Franchin E, Dal Bello F, Gatti F, Palù G. HIV-proviral DNA and plasma-RNA sequencing for detection of drug resistance mutations in antiretroviral naive patients. 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, July 24-27, 2005.
  78. Prospero M, Zazzi M, Gonnelli A, Trezzi M, Corsi P, Morfini M, Nerli A, De Gennaro M, Giacometti A, Ulivi G, Di Giambenedetto S, De Luca A. Modelling in-vivo HIV evolutionary mutational pathways under AZT-3TC regimen through Markov Chains. BioSapiens-viRgil Workshop on Bioinformatics for Viral Infections. Bonn, September 21-23, 2005.
  79. Galli A, Lai A, Corvasce S, Saladini F, Riva C, Deho L, Romano L, Galli M, Zazzi M, Balotta C. Recombination break-points detected in C-terminal protease and N-terminal RT regions of HIV-1 unique recombinant forms do not influence viral replication capability. 13th Conference on Retroviruses and Opportunistic Infections. Denver, February 5-8, 2006.
  80. Micheli V, Meraviglia P, Romano L, Vicenti I, Cordier L, Jacchetti G, Cargnel A, Zazzi M. Development and evolution of genotypic resistance to T20. Fourth European HIV Drug Resistance Workshop. Monte Carlo, March 29-31, 2006.
  81. Gianotti N, Trezzi M, Gonnelli A, De Luca A, Di Gianbenedetto S, Di Pietro M, Menzo S, Corsi P, Boeri E, Paolini E, Pezzotti P, Zazzi M, ARCA Collaborative Group. Increasing exposure to some protease inhibitors (PIs) predicts increasing genotypic resistance to tipranavir (TPV) in PI-experienced, TPV-naive, HIV-infected patients in a large Italian database (ARCA). Fourth European HIV Drug Resistance Workshop. Monte Carlo, March 29-31, 2006.
  82. van de Vijver DAMC, Wensing AMJ, Åsjö B, Bruckova M, Brun-Vézinet F, Bruun Jorgensen L, Camacho R, Horban A, Linka M, Lazanas M, Loveday C, MacRae E, Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Ruiz L, Schmit JC, Stanczak G, Stanojevic M, Vandamme A-M, Vercauteren J, Zazzi M, Boucher CAB on behalf of the SPREAD Programme. Substantial concordance for predicting susceptibility to antiretroviral drugs in 2000 isolates using three European HIV drug resistance interpretation systems. Fourth European HIV Drug Resistance Workshop. Monte Carlo, March 29-31, 2006.
  83. van de Vijver DAMC, Wensing AMJ, Åsjö B, Bruckova M, Bruun Jorgensen L, Camacho R, Horban A, Linka M, Lazanas M, Loveday C, MacRae E, Nielsen C, Paraskevis D, Poljak D, Puchhammer-Stöckl E, Ruiz L, Schmit JC, Stanczak G, Stanojevic M, Vandamme A-M, Vercauteren J, Zazzi M, Boucher CAB on behalf of the SPREAD

- Programme. Patterns of predicted drug susceptibility and its change over time among 2000 isolates across Europe. Fourth European HIV Drug Resistance Workshop. Monte Carlo, March 29-31, 2006.
84. Paraskevis D, Rambaut A, Magiorkinis G, Hatzakis A, Wensing AMJ, van de Vijver DA, Angarano G, Åsjö B, Balotta C, Boeri E, Camacho R, Chaix M-L, Costagliola D, de Luca A, de Mendoza C, Derdelinckx I, Grossman Z, Hamouda O, Hemmer R, Hoepelman IM, Horban A, Korn K, Kücherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, Meyer L, Nielsen C, Op de Coul ELM, Ormaasen V, Perrin L, Puchhammer-Stöckl E, Ruiz L, Salminen M, Schmit JCC, Roman F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme A-M, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CA, Vandamme A-M for the CATCH Programme. Estimation of HIV-1 subtype B Migration within Europe based on phylogenetic analyses of 1101 sequences. Fourth European HIV Drug Resistance Workshop. Monte Carlo, March 29-31, 2006.
  85. Violin M, Galli A, Corvasce S, Vellica R, Caramma I, Franzetti M, Andreoni M, Antinori A, Bruzzone B, Micheli V, Monno L, De Luca A, Ceccherini-Silberstein F, Palmisano L, Zazzi M, Balotta C for the START Study. Study of antiretroviral resistance in treated patients with virological failure (START study): an Italian survey over the period 2003–2005. XV International HIV Drug Resistance Workshop. Sitges (Spain), June 13-17, 2006.
  86. Galli A, Lai A, Romano L, Riva C, Violin M, Saladini F, Dehò L, Franzetti M, Zazzi M, Balotta C. Identification of recombination hotspots and RNA hairpins at 3'-end of RT fingers region of unique recombinant forms. XV International HIV Drug Resistance Workshop. Sitges (Spain), June 13-17, 2006.
  87. De Luca A, Perno CF, Ceccherini-Silberstein F, Romano L, Corsi P, Gonnelli A, Martinelli C, Chiodera A, De Gennaro M, Vivarelli A, Trezzi M, Almi P, Punzi G, Monno L, Zazzi M for the ARCA Collaborative Group. Polymorphisms in the viral reverse transcriptase predict the evolution towards distinct thymidine analogue mutational patterns: a longitudinal analysis. XV International HIV Drug Resistance Workshop. Sitges (Spain), June 13-17, 2006.
  88. Larder B, Montaner J, Harrigan R, Revell A, Wang D, Baxter J, Emery S, Gatell J, Geretti AM, Perez-Elias MJ, Ruiz L, Torti C, Zazzi M, Wegner S, Lane H.C. Harnessing the power of artificial intelligence to optimise individual salvage therapy. XVI International AIDS Conference. Toronto, 13-18 August 2006.
  89. Velleca R, Corvasce S, Violin M, Galli A, Andreoni M, Antinori A, Monno L, De Luca A, Ceccherini-Silberstein F, Palmisano L, Zazzi M, Balotta C for the START Study. Studio multicentrico per la valutazione della prevalenza dei ceppi di HIV-1 resistenti nella popolazione trattata (START: study of antiretroviral resistance in treated patients with virological failure). Quinto Congresso Nazionale SIMIT. Taormina, 11-14 ottobre 2006.
  90. Ventura A, Bisio F, Nigro N, Bomba A, Mayinda FA, Miguel LM, Nzagou AC, Moudilou LF, Ratto S, Icardi G, Zazzi M, Viscoli C, Bruzzone B. Difficoltà diagnostiche nell'ambito della diagnosi precoce nella trasmissione materno infantile dell'HIV-1 nei paesi in via di sviluppo. Quinto Congresso Nazionale SIMIT. Taormina, 11-14 ottobre 2006.
  91. Rosen-Zvi M, Neuvirth H, Aharoni E, Zazzi M, Tishby N. Consistent dimensionality reduction scheme and its application to clinical HIV data. NIPS 2006 workshop: Novel Applications of Dimensionality Reduction. Whistler, Canada, December 9, 2006.
  92. Rusconi S, Gianotti N, Adorni F, Boeri E, Menzo S, Gonnelli A, Micheli V, Meraviglia P, Trezzi M, Paolini E, Giacometti A, Corsi P, Di Pietro M, Monno L, Punzi G, Zazzi M. Determinants of genotypic resistance to darunavir (TMC114) in a large Italian resistance database (ARCA). Fifth European HIV Drug Resistance Workshop. Cascais, March 28-30, 2007.
  93. Prosperi M, Corsi P, Di Giambenedetto S, Zazzi M, Callegaro A, Maggiolo F, Francisci D, Trezzi M, Di Pietro M, De Luca A. First-line HAART failures: genotypic HIV-1 resistance patterns and response to second-line therapies in the ARCA cohort. Fifth European HIV Drug Resistance Workshop. Cascais, March 28-30, 2007.
  94. Di Giambenedetto S, De Luca A, Prosperi M, Nasta P, Parainfo G, Ladina N, Zazzi M, Trezzi M, Corsi P, Carosi G. Efficacy of antiretroviral regimens containing abacavir (ABC) and tenofovir (TDF) in treatment-experienced patients: predictors of response and drug resistance evolution in failing patients. Fifth European HIV Drug Resistance Workshop. Cascais, March 28-30, 2007.
  95. Galli A, Lai A, Romano L, Riva C, Violin M, Saladini F, Dehò L, Franzetti M, Zazzi M, Balotta C. Recombination hotspots and underlying RNA hairpins in the pol gene of HIV-1 may facilitate the independent evolution of regions involved in drug resistance. Fifth European HIV Drug Resistance Workshop. Cascais, March 28-30, 2007.
  96. Peres Y, Ber groth T, Denholm-Price J, Incardona F, Kaiser R, Kent C, Prosperi M, Schuelter E, Sonnerborg A, Zazzi M. EuResist: Integrating and exchanging European HIV data. AREVIR-GENAFOR Meeting. Bonn, April 19-20, 2007.
  97. Altmann A, Däumer M, Sing T, Beerenwinkel N, Schülter E, Peres Y, Sonnerborg A, Zazzi M, Kaiser R, Lengauer T. Geno2pheno-THEO: predicting response to combination ART on a large independent dataset. AREVIR-

- GENAFOR Meeting. Bonn, April 19-20, 2007.
98. Rosen-Zvi M, Aharoni E, Altmann A, Kaiser R, Lengauer T, Neuvirth H, Prosperi M, Bazsó F, Incardona F, Zazzi M. EuResist: European data – European interpretation systems. AREVIR -GENAFOR Meeting. Bonn, April 19-20, 2007.
  99. Aharoni E, Altmann A, Borgulya G, D'Autilia R, Incardona F, Kaiser R, Kent C, Lengauer T, Neuvirth H, Peres Y, Petroczi A, Prosperi M, Rosen-Zvi M, Schülter E, Sing T, Sönnernborg A, Thompson R, Zazzi M. Integration of Viral Genomics with Clinical Data to Predict Response to Anti-HIV Treatment. IST-Africa. Maputo, Mozambique. May 9-11, 2007.
  100. Razzolini F, Saladini F, Vicenti I, Romano L, Zazzi M. Increasing circulation and diversification of HIV-1 non-B subtypes in Italy over a 10-year observation period. Seventh Congress of the Italian Society of Virology. Orvieto, June 24-26, 2007.
  101. Caudai C, Meini G, Toti M, Zazzi M. Lack of selection of lamivudine-resistant mutants in HBV/HIV coinfection during lamivudine-including antiretroviral therapy. Seventh Congress of the Italian Society of Virology. Orvieto, June 24-26, 2007.
  102. Fanti I, De Luca A, Zazzi M, Ulivi G, Micarelli A, Prosperi MCF. Improved HIV-1 coreceptor usage prediction indexed BLAST-based local smoothing kernel methods, rules and decision trees with grid multiple statistical validation. XVI International HIV Drug Resistance Workshop. Barbados, June 12-16, 2007.
  103. Altmann A, Sing T, Vermeiren H, Winters B, Van Craenenbroeck E, Van der Borgh K, Rhee SY, Shafer RW, Schülter E, Kaiser R, Peres Y, Sonnerborg A, Fessel WJ, Incardona F, Zazzi M, Bachelier L, Van Vlijmen H, Lengauer T. Inferring Virological Response from Genotype: With or without “intermediate” predicted phenotypes? XVI International HIV Drug Resistance Workshop. Barbados, June 12-16, 2007.
  104. Caramma I, Violin M, Velleca R, Corvasce S, Franzetti M, Antinori A, Bonora S, Callegaro AP, Capetti A, Bruzzone B, De Luca A, Ceccherini-Silberstein F, Gianotti N, Maggiolo F, Monno L, Mazzotta F, Micheli V, Torti C, Zazzi M, Balotta C for the START Study. Study of Antiretroviral Resistance in Treated Patients with Virological Failure (START Study): Temporal Trends of Class Resistance Evaluated in Patients Failing Last HAART. XVI International HIV Drug Resistance Workshop. Barbados, June 12-16, 2007.
  105. Caramma I, Violin M, Velleca R, Corvasce S, Franzetti M, Andreoni M, Antonelli G, Ceccherini-Silberstein F, Di Giambenedetto S, Lo Caputo S, Maserati R, Re MC, Sacchi P, Saracino A, Sighinolfi L, Paolucci S, Trotta MP, Vullo V, Zazzi M, Balotta C. Temporal Trends of Resistance in Patients Failing Last HAART in the Italian START Study (Study of Antiretroviral Resistance in Treated Patients with Virological Failure). 11th European AIDS Conference/EACS. 24-27 October 2007, Madrid, Spain.
  106. Di Vincenzo P, Rusconi S, Adorni F, Vitiello P, Maggiolo F, Francisci D, Di Biagio A, Monno L, Antinori A, Boeri E, Punzi G, Perno CF, Callegaro A, Bruzzone B, Zazzi M on behalf of the ARCA Collaborative Group. Prevalence of mutations and determinants of genotypic resistance to Etravirine (tmc125) in a large Italian resistance database (ARCA). Sixth European HIV Drug Resistance Workshop. 26 – 28 March, 2008, Budapest, Hungary.
  107. Ferramosca S, Vitiello P, Rossotti R, Di Vincenzo P, Viganò O, Capasso M, Lo Cicero M, Galli M, Moroni M, Zazzi M, Micheli V, Rusconi S. HIV gp41 resistance evolution in subjects treated with salvage therapy including a potent boosted PI and the cyclic use of enfuvirtide. Sixth European HIV Drug Resistance Workshop. 26 – 28 March, 2008, Budapest, Hungary.
  108. Di Giambenedetto S, Prosperi M, Bracciale L, Callegaro AP, Maggiolo F, Di Garbo A, Bruzzone B, Bonora S, Baldanti F, Francisci D, Menzo S, Colao G, Zazzi M, Monno L, De Luca A. Validation and implementation of clinically relevant interpretation rules of HIV-1 genotypic resistance for atazanavir/ritonavir in HAART experienced patients. Sixth European HIV Drug Resistance Workshop. 26 – 28 March, 2008, Budapest, Hungary.
  109. Altmann A, Rosen-Zvi M, Prosperi M, Aharoni E, Neuvirth H, Schuelter E, Buch J, Peres Y, Incardona F, Sonnerborg A, Kaiser R, Zazzi M, Lengauer T. The EuResist approach for predicting response to anti HIV-1 therapy. Sixth European HIV Drug Resistance Workshop. 26 – 28 March, 2008, Budapest, Hungary.
  110. Rosen-Zvi M, Schuelter E, Altmann A, Sierra-Aragon S, Zazzi M, Sonnerborg A, Oette M, Lengauer T, Kaiser R on behalf of the EuResist Group. Sustaining lamivudine/emtricitabine, abacavir, zidovudine or atazanavir from a previous treatment shows a clinical benefit. XVII International HIV Drug Resistance Workshop. Sitges, June 10-14, 2008.
  111. De Luca A, Di Giambenedetto S, Marando F, Maserati R, Gianotti N, Narciso P, Antinori A, Di Perri G, Baldanti F, Zazzi M, Perno CF, Santoro MM for the TMC114-C226 and the ARCA study groups. Improved interpretation and clinical validation of substitutions in HIV-1 protease predicting the virological response to darunavir/ritonavir. XVII International HIV Drug Resistance Workshop. Sitges, June 10-14, 2008.

112. Di Giambenedetto S, Prosperi M, Bracciale L, Callegaro MP, Maggiolo F, Di Garbo A, Bruzzone B, Bonora S, Baldanti F, Francisci D, Zazzi M, Monno L, De Luca A. A rigorous statistical learning method for the estimation and validation of weighted drug susceptibility scores applied to in vivo virological outcome prediction of atazanavir/ritonavir containing HAART. XVII International HIV Drug Resistance Workshop. Sitges, June 10-14, 2008.
113. Gianotti N, Galli L, Zazzi M, Ghisetti V, Bonora S, Micheli V, Meraviglia P, Corsi P, Bruzzone B, Menzo S, Di Giambenedetto S, De Luca A, Filice G, Penco G, Castagna A, a nome del database ARCA. Le mutazioni 33F e 46I della proteasi predicono l'assenza di recupero immunologico a lungo termine, indipendentemente dell'efficacia del nuovo regime, in pazienti con infezione da HIV in fallimento virologico. Risultati dal database ARCA. Settimo Congresso Nazionale SIMIT – Bergamo, 19-22 novembre 2008.
114. Maserati R, De Silvestri A, Uglietti A, Colao G, Di Biagio A, Bruzzone B, Di Pietro M, Re MC, Tinelli C, Zazzi M and ARCA Study Group. Emerging Mutations at Failure of HAART Containing Lamivudine/Tenofovir or Emtricitabine/Tenofovir: The ARV Resistance Cohort Analysis Database. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, February 9-11, 2009.
115. Balotta C, Casazza G, Antinori A, Bonora S, De Luca A, Ceccherini-Silberstein F, Spagnuolo V, Lapadula G, Callegaro A, Zazzi M. Decreasing Temporal Trends of Class Resistance in a Multicenter National-based Study over a 5-Year Interval. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, February 9-11, 2009.
116. Frenzt D, Boucher CAB, Assel M, Bubak M, De Luca A, Incardona F, Libin P, Ruiz L, Sloot P, Torti C, Vandamme AM, Zazzi M, Van de Vijver DAMC. Predicting virological response using genotypic approaches for tenofovir. 7th European HIV Drug Resistance workshop. 25-27 March 2009, Stockholm, Sweden.
117. Prosperi M, Rosen\_Zvi M, Altmann A, Aharoni E, Peres Y, Sonnerborg A, Incardona F, Struck D, Kaiser R, Zazzi M. Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models. 7th European HIV Drug Resistance workshop. 25-27 March 2009, Stockholm, Sweden.
118. Bracciale L, Fabbiani M, Razzolini F, Balestrieri M, Colafigli M, Marzocchetti A, Di Gianbenedetto S, Zazzi M, De Luca A. Baseline and follow-up gp120-V3 genotyping using plasma viral RNA and whole blood viral DNA in patients whose viral tropism had been determined by the enhanced sensitivity Trofile. 7th European HIV Drug Resistance workshop. 25-27 March 2009, Stockholm, Sweden.
119. De Luca A, Di Giambenedetto S, Marando F, Maserati R, Gianotti N, Narciso P, Antinori A, Di Perri G, Baldanti F, Micheli V, Zazzi M, Perno CF, Santoro MM, for the TMC114-C226 and the ARCA study groups. Validation of available rules and update of a new genotypic score for HIV-1 protease substitutions predicting the virological response to darunavir/ritonavir. 7th European HIV Drug Resistance workshop. 25-27 March 2009, Stockholm, Sweden.
120. Altmann A, Thielen A, Frenzt D, Van Laethem K, Bracciale L, Incardona F, Sönnnerborg A, Zazzi M, Kaiser R, Lengauer T. Keeping models that predict response to antiretroviral therapy up-to-date: fusion of pure data-driven approaches with rules-based methods. 7th European HIV Drug Resistance workshop. 25-27 March 2009, Stockholm, Sweden.
121. Vandekerckhove L, Wensing AMJ, Kaiser R, Brun-Vézinet F, Clotet B, De Luca A, Dressler S, Garcia F, Geretti A, Klimkait T, Korn K, Masquelier B, Perno C, Schapiro JM, Sönnnerborg A, Vandamme AM, Walter H, Zazzi M and Boucher CAB. Clinical management of HIV-1 tropism testing: development of European Guidelines. 7th European HIV Drug Resistance workshop. 25-27 March 2009, Stockholm, Sweden.
122. Sangeda RZ, Deforche K, Vercauteren J, Libin P, Imbrechts S, Theys K, Grossman Z, Camacho R, Van Laethem K, Zazzi M, Sönnnerborg A, Kaiser R, De Luca A, Torti C, Ruiz L, van de Vijver D, Shafer RW, Van Wijngaerden E, Vandamme AM, for the Virolab and EuResist projects. Evaluation of longitudinal fitness landscapes in prediction of treatment outcome in a clinical dataset of HIV-1 treated patients. 7th European HIV Drug Resistance workshop. 25-27 March 2009, Stockholm, Sweden.
123. Altmann A, Weisser H, Incardona F, Sonnerborg A, Zazzi M, Kaiser R, Lengauer T, Walter H. Do not blame the fitness! - Only slight impact of predicted replicative capacity for therapy response prediction. 7th European HIV Drug Resistance workshop. 25-27 March 2009, Stockholm, Sweden.
124. Riva C, Galli A, Saladini F, Lai A, Oliva A, Caramma I, Vicenti I, Razzolini F, Balotta C, Zazzi M. Increasing prevalence and diversity of HIV-1 non-B subtypes, circulating and unique recombinant forms in Italy. 7th European HIV Drug Resistance workshop. 25-27 March 2009, Stockholm, Sweden.
125. Micheli V, Zazzi M, Meraviglia P, Corsi P, Gonnelli A, Penco G, Callegaro A, Maggiolo F, Gianotti N, Calza L, Butini L, Casazza G, Gismondo MR. HIV-1 pol evolution under lamivudine pressure. 19th European Congress of Clinical Microbiology and Infectious Diseases. Helsinki, 16 - 19 May 2009.

126. Svicher V, Armenia D, Santoro MM, Forbici F, Bruzzone B, Setti M, Corsi P, Maserati R, Mussini C, Zazzi M, De Luca A, Andreoni M, Narciso P, Antinori A, Perno CF, Ceccherini-Silberstein F. Impact of mutations at position 135 of HIV-1 reverse transcriptase on virologic response to a first line NNRTI-containing HAART. ICAR 2009 – Italian Conference on AIDS and Retroviruses. Milano 24-26 Maggio 2009.
127. Santoro M, Ceccherini Silberstein F, Forbici F, Zaccarelli M, Boumis E, Palamara G, Callegaro A, Francisci D, Carnevale G, Maggiolo F, Narciso P, Antinori A, Zazzi M, Mussini C. Evaluation of drug resistance emergence in HIV-1 infected patients failing a first-line highly active antiretroviral therapy containing NNRTIs with or without thymidine analogues. ICAR 2009 – Italian Conference on AIDS and Retroviruses. Milano 24-26 Maggio 2009.
128. Polilli E, Manzoli L, Cosentino L, Corsi P, Punzi G, Monno L, Trezzi M, Francisci D, Zazzi M, Parruti G. Comparison of the duration of first and second HAART lines in patients undergoing HIV-resistance testing in 2000-2001 vs 2005-2006 in the ARCA database. ICAR 2009 – Italian Conference on AIDS and Retroviruses. Milano 24-26 Maggio 2009.
129. Balotta C, Violin M, Casazza G, Antinori A, Bonora S, De Luca A, Capetti A, Ceccherini-Silberstein F, Micheli V, Spagnuolo V, Bruzzone B, Torti C, Callegaro AP, Zazzi M for the START Study. Decreasing temporal trends of class resistance in a multicenter national based study (START study) over the 2003-2007 period. ICAR 2009 – Italian Conference on AIDS and Retroviruses. Milano 24-26 Maggio 2009.
130. Di Giambenedetto S, Bracciale L, Fabbiani M, Razzolini F, Balestrieri M, Colafigli M, Marzocchetti A, Zazzi M, De Luca A. Correlation between viral trpism determined by Trofile phenotypic assay and gp120-V3 genotyping of HIV RNA and DNA in 37 patients at baseline and during follow-up. ICAR 2009 – Italian Conference on AIDS and Retroviruses. Milano 24-26 Maggio 2009.
131. Prosperi MCF, Rosen-Zvi M, Altmann A, Aharoni E, Peres Y, Sönnnerborg A, Incardona F, Struck D, Kaiser R, Zazzi M for the EuResist study Group. Prediction Of Antiretroviral Therapy Outcomes In Poor Resource Countries: Comparison Between Genotype Resistance Testing Based vs. Treatment History Models. Fifth EDCTP Forum. Arusha, Tanzania, October 12-14, 2009.
132. Incardona F, Aris E, Janabi M, Swai A, Mugusi F, Bakari M, Nagu T, Mugusi S, Wondwossen A, Aderaye G, Lindquist L, Sönnnerborg A, Bontell I, Zazzi M, Kaiser R, Lengauer T, Prosperi M, Altmann A, Sandstrom E. Expanding the world's largest HIV drug resistance database, EuResist, into an African context. Fifth EDCTP Forum. Arusha, Tanzania, October 12-14, 2009.
133. Theys, K., Sangeda, RZ, Camacho R, Clotet B, Van Laethem K, Zazzi M, Sonnerborg A, Kaiser R, De Luca A, Torti C, Wensing AMJ, Stanczak G, Linka M, Poljak M, Lepej SZ, Van Wijngaerden E., Verhofstede C, Rhee S-Y, Vandamme AM for the EHR, Virolab, EuResist and BREACH Projects. Untangling pathways to tipranavir resistance in patients infected with various HIV-1 subtypes. 12th European AIDS Conference/EACS, 11-14 November 2009, Cologne, Germany. Abstract PE7.4/9.
134. Vandekerckhove L, Wensing AMJ, Kaiser R, Brun-Vezinet F, Clotet B, De Luca A, Dressler S, Garcia F, Geretti AM, Klimkait T, Korn K, Masquelier B, Perno CF, Schapiro JM, Sonnerborg A, Soriano V, Vandamme AM, Walter H, Zazzi M, Boucher CAB on behalf of the European Consensus Group on clinical management of tropism testing. European consensus on clinical use and interpretation of HIV-1 tropism testing. 12th European AIDS Conference/EACS, 11-14 November 2009, Cologne, Germany. Abstract LBPE1.2/9.
135. Di Giambenedetto S, Dunn D, Zazzi M, Fanti I, Camacho R, Manca N, Kaiser R, Sonnerborg A, Codoner FM, Van Laethem K, Bansi L, Ghisetti V, van de Vijver D, Assel M, Prosperi M, De Luca A on behalf of Virolab, Euresist, Chain. Calendar trends in antiretroviral drug resistance in treatment-experienced patients in Europe. 12th European AIDS Conference/EACS, 11-14 November 2009, Cologne, Germany. Abstract PE3.1/8.
136. Martinelli L, Masini G, Tosti A, Zazzi M, Baldelli F, Francisci D. Antiretroviral drug susceptibility among drug-naive adults with chronic or recent HIV infection in Umbria region. 12th European AIDS Conference/EACS, 11-14 November 2009, Cologne, Germany. Abstract PE3.4/7.
137. Prosperi MCF, Bracciale L, Di Giambenedetto S, Fabbiani M, Razzolini F, Meini G, Colafigli M, Marzocchetti A, Zazzi M, De Luca A. Use of gp120-V3 RNA and DNA genotype to predict tropism in HIV-infected patients. 12th European AIDS Conference/EACS, 11-14 November 2009, Cologne, Germany. Abstract PE3.4/9.
138. Ceccherini-Silberstein F, Santoro MM, Forbici F, Zaccarelli M, Boumis E, Palamara G, Callegaro A, Francisci D, Carnevale G, Maggiolo F, Narciso P, Antinori A, Zazzi M, Mussini C, Perno CF. Different drug-resistance development in HIV-1-infected patients failing a first-line antiretroviral therapy containing NNRTIs with or without thymidine analogues. 12th European AIDS Conference/EACS, 11-14 November 2009, Cologne, Germany. Abstract PE3.4/10.
139. Svicher V, Cammarota R, Artese A, D'Arrigo R, Parisi R, Zazzi M, Antinori A, Angarano G, Nozza S, Perno CF, and Oscar Study Group. New V3-genetic Signatures Modulate Co-receptor Usage in vivo and the Interaction



- with CCR5 N-terminus. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, February 16 - 19, 2010.
140. Rusconi S, Vitiello P, Adorni F, Bruzzone B, De Luca A, Micheli V, Meraviglia P, Maserati R, Di Pietro M, Colao G, Penco G, Di Biagio A, Punzi G, Monno L, Zazzi M on behalf of the ARCA Collaborative Group. Determinants of virological response to raltegravir (RAL)-containing regimens and prevalence of RAL-resistance associated mutations at failure in ARCA. Eighth European HIV Drug Resistance Workshop. 17-19 March 2010. Sorrento, Italy.
  141. Prosperi M, Dunn D, Di Giambenedetto S, Zazzi M, Camacho R, Fanti I, Torti C, Sonnerborg A, Kaiser R, Codofier F, Van Laethem K, Bansi L, Asboe D, van de Vijver D, De Luca A for the Virolab, EuResist, CHAIN and Dynanets consortia. Detection of drug resistance mutations (DRM) at low viral load in a European multicohort study (SEHERE). Eighth European HIV Drug Resistance Workshop. 17-19 March 2010. Sorrento, Italy.
  142. Di Giambenedetto S, Fanti I, Prosperi M, Bruzzone B, Baldanti F, Penco G, Meini G, Di Biagio A, Paolini E, Micheli V, Meraviglia P, Chiodera A, Corsi P, Gonnelli A, Zazzi M, De Luca A. Emergence of resistance to the new drug classes in an Italian National database: 2007-2009. Eighth European HIV Drug Resistance Workshop. 17-19 March 2010. Sorrento, Italy.
  143. Svicher V, Alteri C, Artese A, D'Arrigo R, Alcaro S, Ceccherini F, Cammarota R, Bagnarelli P, Antonelli G, Micheli V, Ghisetti V, Gennari W, Baldanti F, Callegaro AP, Bruzzone B, Fadda G, De Luca A, Re MC, Andreoni M, Zazzi M, Antinori A, Angarano G, Parisi S, Lazzarin A, Perno CF on behalf of OSCAR group. New HIV-1 gp120 V3 Signatures Modulate Co-receptor Usage in Vivo and the Interaction with CCR5 N-terminus. Eighth European HIV Drug Resistance Workshop. 17-19 March 2010. Sorrento, Italy.
  144. Beheydt G, Vercauteren J, Libin P, Imbrechts S, Camacho R, Clotet B, De Luca A, Grossman Z, Kaiser R, Sonnerborg A, Torti C, Van Wijngaerden E, Zazzi M, Geretti AM, Vandamme AM, Prosperi M. Rega 8: an improved genotypic interpretation system that significantly predicts HIV-therapy response for B and non-B subtypes. Eighth European HIV Drug Resistance Workshop. 17-19 March 2010. Sorrento, Italy.
  145. Svicher V, Alteri C, Artese A, Costa G, Mercurio F, D'Arrigo R, Alcaro S, Ceccherini F, Bagnarelli P, Antonelli G, Micheli V, Ghisetti V, Gennari W, Baldanti F, Callegaro AP, Bruzzone B, Fadda G, Re MC, De Luca A, Andreoni M, Antinori A, Zazzi M, Canducci F, Clementi M, Angarano G, Parisi S, Lazzarin A, Perno CF on behalf of OSCAR group. Specific Genetic Signatures in V3 Base Can Modulate Co-receptor Usage in Vivo, the Interaction with Neutralizing Antibodies, and HIV-1 Cytopathic Effect. International HIV & Hepatitis Virus Drug Resistance Workshop and Curative Strategies. June 8-12, 2010. Dubrovnik, Croatia.
  146. Sierra S, Balduin M, Zazzi M, Sonnerborg A, Geretti AM, Vandekerckhove L, Verhofstede C, Berg J, Puchhammer-Stöckl E, Simon B, Kessler H, Wolf E, Thielen A, Däumer M, Kaiser R. Pairwise comparison of genotypic coreceptor tropism prediction between one reference center and 10 European laboratories. International HIV & Hepatitis Virus Drug Resistance Workshop and Curative Strategies. June 8-12, 2010. Dubrovnik, Croatia.
  147. Beheydt G, Zazzi M, Carvalho AP, Diogo I, Ram D, Rudich H, Camacho R, Grossman Z, Van Laethem K, Vandamme A-M. Study of the Regimen-Specific HIV-1 Genotypic Susceptibility Score after Treatment Failure. International HIV & Hepatitis Virus Drug Resistance Workshop and Curative Strategies. June 8-12, 2010. Dubrovnik, Croatia.
  148. Franzetti M, Casazza G, Meini G, Callegaro AP, Corsi P, Maggiolo F, Boeri E, Paolucci S, Gianotti N, Francisci D, Orani A, Filice G, Carli T, Zazzi M, Balotta C. Evaluation of virological response to cART in patients carrying non-B subtype matched for baseline genotype with B subtype. International HIV & Hepatitis Virus Drug Resistance Workshop and Curative Strategies. June 8-12, 2010. Dubrovnik, Croatia.
  149. Alteri C, Svicher V, Artese A, Mercurio F, D'Arrigo R, Alcaro S, Ceccherini F, Giacometti A, Vullo V, D'Arminio Monforte A, Di Perri G, Mussini C, Maserati R, Maggiolo F, Viscoli C, Cauda R, Borderi M, Gori A, De Luca A, Andreoni M, Antinori A, Zazzi M, Nozza S, Clementi M, Angarano G, Parisi S, Lazzarin A, Perno CF on behalf of OSCAR group. Specific Genetic Signatures in V3 Base Can Modulate Co-receptor Usage in Vivo, the Interaction with Neutralizing Antibodies, and HIV-1 Cytopathic Effect. Italian Conference on AIDS and Retroviruses. 20-22 June, Brescia, Italy.
  150. Violin M, Casazza G, Meini G, Callegaro AP, Corsi P, Maggiolo F, Boeri E, Baldanti F, Gianotti N, Francisci D, Orani A, Zazzi M, Balotta C. Specific non-B subtypes spread and response to HAART compared to B subtype with baseline wild-type genotype. Italian Conference on AIDS and Retroviruses. 20-22 June, Brescia, Italy.
  151. Bartha I, Assel M, Sloot P, Zazzi M, Torti C, Kaiser R, de Luca A, Sonnerborg A, Vandamme A, Paredes R, van de Vijver D, Müller V. Estimating the frequency of superinfection in a large European collaborative HIV database. XIII International AIDS Conference. Wien, July 18-23, 2010.

152. Beheydt G, Zazzi M, Carvalho AP, Diogo I, Ram D, Rudich H, Camacho R, Grossman Z, Vandamme A-M, Van Laethem K. The genotypic susceptibility score of Rega v8.0.2 after treatment failure. 16th International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology, 29 August - 3 September 2010, Bethesda, USA.
153. Li G, Beheydt G, Bielza C, Larrañaga P, Camacho R, Grossman Z, Torti C, Zazzi M, Prosperi M, Kaiser R, Van Laethem K, De Maeyer M, Jansen M, Vandamme A-M. Learning ancestral polytrees for HIV-1 mutation pathways against protease inhibitor Nelfinavir. Ninth European Conference on Computational Biology, 2010, September 26-29, Ghent, Belgium.
154. Vandekerckhove LPR, Wensing AMJ, Kaiser R, Brun-Vézinet F, Clotet B, De Luca A, Dressler S, Garcia F, Geretti AM, Klimkait T, Korn K, Masquelier B, Perno CF, Schapiro JM, Soriano V, Sönnnerborg AM, Vandamme AM, Verhofstede C, Walter H, Zazzi M, Boucher CAB on behalf of the European Consensus Group on clinical management of tropism testing. Consensus statement of the European guidelines on clinical management of HIV-1 tropism testing vs 1.0. Tenth International Congress on Drug Therapy in HIV Infection. 7-11 November 2010 Glasgow, UK.
155. Pironti A, Sönnnerborg A, Zazzi M, Kaiser R, Struck D, Clotet B, Vandamme AM, Incardona F, Lengauer T, Rosen-Zvi M, Prosperi M. The EuResist expert model for customised HAART optimisation: 2010 update and extension to newest compounds. Tenth International Congress on Drug Therapy in HIV Infection. 7-11 November 2010 Glasgow, UK.
156. Sterrantino G, Borchi B, Pozzi M, Meini G, Zazzi M, Leoncini F. Test genotipico nella pratica clinica per la valutazione del tropismo di HIV-1. Nono Congresso Nazionale SIMIT. Roma, 24-27 Novembre 2010.
157. Svicher V, Alteri C, Artese A, Costa G, Mercurio F, D'Arrigo R, Alcaro S, Ceccherini-Silberstein F, Bagnarelli P, Antonelli G, Micheli V, Ghisetti V, Gennari W, Baldanti F, Callegaro AP, Bruzzone B, Fadda G, Re MC, De Luca A, Andreoni M, Antinori A, Zazzi M, Canducci F, Clementi M, Angarano G, Parisi SG, Lazzarin A, Perno CF e OSCAR study group. Nuovi determinanti genetici nel dominio V3 della glicoproteina di HIV gp120 modulano l'uso dei co-recettori e l'interazione con la porzione n-terminale del CCR5. Nono Congresso Nazionale SIMIT. Roma, 24-27 Novembre 2010.
158. Santoro MM, Svicher V, Cozzi-Lepri A, Fabeni L, Bruzzone B, Mussini C, De Luca A, Andreoni M, Antinori A, Zazzi M, Perno CF, D'Arminio Monforte A, Ceccherini-Silberstein F for Icona Foundation. Impact of natural polymorphisms of HIV-1 reverse transcriptase on virologic response to a first line NNRTI-containing HAART. 15th International Workshop on HIV Observational Databases, Praha, 24-26 March 2011.
159. Prosperi MCF, Di Giambenedetto S, Fanti I, Meini G, Bruzzone B, Callegaro A, Penco G, Bagnarelli P, Micheli V, Paolini E, Di Biagio A, Ghisetti V, Di Pietro M, Zazzi M, De Luca A. A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen. 9th European Workshop on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance. 23-25 March 2011, Cyprus.
160. Rosen-Zvi M, Zazzi M, Incardona F, Aaroni E, Kaiser R, Lengauer T, Camacho R, Clotet B, Vandamme AM, Schmit JC, Sönnnerborg A - for the EuResist Network. Declining differences in treatment outcome among different patient categories in Europe, 1992-2010. 9th European Workshop on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance. 23-25 March 2011, Cyprus.
161. Pironti A, Altmann A, Schuster E, Boch J, Balduin M, Reuter S, Zazzi M, van de Vijver D, Oette M, Kaiser R, Lengauer T. A computational method for predicting first-line HIV antiretroviral therapy success. 9th European Workshop on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance. 23-25 March 2011, Cyprus.
162. Sterrantino G, Zaccarelli M, Zazzi M, De Luca A, Borghi V, Meraviglia P, Corsi P, Bonora S, Colao G, Baldanti F, Di Giambenedetto S, Carli T, Maggiolo F, Antinori A, Leoncini F. Minimal emergence of darunavir resistance at treatment failure: are interpretation algorithms adequate? 9th European Workshop on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance. 23-25 March 2011, Cyprus.
163. Di Giambenedetto S, Santangelo R, Meini G, Fabbiani M, Prosperi M, Marchetti S, Fortuna S, Navarra P, Fadda G, Cauda R, Zazzi M, De Luca A. HIV-1 gp120 substitutions and plasma maraviroc concentration: contribution to virological failure during maraviroc-based salvage therapy. 9th European Workshop on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance. 23-25 March 2011, Cyprus.
164. Vandekerckhove LPR, Wensing AMJ, Kaiser R, Brun-Vézinet F, Clotet B, De Luca A, Dressler S, Garcia F, Geretti AM, Klimkait T, Korn K, Masquelier B, Perno CF, Schapiro JM, Soriano V, Sönnnerborg A, Vandamme AM, Verhofstede C, Walter H, Zazzi M and Boucher CAB on behalf of the European Consensus Group on clinical management of tropism testing. European guidelines on clinical management of HIV-1 tropism testing; Consensus Statement version 1.0. 9th European Workshop on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance. 23-25 March 2011, Cyprus.

165. Rossotti R, Fonte L, Meini G, Maggiolo F, Di Giambenedetto S, Pecorari M, Corsi P, Monno L, Giacometti A, Francisci D, Setti M, Maserati R, Bonfanti P, Orani A, Zazzi M. Rilpivirine Is Coming: How Will It Impact On HIV-1-Infected Italian Population? ICAR 2011. Italian Conference on AIDS and Retroviruses. March 27-29, 2011. Florence, Italy.
166. Saladini F, Rosi A, Vicenti I, Meini G, Zazzi M. Development of recombinant virus assays for phenotypic evaluation of the susceptibility to integrase inhibitors and HIV coreceptor tropism. ICAR 2011. Italian Conference on AIDS and Retroviruses. March 27-29, 2011. Florence, Italy.
167. Lai A, Zehender G, De Luca A, Micheli V, Meraviglia P, Corsi P, Bagnarelli P, Almi P, Zoncada A, Baldanti F, Gonnelli A, Colao G, Tacconi D, Simonetti FR, Ciccozzi M, Zazzi M, Balota C. High proportion of HIV-1 subtype F1 transmission networks among Italian heterosexual males associated with introduction events from South America. ICAR 2011. Italian Conference on AIDS and Retroviruses. March 27-29, 2011. Florence, Italy.
168. Armenia D, Malet I, Fabeni L, Reigadas S, Guillot V, Dunn D, Kaiser R, Zazzi M, Van Laethem K, Artese A, Masquelier B, Garcia F, Calvez V, Antinori A, Marcelin AG, Perno CF, Geretti AM, Ceccherini-Silberstein F on behalf of the CORONET study group and in collaboration with CHAIN. Impact of baseline HIV-1 integrase polymorphisms on virological outcome in a large European cohort of patients starting a Raltegravir-containing regimen. International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies. June 7-11, 2011. Los Cabos, Mexico.
169. Lai A, Zehender G, Franzetti M, Simonetti F, De Luca A, Micheli V, Meraviglia P, Corsi P, Bagnarelli P, Aimi P, Zoncada A, Baldanti F, Gonnelli A, Colao G, Tacconi D, Zazzi M, Balotta C. High proportion of HIV-1 subtype F1 epidemiological networks among Italian heterosexual males associated with introduction events from south America and high proportion of resistance within clusters. International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies. June 7-11, 2011. Los Cabos, Mexico.
170. Santoro MM, Ceccherini-Silberstein F, Forbici F, Bansi L, Dunn D, Fearnhill E, Boumis E, Narciso P, Antinori A, Palamara G, Callegaro A, Francisci D, Zoncada A, Maggiolo F, Zazzi M, Sabin C, Perno CF, Mussini C. Different drug-resistance development in HIV-1 infected patients failing a first-line antiretroviral therapy containing NNRTIs. Sixth IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 17-20, 2011. Rome, Italy.
171. Vicenti I, Rosi A, Sidella L, Saladini F, Meini G, Rubino M, Almi P, De Luca A, Di Giambenedetto S, Zazzi M, Caudai C. Naturally occurring resistance related mutations to Hepatitis C protease inhibitors in treatment-naïve patients. National Congress of the Italian Society for Virology. Orvieto (TR) – Italy. September 12-14, 2011.
172. Meini G, Balestrieri M, Cianchino S, Tacconi D, Rossi de Gasperis M, Concato F, Vicenti I, Rosi A, Saladini F, Callea F, Zazzi M. Frequent detection of antiretroviral drug resistance in HIV-1-infected children followed at a donor-funded rural paediatric clinic in Dodoma, Tanzania. 10th National Congress of the Italian Society for Virology. Orvieto (TR) – Italy. September 12-14, 2011.
173. Rosi A, Vicenti I, Saladini F, Meini G, Zazzi M. Development of a multiplex Sequence specific Primer PCR for the detection of HLA-B\*5701 and CCR5delta32 alleles in HIV-positive patients. National Congress of the Italian Society for Virology. Orvieto (TR) – Italy. September 12-14, 2011.
174. Saladini F, Rosi A, Vicenti I, Meini G, Zazzi M. Use of recombinant virus assays for in vitro evaluation of susceptibility to integrase inhibitors and HIV coreceptor tropism. National Congress of the Italian Society for Virology. Orvieto (TR) – Italy. September 12-14, 2011.
175. Rossetti B, Bianco C, Bellazzi LI, Bruzzone B, Colao G, Corsi P, Monno L, Pagano G, Paolucci S, Punzi G, Setti M, Zazzi M, De Luca A. Risposta virologica ed immunologica a regimi ART contenenti maraviroc in pazienti con infezione da HIV nella pratica clinica: ruolo del tropismo e dei trattamenti concomitanti. 10° Congresso Nazionale SIMIT. Porto Arsenale La Maddalena. 5-8 Ottobre 2011.
176. D'Avino A, Bianco C, Fanti I, Colafigli M, Francisci D, Zoncada A, Rusconi S, Ghisetti V, Maggiolo F, Gismondo MR, Meraviglia P, Di Biagio A, Zazzi M, De Luca A. Efficacia virologica e predittori di successo virologico dei trattamenti antiretrovirali contenenti Abacavir nella coorte ARCA. 10° Congresso Nazionale SIMIT. Porto Arsenale La Maddalena. 5-8 Ottobre 2011.
177. Meini G, Saladini F, Bianco C, Monno L, Punzi G, Pecorari M, Borghi V, Di Pietro M, Filice G, Gismondo MR, Micheli V, Penco G, Carli T, De Luca A, Zazzi M for the ARCA Collaborative Group. Prevalenza delle mutazioni putative di resistenza a dolutegravir in pazienti raltegravir-naïve e in fallimento con raltegravir. 10° Congresso Nazionale SIMIT. Porto Arsenale La Maddalena. 5-8 Ottobre 2011.
178. Almi P, Vicenti I, Di Giambenedetto S, Saladini F, Pippi F, Meini G, Colafigli M, Rubino M, Rosi A, Rossetti B, Sidella L, Bianco C, Caudai C, De Luca A, Zazzi M. Polimorfismi naturali della regione NS3 di HCV genotipo 1 in pazienti con o senza coinfezione con virus HIV: prevalenza e predittori di mutazioni di resistenza agli inibitori

- della NS3-proteasi di HCV e di altre mutazioni. 10° Congresso Nazionale SIMIT. Porto Arsenale La Maddalena. 5-8 Ottobre 2011.
179. Bianco C, Rossetti B, Bellazzi LI, Bruzzone B, Colao G, Corsi P, Monno L, Pagano G, Paolucci S, Punzi G, Setti M, Zazzi M, De Luca A. Virological and immunological response to ART regimens containing maraviroc in HIV-infected patients in clinical practice: role of different tropism testing results and concomitant treatments. 13th European AIDS Conference/EACS. October 12-15, 2011. Belgrade, Serbia.
  180. D'Avino A, Rossetti B, Colafigli M, Fanti I, Francisci D, Zoncada A, Rusconi S, Ghisetti V, Maggiolo F, Gismondo MR, Meraviglia P, Di Biagio A, Zazzi M, De Luca A. Virological outcome of abacavir-containing antiretroviral regimens and predictors of treatment success in a large Italian cohort. 13th European AIDS Conference/EACS. October 12-15, 2011. Belgrade, Serbia.
  181. Lai A, Zehender G, Franzetti M, Simonetti F, De Luca A, Micheli V, Meraviglia P, Corsi P, Bagnarelli P, Aimi P, Zoncada A, Baldanti F, Gonnelli A, Colao G, Tacconi D, Zazzi M, Balotta C. Phylogeny of Italian F1 subtype provides evidence of multiple introductions from South American MSMs among Italian heterosexual males and high rate of HIV-1 resistant clusters. 13th European AIDS Conference/EACS. October 12-15, 2011. Belgrade, Serbia.
  182. Saladini F, Meini G, Bianco C, Monno L, Punzi G, Pecorari M, Borghi V, Di Pietro M, Filice G, Gismondo MR, Micheli V, Penco G, Carli T, De Luca A, Zazzi M for the ARCA Collaborative Group. Prevalence of mutations related to possible resistance to dolutegravir in raltegravir naïve and pretreated patients. 13th European AIDS Conference/EACS. October 12-15, 2011. Belgrade, Serbia.
  183. Zaccarelli M, Sterrantino G, Gonnelli A, Bruzzone B, Micheli V, Meini G, Antinori A, Zazzi M. Mutation resistance patterns associated with darunavir virological failure in highly experienced patients. 13th European AIDS Conference/EACS. October 12-15, 2011. Belgrade, Serbia.
  184. Di Giambenedetto S, Vicenti I, Almi P, Saladini F, Pippi F, Meini G, Colafigli M, Rubino M, Rosi A, Rossetti B, Sidella L, Bianco C, Caudai C, De Luca A, Zazzi M. Natural variation of the NS3 region in HCV genotype 1 patients with or without HIV-1 infection: prevalence and predictors of resistance mutations to HCV NS3-protease inhibitors and other substitutions. 13th European AIDS Conference/EACS. October 12-15, 2011. Belgrade, Serbia.
  185. Beheydt G, Theys K, Clotet B, Schülter E, Schmit J-C, Sönnnerborg A, Zazzi M, Van Laethem K, Camacho R, Vandamme AM. Bayesian Network Analysis of Mutational Pathways to Darunavir Resistance. Nineteenth Conference on Retroviruses and Opportunistic Infections. March 5-8, 2012. Seattle.
  186. Franzetti M, Violin M, Antinori A, De Luca A, Ceccherini-Silberstein F, Gianotti N, Torti C, Bonora S, Zazzi M, Balotta C, START Study. Substantial Decrease of Class Resistance: START Study, 2003 to 2010. Nineteenth Conference on Retroviruses and Opportunistic Infections. March 5-8, 2012. Seattle.
  187. Zaccarelli M, Sterrantino G, Di Giambenedetto S, De Luca A, Meraviglia P, Bonora S, Carli T, Maggiolo F, Colao G, Baldanti F, Zazzi M. Failure of Darunavir/Ritonavir-containing regimens is better predicted by historical than current protease inhibitors resistance data. 10th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance. 28 – 30 March 2012, Barcelona, Spain.
  188. Prosperi M, Vicenti I, Rosi A, Meini G, Saladini F, Caudai C, Rossetti B, Bianco C, Almi P, Di Giambenedetto S, Zazzi M, De Luca A. Genetic Fingerprints and Variability of the Non-Structural Region 3 of Genotype 1a vs. 1b Hepatitis C Virus in the Italian and Worldwide Population. 10th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance. 28 – 30 March 2012, Barcelona, Spain.
  189. Sterrantino G, Zaccarelli M, Di Giambenedetto S, De Luca A, Francisci D, Punzi G, Monno L, Bruzzone B, Meini G, Paolucci S, Di Biagio A, Nerli A, Paolini E, Bellazzi LI, Zazzi M. X4/DM HIV tropism is associated with genotypic resistance to protease and reverse transcriptase inhibitors, both in naïve and in experienced patients. 10th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance. 28 – 30 March 2012, Barcelona, Spain.
  190. Lai A, Franzetti M, Simonetti FR, Rosi A, Bozzi G, Micheli V, Meraviglia P, Corsi P, De Luca A, Zehender G, Zazzi M, Balotta C. Phylogeny of HIV-1 subtype C provides evidence of epidemiological interactions between Italian heterosexual males and South American MSM. 10th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance. 28 – 30 March 2012, Barcelona, Spain.
  191. Simonetti FR, Lai A, Brinidicci G, Bozzi G, Punzi G, Zazzi M, Monno L, Balotta C, Angarano G. Outbreak of a novel HIV-1 CB recombinant among Italian young MSM with a recent infection. 10th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance. 28 – 30 March 2012, Barcelona, Spain.
  192. Colafigli M, Rossetti B, Bruzzone B, Corsi P, Colao G, Monno L, Punzi G, Bellazzi LI, Paolucci S, Pagano G, Setti M, Sterrantino G, Zaccarelli M, Zazzi M, De Luca A, Di Giambenedetto S. Predictors of genotypically-determined R5 tropism in HIV-infected patients in a large Italian cohort. 10th European Meeting on HIV &

- Hepatitis Treatment Strategies & Antiviral Drug Resistance. 28 – 30 March 2012, Barcelona, Spain.
193. De Luca A, Meini G, Rossetti B, Bianco C, Di Giambenedetto S, Sighinolfi L, Monno L, Castagna A, Capobianchi MR, d'Arminio Monforte A, Zazzi M for the ICONA Foundation Study. HIV-1 co-receptor tropism evolution in naïve patients undergoing successful ART: concordance of DNA vs. RNA and triplicate versus singlicate population sequencing. 10th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance. 28 – 30 March 2012, Barcelona, Spain.
  194. Bogojeska J, Stöckel D, Zazzi M, Kaiser R, Incardona F, Rosen-Zvi M, Lengauer T. History-alignment models for bias-aware prediction of virological response to HIV combination therapy. 15th International Conference on Artificial Intelligence and Statistics (AISTAS 2012): 118-126. La Palma, Canary Islands. April 21-23, 2012.
  195. Lai A, Franzetti M, Simonetti F, Bozzi G, De Luca A, Micheli V, Meraviglia P, Corsi P, Bagnarelli P, Almi P, Zoncada A, Baldanti F, Gonnelli A, Colao G, Tacconi D, Zazzi M, Balotta C. Contact tracing and TDR of F1, C and A1 subtypes circulating in Italy are associated with modality of infection and geographical origin of patients. International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies. Sitges, June 5-9, 2012.
  196. Lai A, Franzetti M, Simonetti FR, Bozzi G, De Luca A, Micheli V, Meraviglia P, Corsi P, Bagnarelli P, Almi P, Zoncada A, Baldanti F, Gonnelli A, Colao G, Tacconi D, Binda F, Zazzi M, Balotta C. HIV-1 A1 subtype of both African and East European origin in Italy unveils high burden of transmission chains involving intravenous drug users. ICAR 2012. Italian Conference on AIDS and Retroviruses. Napoli, 10-12 giugno 2012.
  197. Bozzi G, Lai A, Franzetti M, Simonetti FR, Montagnani F, Micheli V, Meraviglia P, Corsi P, Bagnarelli P, Almi P, Zoncada A, Baldanti F, Gonnelli A, Colao G, Tacconi D, Zazzi M, Balotta C. F1 and C subtype tracing in Italy reveals an association with distinct modality of infection and different proportion of TDR according to patients geographical origin. ICAR 2012. Italian Conference on AIDS and Retroviruses. Napoli, 10-12 giugno 2012.
  198. Simonetti FR, Brindicci G, Lai A, Bozzi G, Punzi G, Zazzi M, Monno L, Balotta C, Angarano G. Outbreak of a novel HIV-1 CB recombinant in Italy: a potential new CRF? ICAR 2012. Italian Conference on AIDS and Retroviruses. Napoli, 10-12 giugno 2012.
  199. Rossetti B, Marzocchetti A, Saladini F, Callegaro A, Colafigli M, Penco G, Micheli V, Francisci D, Meraviglia P, Carli T, Di Giambenedetto S, Chiodera A, Di Biagio A, De Luca A, Zazzi M for the ARCA Database Study Group. Durability of anti-HIV treatments over calendar years. Sub-analysis of regimens including Abacavir/Lamivudine versus Tenofovir/Emcitabine. ICAR 2012. Italian Conference on AIDS and Retroviruses. Napoli, 10-12 giugno 2012.
  200. Marzocchetti A, Sterrantino G, Rosi A, Borghi V, Bruzzone B, Bellazzi LI, Paolucci S, Punzi G, Colao G, Setti M, Monno L, Pecorari M, Montagnani F, De Luca A, Zazzi M for the ARCA Database Study Group. Virological response to Abacavir/Lamivudine/Nevirapine. ICAR 2012. Italian Conference on AIDS and Retroviruses. Napoli, 10-12 giugno 2012.
  201. Colafigli M, Rossetti B, Bruzzone B, Corsi P, Colao G, Monno L, Punzi G, Bellazzi LI, Paolucci S, Pagano G, Setti M, Sterrantino G, Zaccarelli M, Zazzi M, De Luca A, Di Giambenedetto S. Predictors of genotypically-determined R5 tropism in HIV-infected patients in a large Italian Cohort. ICAR 2012. Italian Conference on AIDS and Retroviruses. Napoli, 10-12 giugno 2012.
  202. Sterrantino G, Zaccarelli M, Di Giambenedetto S, De Luca A, Francisci D, Punzi G, Monno L, Bruzzone B, Meini G, Paolucci S, Di Biagio A, Nerli A, Paolini E, Bellazzi LI, Zazzi M for the ARCA Database Study Group. X4/DM HIV tropism is associated with genotypic resistance to protease and reverse transcriptase inhibitors, both in naïve and in experienced patients. ICAR 2012. Italian Conference on AIDS and Retroviruses. Napoli, 10-12 giugno 2012.
  203. Bernini L, Francisci D, Zazzi M, Tosti A, Malincarne L, Cecchini E, Baldelli F. Prevalence and distribution of HIV-1 non-B subtypes infections in newly diagnosed patients attending the Infectious Diseases Clinic of Perugia, Umbria (2003-2010). ICAR 2012. Italian Conference on AIDS and Retroviruses. Napoli, 10-12 giugno 2012.
  204. Di Biagio A, Prinapori R, Giannarelli D, Maggiolo F, Viscoli C, Di Giambenedetto S, Borghi V, Penco G, Cicconi P, Francisci D, Sterrantino G, Zoncada Z, Monno L, Capetti A, Giacometti A, Zazzi M for the ARCA Collaborative Group. ARCA database analysis of first-line antiretroviral regimens persistency in HIV-1 infected patients. ICAR 2012. Italian Conference on AIDS and Retroviruses. Napoli, 10-12 giugno 2012.
  205. Bianco C, Marzocchetti A, Bruzzone B, Pecorari M, Borghi V, Colafigli M, Paolini E, Saladini F, Sterrantino G, Di Giambenedetto S, Paolucci S, Boeri E, Gismondo MR, Zazzi M, De Luca A for the ARCA Database Study Group. Evaluation of resistance mutation patterns in HIV+ patients treated with Tenofovir /Emtricitabine versus Tenofovir/Lamivudine-containing regimens. ICAR 2012. Italian Conference on AIDS and Retroviruses. Napoli, 10-12 giugno 2012.

206. Marzocchetti A, Colafigli M, Bruzzone B, Di Giambenedetto S, Pecorari M, Meini G, Bagnarelli P, Biondi ML, Maggiolo F, Rusconi S, Di Pietro M, Sacchini D, De Luca A, Zazzi M for the ARCA Database Study Group. Immunological response to Abacavir/Lamivudine versus Tenofovir/Emtricitabine containing regimens. ICAR 2012. Italian Conference on AIDS and Retroviruses. Napoli, 10-12 giugno 2012.
207. Saladini F, Prosperi M, Di Giambenedetto S, Colafigli M, Fabbiani M, Rosi A, Meini G, Caudai C, Rossetti B, Bianco C, Almi P, Zazzi M, De Luca A. Impronta genetica e variabilità della regione non-strutturale 3 dei genotipi 1a/1b del virus dell'epatite C nella popolazione italiana e mondiale. 11° Congresso Nazionale SIMIT, Chieti-Pescara, 17-20 Ottobre 2012.
208. Schuelter E, Luebke N, Jensen B, Zazzi M, Sönnnerborg A, Lengauer T, Incardona F, Camacho R, Schmit J, Clotet B, Kaiser R, Pironti A. Etravirine in protease inhibitor-free antiretroviral combination therapies. Eleventh International Congress on Drug Therapy in HIV Infection. Glasgow, 11-15 November 2012.
209. Zaccarelli M, Sterrantino G, Francisci D, Di Biagio A, Di Giambenedetto S, De Luca A, Punzi G, Bruzzone B, Meini G, Zazzi M, for the ARCA Database Study Group. Is there a relationship between HIV tropism and historical genotypic resistance in treatment-experienced patients? Eleventh International Congress on Drug Therapy in HIV Infection. Glasgow, 11-15 November 2012.
210. Lai A, Franzetti M, Prosperi M, Sterrantino G, Saladini F, Bruzzone B, Zazzi M, Ciccozzi M, Balotta C, De Luca A. Multiple Patterns of Transmission of HIV-1 B Subtype in Italy Detected by a Nationwide Large-scale Phylogeny. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, March 3-6, 2013.
211. Colafigli M, Meini G, Gagliardini R, Francisci D, Ghisetti V, Di Pietro M, Di Biagio A, Pecorari M, Setti M, Borghi V, Gianotti N, Maggiolo F, Zazzi M, De Luca A, Di Giambenedetto S. Low level viremia and HIV-1 drug resistance in patients with virological rebound after suppression with a first line antiretroviral regimen. 11th European Workshop on HIV & Hepatitis. 20 – 22 March 2013, Rome, Italy.
212. Swartz JE, de Vries A, Ammerlaan H, Begovac J, Bierman WF, Boucher CAB, van der Ende ME, Grossman Z, Kaiser R, Levi I, Mudrikova T, Paredes R, Perez-Bercoff D, Pronk M, Richter C, Schmit JC, Vandekerckhove L, Vercauteren J, Zazzi M, Zidovec Lepej S, DeLuca A, Wensing AMJ on behalf of the European Society for Antiviral Resistance – ESAR. Efficacy of Tenofovir and Efavirenz in combination with Lamivudine or Emtricitabine in antiretroviral-naïve patients in clinical practice in Europe. 11th European Workshop on HIV & Hepatitis. 20 – 22 March 2013, Rome, Italy.
213. Vercauteren J, Beheydt G, Prosperi M, Libin P, Camacho RJ, Clotet B, De Luca A, Grossman Z, Kaiser R, Sönnnerborg A, Torti C, Zazzi M, Geretti AM, Van Wijngaerden E, Schmit JC, Vandamme AM, Van Laethem K. Clinical evaluation of Rega 8: An updated genotypic interpretation system that significantly predicts HIV-therapy response. 11th European Workshop on HIV & Hepatitis. 20 – 22 March 2013, Rome, Italy.
214. Lai A, Bozzi G, Morlacchi T, Franzetti M, Simonetti FR, Binda F, De Luca A, Micheli V, Meraviglia P, Bagnarelli P, Di Biagio A, Monno L, Meini G, Zazzi M, Balotta C. Epidemiological networks and phylogeographic tracing of A1 subtype in Italy indicate three penetration events sustained by two distinct local variants. 11th European Workshop on HIV & Hepatitis. 20 – 22 March 2013, Rome, Italy.
215. Rossetti B, Bianco C, Fabbiani M, Colafigli M, Pecorari M, Borghi V, Zoncada A, Bruzzone B, Penco G, Bartolozzi D, Paolucci S, Gonnelli A, Rosi A, Zazzi M, De Luca A. Impact of transmitted resistance to antiretroviral drugs on predicted HIV-1 susceptibility to single-tablet-regimens (STR). 11th European Workshop on HIV & Hepatitis. 20 – 22 March 2013, Rome, Italy.
216. Di Biagio A, Rusconi S, Marzocchetti A, Monno L, Punzi G, Bruzzone B, Colao G, Penco G, Zazzi M, De Luca A for the ARCA Collaborative Study Group. High viral load, drug resistance and the probability of virologic and immunologic success of initial cART in the real world: the efficacy of different regimens. ICAR 2013. Italian Conference on AIDS and Retroviruses. Torino, 12-14 maggio 2013.
217. Rossetti B, Bianco C, Fabbiani M, Colafigli M, Pecorari M, Borghi V, Zoncada A, Bruzzone B, Penco G, Bartolozzi D, Paolucci S, Gonnelli A, Rosi A, Zazzi M, De Luca A. Low impact of transmitted resistance to antiretroviral drugs on predicted HIV-1 susceptibility to current and future single-tablet-regimens (STR). ICAR 2013. Italian Conference on AIDS and Retroviruses. Torino, 12-14 maggio 2013.
218. Trezzi M, Catalani C, Meini G, Francisci D, Di Giambenedetto S, Colafigli M, Monno L, Punzi G, Bruzzone B, Rusconi S, Paolini E, Bartolozzi D, Borghi V, Colao G, Pecorari M, Zazzi M for the ARCA Database Study Group. Impact of HIV-1 Genotypic Resistance Testing and Adherence to treatment Guidelines in drug naïve patients. ICAR 2013. Italian Conference on AIDS and Retroviruses. Torino, 12-14 maggio 2013.
219. Lai A, Simonetti FR, Monno L, Morlacchi T, Brindicci G, Punzi G, Binda F, Bozzi G, Zazzi M, Angarano G, Balotta C. An HIV-1 outbreak among young Italian MSM led to the identification of a new circulating recombinant form. ICAR 2013. Italian Conference on AIDS and Retroviruses. Torino, 12-14 maggio 2013.
220. Franzetti M, Lai A, Prosperi M, Sterrantino G, Saladini F, Bruzzone B, Zazzi M, Ciccozzi M, De Luca A, Balotta C.

- Epidemiological patterns of transmission of HIV-1 subtype and transmitted drug resistance in Italy according to a nationwide large-scale phylogeny. ICAR 2013. Italian Conference on AIDS and Retroviruses. Torino, 12-14 maggio 2013.
221. Saladini F, Giannini A, Boccuto A, Rosi A, Meini G, Vicenti I, Materazzi A, Poggi A, Del Pin B, Di Pietro M, Zazzi M. Phenotypic characterization of an unusual Y143G integrase mutant selected by a raltegravir containing regimen. ICAR 2013. Italian Conference on AIDS and Retroviruses. Torino, 12-14 maggio 2013.
  222. Saladini F, Meini G, Bianco C, Monno L, Punzi G, Pecorari M, Borghi V, Di Pietro M, Filice G, Gismondo MR, Micheli V, Penco G, Carli T, De Luca A, Zazzi M for the ARCA Collaborative Group. Impact of failure of raltegravir containing therapy on the activity of upcoming integrase inhibitor based fixed dose combinations. ICAR 2013. Italian Conference on AIDS and Retroviruses. Torino, 12-14 maggio 2013.
  223. De Luca A, Di Giambenedetto S, Prosperi M, Lo Presti A, Torti C, Caudai C, Vicenti I, Saladini F, Almi P, Grima P, Blanc P, Fabbiani M, Rossetti B, Gagliardini R, Ciccozzi M, Zazzi M. Two distinct HCV genotype 1a clades: geographical distribution and association with natural resistance mutations to HCV NS3/4A inhibitors. International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies. Toronto, June 4-8, 2013.
  224. Schülter E, Zazzi M, Sönnnerborg A, Camacho R, Lengauer T, Kaiser R, EuResist Study Group. Comparison of Truvada+Darunavir and Truvada+Lopinavir Regimens in a European Cohort. 14th European AIDS Conference/EACS. 16-19 October 2013, Brussels, Belgium.
  225. Rossetti B, Lamonica S, Meini G, Bianco C, Vignale F, Gagliardini R, Francisci D, Latini A, Colafigli M, Zazzi M, Di Giambenedetto S, De Luca A. Tropismo di HIV-1 su DNA virale ed analisi dei relativi determinanti in pazienti virosoppressi nello studio GUSTA. Dodicesimo Congresso Nazionale SIMIT. Milano, 27-30 ottobre 2013.
  226. Rossetti B, Bianco C, Farina M, Navarra P, Zanelli C, Caudai C, Zazzi M, De Luca A. Fallimento virologico precoce con selezione rapida di farmacoresistenza in un paziente con HCV genotipo 1, trattato con peginterferon, ribavirina e telaprevir. Dodicesimo Congresso Nazionale SIMIT. Milano, 27-30 ottobre 2013.
  227. Saladini F, Giannini A, Boccuto A, Rosi A, Meini G, Materazzi A, Vicenti I, Zazzi M. Phenotypic characterization of a unique HIV-1 strain with a two-aminoacid deletion in the  $\beta$ 3- $\beta$ 4 hairpin loop domain of reverse transcriptase. 12th European Meeting on HIV and Hepatitis Treatment Strategies and Antiviral Drug Resistance - Barcelona, March 26-28, 2014.
  228. Rossetti B, Bianco C, Lamonica S, Meini G, Ciccarelli N, Lombardi F, Vignale F, Latini A, Colafigli M, Grima P, Francisci D, Mezzaroma I, Zazzi M, Rusconi S, Micheli V, Di Biagio A, Bruzzone B, Orofino G, Ghisetti V, Vullo V, Mastroianni C, Di Giambenedetto S, De Luca A, on behalf of GUSTA study group. Genotypic testing on HIV-1 DNA in virologically suppressed patients and analysis of its determinants: results from the GUSTA study. 12th European Meeting on HIV and Hepatitis Treatment Strategies and Antiviral Drug Resistance - Barcelona, March 26-28, 2014.
  229. Rossetti B, Bianco C, Lamonica S, Lombardi F, Ciccarelli N, Meini G, Vignale F, Latini A, Colafigli M, Grima P, Tosti A, Mezzaroma I, Vullo V, Zazzi M, Rusconi S, Micheli V, Di Biagio A, Bruzzone B, Orofino G, Ghisetti V, Mastroianni C, Trezzi T, Sterrantino G, Viale P, Re MC, Di Giambenedetto S, De Luca A, on behalf of GUSTA study group. Genotypic co-receptor tropism testing on HIV-1 DNA in virologically suppressed infected patients: feasibility and analysis of determinants of R5 virus: preliminary results from the GUSTA STUDY. Sesta Conferenza ICAR 2014. Roma, 25-27 Maggio 2014.
  230. Franzetti M, Lai A, Bozzi G, Binda F, Saladini F, Punzi G, Bruzzone B, Di Biagio A, De Luca A, Monno L, Zazzi M, Balotta C. Analysis of gp41 polymorphisms in subjects naïve for antiretrovirals. Sesta Conferenza ICAR 2014. Roma, 25-27 Maggio 2014.
  231. Bozzi G, Lai A, Franzetti M, Binda F, Sorrentino C, Brindicci G, Simonetti FR, Zazzi M, Angarano G, Galli M, Monno L, Balotta C. An Italian outbreak of a novel CRF01\_AE variant among young MSM. Sesta Conferenza ICAR 2014. Roma, 25-27 Maggio 2014.
  232. Lai A, Franzetti M, Prosperi M, Sterrantino G, Saladini F, Bruzzone B, Zazzi M, Ciccozzi M, De Luca A, Balotta C. HIV transmission networks in Italy: epidemiological characteristics and trend. Sesta Conferenza ICAR 2014. Roma, 25-27 Maggio 2014.
  233. Lai A, Franzetti M, Prosperi M, Sterrantino G, Saladini F, Bruzzone B, Zazzi M, Ciccozzi M, De Luca A, Balotta C. Epidemiological characteristics and trend of HIV-1 transmission chains in Italy. International Workshop on Antiviral Drug Resistance: Meeting the Global Challenge. June 3-7 2014, Berlin, Germany.
  234. Time on drug analysis based on real life data. Schülter E, Kaiser R, Zazzi M, Sönnnerborg A, Camacho R, Verheyen J, the EuResist Network Study Group. International Workshop on Antiviral Drug Resistance: Meeting the Global Challenge. June 3-7, 2014, Berlin, Germany.

235. Improved weighted darunavir genotypic mutation score predicting treatment response for HIV-1 subtype B and non-B infected patients receiving darunavir in a salvage regimen. De Luca A, Flandre P, Castagna A, Ceccherini-Silberstein F, Cozzi-Lepri A, Churchill D, De Wit S, Dunn D, Fuchs W, Garcia F, Günthard H, Imaz A, Kordossis T, Mussini C, Obel N, Roca B, Santoro MM, Schuelter E, Torti C, van Sighem A, Wensing AM, Wittkop L, Zangerle R, Zazzi M, Descamps D, CHAIN and COHERE in Eurocoord. International Workshop on Antiviral Drug Resistance: Meeting the Global Challenge. June 3–7 2014, Berlin, Germany.
236. Saladini F, Giannini A, Omesuh F, Boccuto A, Zazzi M. The HIV1 reverse transcriptase E138A polymorphism decreases the genetic barrier to resistance to etravirine in vitro. 12th National Congress of the Italian Society for Virology - Orvieto, September 22-24, 2014.
237. Vicenti I, Meini G, Vergori A, Rossetti B, Cusi MG, Zazzi M, De Luca A. Analysis of host and virus related determinants of hepatitis B surface antigen (HBsAg) control, either spontaneous or induced by treatment with HBV polymerase inhibitors. 12th National Congress of the Italian Society for Virology - Orvieto, September 22-24, 2014.
238. Meini G, Bianco C, Rossetti B, Lamonica S, Mondini A, Belmonti S, Fanti I, Di Giambenedetto S, Zazzi M, De Luca A. Switch to raltegravir-based regimens and HIV reservoir decrease in patients with suppressed HIV RNA. 12th National Congress of the Italian Society for Virology - Orvieto, September 22-24, 2014.
239. Schulter E, Kaiser R, Zazzi M, Sonnerborg A, Camacho R, Verheyen J. Time on drug analysis based on real life data. International Congress of Drug Therapy in HIV Infection 2–6 November 2014, Glasgow, UK.
240. Bianco C, Meini G, Rossetti B, Lamonica S, Mondini A, Belmonti S, Fanti I, Ciccarelli N, Di Giambenedetto S, Zazzi M, De Luca A. Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA. International Congress of Drug Therapy in HIV Infection 2–6 November 2014, Glasgow, UK.
241. Lai A, Franzetti M, Gianotti N, Saladini F, Binda F, Punzi G, Spagnuolo V, Mussini C, Castagna A, Monno L, Zazzi M, C Balotta. gp41 Mutations in Patients with Virological Failure on Protease Inhibitors Are Independent from PI Mutations. XXIV International HIV Drug Resistance Workshop. Seattle (WA), February 21-22, 2015.
242. Vergori A, Bianco C, Di Giambenedetto S, Meraviglia P, Bartolozzi D, Filice G, Monno L, Penco G, Borghi V, Almi P, Butini L, Castelli P, Zazzi M, De Luca A, Rossetti B for the ARCA Collaborative Group. Virologic and immunologic outcome in treatment-experienced HIV-1 infected patients receiving Raltegravir containing regimens. Italian Conference on AIDS and Retroviruses. Riccione, May 17-19, 2015.
243. Vergori A, Rossetti B, Vicenti I, Meini G, Lentini G, Cusi MG, Zazzi M, De Luca A. Analysis of genetic and viral determinants of HBsAg levels in chronic carriers. Italian Conference on AIDS and Retroviruses. Riccione, May 17-19, 2015.
244. Rossetti B, Vergori A, Bianco C, Monno L, Punzi G, Borghi V, Pecorari M, Francisci D, Bellazzi LI, Paolucci S, Bruzzone B, Toscano L, Saladini F, Zazzi M, De Luca A for the ARCA Collaborative Group. Prevalence of resistance mutations to Integrase Inhibitors in INI-naïve and INI-experienced HIV-1 infected patients in a large Italian cohort. Italian Conference on AIDS and Retroviruses. Riccione, May 17-19, 2015.
245. Allice T, Milia MG, Burdino W, Gregori G, Ruggiero T, Bottoni A, Cazzadore M, Zazzi M, Ghisetti V. Evaluation of the new commercial Duplica-RealTime HLA-B\*5701 EZ Screen test for HLAB\*5701 typing. Italian Conference on AIDS and Retroviruses. Riccione, May 17-19, 2015.
246. Meini G, Bruzzone B, D'Arrigo R, Dello Russo C, Ghisetti V, Allice T, Lipsi MR, Paolucci S, Baldanti F, Turriziani O, Falasca F, Zanussi S, Basaglia G, Pirazzoli A, Navarra P, Zazzi M. First external quality assurance program of the Italian HLA-B\*5701 Network assessing the performance of clinical virology laboratories in HLA-B\*5701 testing. Italian Conference on AIDS and Retroviruses. Riccione, May 17-19, 2015.
247. Bianco C, Vergori A, Di Giambenedetto S, Bruzzone B, Vicenti I, Zoncada A, Francisci D, Di Biagio A, Colafigli M, Pecorari M, Pignataro AR, Giacometti A, Zazzi M, De Luca A, Rossetti B for the ARCA Collaborative Group. Comparison of virologic and immunologic outcome between patients on a stable tenofovir/emtricitabine-containing regimen continuing tenofovir/emtricitabine or switching to an abacavir/lamivudine containing regimen. Italian Conference on AIDS and Retroviruses. Riccione, May 17-19, 2015.
248. Lai A, Franzetti M, Gianotti N, Binda F, Saladini F, Punzi G, Spagnuolo V, Mussini C, Castagna A, Monno L, Zazzi M, Balotta C. Characterization of gp41 Mutations in Patients with Virological Failure on Protease Inhibitors. Italian Conference on AIDS and Retroviruses. Riccione, May 17-19, 2015.
249. Saladini F, Giannini A, Omesuh F, Boccuto A, Zazzi M. The HIV1 reverse transcriptase E138A polymorphism decreases the genetic barrier to resistance to etravirine in vitro. 13th European Workshop on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance. 3 - 5 June 2015, Barcelona, Spain.
250. Vergori A, Rossetti B, Vicenti I, Meini G, Lentini G, Cusi MG, Zazzi M, De Luca A. Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection. 13th European Workshop on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance. 3 - 5 June 2015, Barcelona, Spain.



251. Rossetti B, Bianco C, Vergori A, Bellazzi LI, Bruzzone B, Colao G, Corsi P, Monno L, Pagano G, Paolucci S, Punzi G, Setti M, Zazzi M, De Luca A. Evaluation of the False Positive Rate as a quantitative predictor of virological and immunological response to Maraviroc including therapy. 13th European Workshop on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance. 3 - 5 June 2015, Barcelona, Spain.
252. Belmonti S, Lombardi F, Fabbiani M, Zazzi M, Borghetti A, Lamonica S, Cauda R, Di Giambenedetto S, De Luca A. Treatment simplification to maraviroc+darunavir/ritonavir maintains control on HIV-1 provirus levels in virologically suppressed patients. 13th European Workshop on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance. 3 - 5 June 2015, Barcelona, Spain.
253. Lombardi F, Belmonti S, Fabbiani M, Colafigli M, Zazzi M, Mondì A, D'Avino A, Gagliardini R, Baldin G, Cauda R, De Luca A, Di Giambenedetto S. Decrease of HIV-DNA after simplification to atazanavir/ritonavir + lamivudine in virologically suppressed HIV-infected patients. 13th European Workshop on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance. 3 - 5 June 2015, Barcelona, Spain.
254. Materazzi A, Saladini F, Di Giambenedetto S, Torti C, Ricciardi B, Gagliardini R, Toscano L, Rossetti B, De Luca A, Almi P, Zazzi M, Caudai C. Natural variability and antiviral resistance mutations in genotype 1 HCV NS5A. 13th National Congress of the Italian Society for Virology. Orvieto (TR), 14-16 September 2015.
255. Geretti AM, Doring M, Schülter E, Boucher C, Incardona F, Kaiser R, Lengauer T, Pfeifer N, Vandamme AM, Zazzi M, EUCO-HIV Study Group. Maraviroc Use and Outcomes across Europe - The European Coreceptor (EUCO) HIV Cohort Study. 15th European AIDS Conference (EACS), 21-24 October 2015, Barcelona.
256. Rossetti B, Picchioni T, Meini G, Zanelli G, Valoriani B, Malcontenti C, Caudai C, Zazzi M, De Luca A. Efficacia, tollerabilità ed analisi delle resistenze in corso di trattamento con antivirali diretti anti-hcv di prima e seconda generazione nella pratica clinica. XIV Congresso Nazionale SIMIT. Catania, 9-11 Novembre 2015.
257. Rossetti B, Gagliardini R, Meini G, Sterrantino G, Colangeli V, Bon I, Latini A, Colafigli M, Vignale F, Rusconi S, Micheli V, Di Biagio A, Bruzzone B, Orofino G, Ghisetti V, Fantauzzi A, Vullo V, Turriziani O, Grima P, Francisci D, Marocco R, Antinori A, Bertoli A, Marchetti G, Trezzi M, Petrelli E, Fabbiani M, Lamonica S, D'Avino A, Zazzi M, Di Giambenedetto S, De Luca A. Lo switch terapeutico a maraviroc (MVC) + darunavir/ritonavir (DRV/r) in pazienti virosoppressi con virus r5 tropico è associato ad un eccesso di fallimenti virologici: risultati a 48 settimane dello studio GUSTA. XIV Congresso Nazionale SIMIT. Catania, 9-11 Novembre 2015.
258. Rossetti B, Bianco C, Vergori A, Bellazzi LI, Bruzzone B, Colao G, Corsi P, Monno L, Paolucci S, Punzi G, Setti M, Zazzi M, De Luca A. Ruolo del false positive rate quale predittore quantitativo di risposta virologica ed immunologica a regimi terapeutici contenenti maraviroc. XIV Congresso Nazionale SIMIT. Catania, 9-11 Novembre 2015.
259. Hofstra LM, Sauvageot N, Albert J, Alexiev I, Struck D, Van de Vijver D, Asjö B, Beshkov D, Coughlan S, Descamps D, Garcia F, Gomes P, Griskevicius A, Hamouda O, Horban A, Kolupajeva T, Kostrikis L, Liitsola K, Linka M, Mor O, Nielsen C, Otelea D, Paraskevis D, Parczewski M, Paredes R, Poljak M, Puchhammer-Stöckl E, Ruelle J, Sönnnerborg A, Staneková D, Stanojevic M, Van Laethem K, Yalcinkaya T, Zazzi M, Zidovec Lepej S, Schmit JC, Boucher CAB, Wensing AMJ. Transmission of HIV drug resistance mutations varies regionally in Europe. 14th European Meeting on HIV & Hepatitis. Treatment Strategies & Antiviral Drug Resistance. 25 - 27 May 2016, Rome, Italy.
260. Vicenti I, Saladini F, Micheli V, Bruzzone B, Zazzi M. Development of an in-house phenotypic HIV-1 coreceptor tropism assay. 14th European Meeting on HIV & Hepatitis. Treatment Strategies & Antiviral Drug Resistance. 25 - 27 May 2016, Rome, Italy.
261. Saladini F, Brai A, Giannini A, Boccutto A, Tintori C, Garbelli A, Maga G, Botta M, Zazzi M. Preliminary evaluation of antiviral activity of candidate HIV inhibitors targeting human DDX3 protein. 14th European Meeting on HIV & Hepatitis. Treatment Strategies & Antiviral Drug Resistance. 25 - 27 May 2016, Rome, Italy.
262. Kostaki E, Flampouris A, Angelis K, Mamais I, Magiorkinis G, Albert J, Altzerinakou MA, Lawyer G, Hamouda O, Struck D, Van Laethem K, Wensing A, Alexiev I, Åsjö B, Balotta C, Gomes P, Coughlan S, Doulis I, Griskevicius A, Grossman Z, Hatzakis A, Horban A, Kikeri M, Kostrikis LG, Lepej SZ, Liitsola K, Linka M, Markozanes G, Nielsen C, Otelea D, Paredes R, Poljak M, PuchhammerStöckl E, Schmit JC, Sönnnerborg A, Staneková D, Stanojevic D, Boucher CAB, on behalf of the SPREAD program, van de Vijver DAMC, Angarano G, Chaix M-L, de Luca A, Korn K, Loveday C, Soriano V, Yerly S, Zazzi M, Vandamme AM, Paraskevis D. Dating regional subtype B subepidemics: evidence for earliest introduction in Western Europe and Caribbean. 14th European Meeting on HIV & Hepatitis. Treatment Strategies & Antiviral Drug Resistance. 25 - 27 May 2016, Rome, Italy.
263. Giannini A, Saladini F, Micheli V, Bruzzone B, Zazzi M, Vicenti I. Development of an in-house phenotypic HIV-1 coreceptor tropism assay. Ottava Conferenza ICAR 2014. Milano, 6-8 Giugno 2016.
264. Rossetti B, Gagliardini R, Meini G, Sterrantino G, Vignale F, Colangeli V, Latini A, Colafigli M, Rusconi S, Orofino G, Vullo V, Tosti A, Trezzi M, Grima P, Fantauzzi A, Marchetti G, Di Biagio A, Fabbiani M, Lamonica S,

- D'Avino A, Zazzi M, Di Giambenedetto S, De Luca A, on behalf of GUSTA group. Long term safety and tolerability of dual therapy with maraviroc (MVC) + darunavir/ritonavir (DRV/r) in viro-suppressed HIV infected patients with R5 viral tropism. Ottava Conferenza ICAR 2014. Milano, 6-8 Giugno 2016.
265. Lai A, Simonetti FR, Brindicci G, Gioffrè S, Bergna A, Punzi G, Zazzi G, Angarano G, Monno L, Balotta C. Local epidemics gone viral: follow-up study reveals the evolution and nation-wide spread of the Italian recombinant form CRF60. Ottava Conferenza ICAR 2014. Milano, 6-8 Giugno 2016.
266. Boccuto A, Brai A, Giannini A, Tintori C, Garbelli A, Maga G, Botta M, Zazzi M, Saladini F. Preliminary evaluation of antiviral activity of candidate HIV inhibitors targeting human DDX3 protein. Ottava Conferenza ICAR 2014. Milano, 6-8 Giugno 2016.
267. Schultze A, Torti C, Cozzi-Lepri A, Vandamme AM, Zazzi M, Sambatakou H, De Luca A, Geretti AM, Sönnernborg A, Lapadula G. Influence of Transmitted Drug Resistance on CD4 Decline Among ART-Naïve HIV Patients. CROI 2017. Washington, February 13–16, 2017.
268. Cento V, Barbaliscia S, Di Maio V.C, Masetti C, Minichini C, Rossetti B, Marengo S, Troshina Y, Baiguera C, Zazzi M, Dentone C, Landonio S, Nicolini L.A., Caudai C, Melis M, Schiavini M, Bruzzone B, Calvaruso V, Micheli V, Paolucci S, Aragri M, Bertoli A, Lenci I, Ruggiero T, Messina V, Boglione L, Buonomo A.R., Cozzolongo R, Morisco F, Barbarini G, Craxi A, Babudieri S, Puoti M, Ciancio A, Rizzardini G, De Luca A, Coppola N, Angelico M, Perno C.F., CeccheriniSilberstein F on behalf of VIRONET-C. Real-life efficacy of HCVretreatment after DAA-failure: the role of NS5A-resistance. 15th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance, 7 – 9 June 2017, Rome, Italy.
269. Di Carlo D, Bezenchek A, Battisti A, Incardona F, Bavaro D.F., Zuccalà P, Bai F, Salomoni E, Giachè S, Gagliardini, R., Di Giambenedetto S, Pecorari M, Zazzi M, De Luca A, Lo Caputo S. Efficacy and durability of maintenance therapy with lamivudine and darunavir/ritonavir or atazanavir/ritonavir in virologically controlled patients from the clinical practice enrolled in ARCA. 15th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance, 7 – 9 June 2017, Rome, Italy.
270. Saladini F, Giannini A, Martini A, Poggi A, Vichi F, Del Pin B, Boccuto A, Vicenti I, Di Pietro M, Zazzi M. Comparison of genotypic and phenotypic drug susceptibility evaluation of a rare case of multidrug resistant HIV-1. 15th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance, 7 – 9 June 2017, Rome, Italy.
271. Saladini F, Giannini A, Boccuto A, Tiezzi D, Vicenti I, Zazzi M. Impact of the HIV-1 integrase natural polymorphism E157Q on susceptibility to integrase inhibitors. 15th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance, 7 – 9 June 2017, Rome, Italy.
272. Rossetti B, Di Giambenedetto S, Torti C, Postorino M, Punzi G, Saladini F, Gennari W, Borghi V, Monno L, Pignataro A, Polillo E, Colafigli M, Poggi A, Tini S, Zazzi M, De Luca A. Evolution of transmitted HIV-1 drug resistance in Italy from 2006 to 2016. 15th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance, 7 – 9 June 2017, Rome, Italy.
273. Modica S, Rossetti B, Lombardi F, Lagi F, Maffeo M, D'aulia R, Pecorari M, Vicenti I, Bruzzone B, Magnani G, Paolucci S, Francisci D, Penco G, Sacchini D, Zazzi M, De Luca A, Di Biagio A. Prevalence of resistance mutations to Integrase Inhibitors in INSTI-experienced HIV-1 infected patients in a large Italian cohort. 15th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance, 7 – 9 June 2017, Rome, Italy.
274. Di Maio V.C, Cento V, Lenci I, Aragri M, Barbaliscia S, Paolucci S, Pollicino T, Coppola N, Melis M, Niero F, Micheli V, Calvaruso V, Francioso S, Bruzzone B, Ruggiero T, Bolis M, Starace M, Bertoli A, Antonucci F. P, Masetti C, D'Ambrosio C, Morisco F, Zazzi M, Rossetti B, De Luca A, Lambiase L, Maida I, Marengo S, Di Biagio A, Sticchi L, Ghisetti V, Cozzolongo R, Rendina M, Ciancio A, Boccaccio V, Grieco A, Brunetto M, Colombatto P, D'Ettore G, Meregalli E, Galli S, Gaeta G.B., Ciancio A, Marinario L, Polilli E, Cacciatore P, Andreone P, Barbarini G, Gulminetti R, Borghi V, Maserati R, Pace Palitti V, Tarquini P, Puoti M, Sangiovanni V, Giorgini A, Paoloni M, Caporaso N, Babudieri S, Gubertini G, Bruno S, Rizzardini G, Pellicelli A, Pasquazzi C, Parruti G, Raimondo G, Baldanti F, Craxi A, Andreoni M, Angelico M, Perno C.F., Ceccherini-Silberstein F, on behalf of HCV Virology Italian Resistance Network (Vironet\_C). High and unpredictable prevalence of resistance in all HCV genotypes at DAA failure may affect the retreatment options and decrease cure rates. 15th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance, 7 – 9 June 2017, Rome, Italy.
275. Vicenti I, Rossetti B, Mariano S, Zazzi M, De Luca A. Distribution of different HBV DNA forms in plasma and PBMCs of chronically infected patients. 15th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance, 7 – 9 June 2017, Rome, Italy.

276. Saladini F, Giannini A, Boccuto A, Tiezzi D, Vicenti I, Zazzi M. Impact of the HIV-1 integrase natural polymorphism E157Q on susceptibility to integrase inhibitors. 9th Italian Conference on AIDS and Antiviral Research – ICAR. Siena, 12-14 giugno 2017.
277. Rossetti B, Vicenti I, Mariano S, Zazzi M, De Luca A. Distribution of different HBV DNA forms in plasma and PBMCs of chronically infected patients. 19th Italian Conference on AIDS and Antiviral Research – ICAR. Siena, 12-14 giugno 2017.
278. Modica S, Rossetti B, Lombardi F, Lagi F, Maffeo M, D'autilia R, Pecorari M, Vicenti I, Bruzzone B, Magnani G, Paolucci S, Francisci D, Penco G, Sacchini D, Zazzi M, De Luca A, Di Biagio A. Prevalence of resistance mutations to Integrase Inhibitors in INSTI-experienced HIV-1 infected patients in a large Italian cohort. 9th Italian Conference on AIDS and Antiviral Research – ICAR. Siena, 12-14 giugno 2017.
279. Saladini F, Giannini A, Martini A, Poggi A, Vichi F, Del Pin B, Boccuto A, Vicenti I, Di Pietro M, Zazzi M. Comparison of genotypic and phenotypic drug susceptibility evaluation of a rare case of multidrug resistant HIV-1. 9th Italian Conference on AIDS and Antiviral Research – ICAR. Siena, 12-14 giugno 2017.
280. Di Carlo D, Bavaro D, Battisti A, Giachè S, Salomoni E, Incardona F, Zuccalà P, Bai F, Colafigli M, Di Giambenedetto S, Pecorari M, Zazzi M, De Luca A, Bezenchek A, Lo Caputo S. Efficacy and discontinuation of dual regimens with 3TC plus PI/r in patients from clinical practice enrolled in ARCA. 9th Italian Conference on AIDS and Antiviral Research – ICAR. Siena, 12-14 giugno 2017.
281. Alice T, Bruzzone B, Milia MG, Burdino E, Gregori G, Ruggiero T, Simoncelli B, Nigro N, Barresi R, Zazzi M, Ghisetti V and the Italian HLA-B\*5701 Network. Evaluation of the new commercial Duplica-RealTime HLA-B\*5701 EZ Type test for the HLA-B\*5701 typing. 9th Italian Conference on AIDS and Antiviral Research – ICAR. Siena, 12-14 giugno 2017.
282. Armenia D, Gori C, Bertoli A, Forbici F, Fedele V, Pizzi D, Gennari W, Monno L, Saladini F, Francisci D, Zaccarelli M, Vergori A, Mastroiosa I, Latini A, Stingone C, Mastroianni CM, Montella F, Mussini C, Andreoni M, Ceccherini-Silberstein F, Zazzi M, Antinori A, Perno CF, Santoro MM. Variability of sumoylation sites in HIV-1 integrase correlates with viro-immunological parameters and integrase resistance. 9th Italian Conference on AIDS and Antiviral Research – ICAR. Siena, 12-14 giugno 2017.
283. Cento V, Di Maio VC, Barbaliscia S, Masetti C, Minichini C, Rossetti B, Marengo S, Troshina Y, Baiguera C, Zazzi M, Dentone C, Landonio S, Nicolini LA, Caudai C, Melis M, Schiavini M, Bruzzone B, Calvaruso V, Micheli V, Paolucci S, Aragri M, Bertoli A, Lenci I, Ruggiero T, Messina V, Boglione L, Buonomo AR, Cozzolongo R, Morisco F, Barbarini G, Craxì A, Babudieri S, Puoti M, Ciancio A, Rizzardini G, De Luca A, Coppola N, Angelico M, Perno CF, Ceccherini-Silberstein F, on behalf of HCV Virology Italian Resistance Network (VIRONET-C). NS5A-resistance may reduce NS5A-based retreatment efficacy after DAA-failure: a real-life experience. 9th Italian Conference on AIDS and Antiviral Research – ICAR. Siena, 12-14 giugno 2017.
284. Di Maio VC, Cento V, Lenci I, Aragri M, Barbaliscia S, Masetti C, Paolucci S, Pollicino T, Coppola N, Melis M, Niero F, Micheli V, Calvaruso V, Francioso S, Bruzzone B, Ruggiero T, Bolis M, Starace M, Bertoli A, Yu La Rosa K, Campoli R, Antonucci FP, D'Ambrosio C, Morisco F, Zazzi M, Rossetti B, De Luca A, Lambiase L, Maida I, Marengo S, Brancaccio G, Nicolini LA, Di Biagio A, Sticchi L, Ghisetti V, Cozzolongo R, Rendina M, Ciaccio A, Boccaccio V, Grieco A, Brunetto M, Colombatto P, D'Ettore G, Meregalli E, Galli S, Gaeta GB, Ciancio A, Marinaro L, Polilli E, Cacciato P, Andreone P, Barbarini G, Gulminetti R, Gennari W, Borghi V, Maserati R, Pace Palitti V, Tarquini P, Puoti M, Sangiovanni V, Giorgini A, Paoloni M, Lichtner M, Ponti ML, Caporaso N, Babudieri S, Gubertini G, Bruno S, Vullo V, Rizzardini G, Pellicelli A, Pasquazzi C, Parruti G, Raimondo G, Baldanti F, Craxì A, Angelico M, Andreoni M, Perno CF, Ceccherini-Silberstein F on behalf of HCV Virology Italian Resistance Network (VIRONET-C). Complex and frequent multiclass HCV resistance in almost all HCV genotypes at DAA failure: what chances for second-line regimens? 9th Italian Conference on AIDS and Antiviral Research – ICAR. Siena, 12-14 giugno 2017.
285. Borghetti A, Colafigli M, Coppola N, Costantini A, Cirioni O, Di Biagio A, Di Sora F, Fabbiani M, Ferrara S, Giacometti A, Latini A, Maddaloni A, Maritati M, Martini M, Orofino G, Pennica A, Penoncelli D, Resnati C, Rusconi S, Sighinolfi L, Sterrantino G, Taramasso L, Zazzi M, Di Giambenedetto S, De Luca A for the Ecco Group. Management of comorbidities in HIV-infected population: results of a multicenter survey in Italy. 9th Italian Conference on AIDS and Antiviral Research – ICAR. Siena, 12-14 giugno 2017.
286. Redi D, Spertilli Raffaelli C, D'Avino A, Postorino MC, Bezenchek A, Scutari R, Emiliozzi A, Di Gaetano M, Barbaliscia S, Fanti I, Di Carlo D, Di Giambenedetto S, Borghi V, Zazzi M, Santoro MM. Virological Response and Resistance Profile in HIV-1 Infected Patients Starting a First-Line Regimen Containing a Protease Inhibitor or an Integrase Inhibitor in Clinical Practice. 9th Italian Conference on AIDS and Antiviral Research – ICAR. Siena, 12-14 giugno 2017.

287. Redi D, Rossetti B, Bellazzi LI, Vicenti I, Colao G, Sterrantino G, Monno L, Punzi G, Borghi V, Pecorari M, Paolucci S, Meraviglia P, Micheli V, Di Giambenedetto S, Zazzi M, De Luca A. Virological and Immunological efficacy of Maraviroc-based regimens in experienced patients with undetectable HIV viral load. 9th Italian Conference on AIDS and Antiviral Research – ICAR. Siena, 12-14 giugno 2017.
288. Rossetti B, Di Giambenedetto S, Torti C, Postorino MC, Punzi G, Saladini F, Gennari W, Borghi V, Monno L, Pignataro AR, Polilli E, Colafigli M, Poggi A, Tini S, Zazzi M, De Luca A. Evolution of transmitted HIV-1 drug resistance in Italy from 2006 to 2016. 9th Italian Conference on AIDS and Antiviral Research – ICAR. Siena, 12-14 giugno 2017.
289. Spertilli Raffaelli C, Paglicci L, Rossetti B, Colafigli M, Punzi G, Borghi V, Pecorari M, Perno CF, Penco G, Antinori A, Zazzi M, De Luca A, Zanelli G. Impact of transmitted drug resistance in naive-patients starting 2 NRTI plus a boosted protease-inhibitor (PI) or integrase-inhibitor (INSTI). 9th Italian Conference on AIDS and Antiviral Research – ICAR. Siena, 12-14 giugno 2017.
290. Lo Caputo S, Rusconi S, Di Biagio A, Chiriani A, Andreoni M, Zazzi M, Bon I, Re MC. HIV genotypic resistance test in Italy: difficulties in application and their impact in clinical practice. 9th Italian Conference on AIDS and Antiviral Research – ICAR. Siena, 12-14 giugno 2017.
291. A. Boccuto, I. Vicenti, F. Saladini, A. Giannini, M. Zazzi. Propagation and titration of ZIKA virus in different cell systems. Primo Congresso Nazionale SIV-ISV. Milano, 25-28 Giugno 2017.
292. I. Vicenti<sup>1</sup>, B. Rossetti, S. Mariano, F. Saladini, M. Zazzi, A. De Luca. Distribution of different HBV DNA forms in plasma and PBMCs of chronically infected patients. Primo Congresso Nazionale SIV-ISV. Milano, 25-28 Giugno 2017.
293. S. Giachè, E. Salomoni, D. Di Carlo, F. Bai, D.F. Bavaro, A. Battisti, F. Incardona, P. Zuccalà, R. Gagliardini, S. Di Giambenedetto, M. Pecorari, M. Zazzi, A. De Luca, S. Lo Caputo, A. Bezenchek. Efficacia dello switch terapeutico a darunavir/ritonavir + lamivudina o atazanavir/ritonavir + lamivudina nella pratica clinica in pazienti virologicamente soppressi arruolati nel database ARCA. Primo Congresso Nazionale SIV-ISV. Milano, 25-28 Giugno 2017.
294. Armenia D, Gori C, Bertoli A, Forbici F, Fedele V, Pizzi D, Gennari W, Monno L, Saladini F, Francisci D, Zaccarelli M, Vergori A, Mastroiosa I, Latini A, Stingone C, Mastroianni CM, Montella F, Mussini C, Andreoni M, Ceccherini-Silberstein F, Zazzi M, Antinori A, Perno CF, Santoro MM. Sumoylation of HIV-1 integrase might be associated with viro-immunological parameters and integrase resistance: a proof of concept study. 48° Congresso della Società Italiana di Microbiologia. Genova 27-30 settembre 2017.
295. Bavaro DF, Di Carlo D, Battisti A, Giachè S, Salomoni E, Incardona F, Zuccalà P, Bai F, Colafigli M, Di Giambenedetto S, Pecorari M, Zazzi M, De Luca A, Bezencheck A, Lo Caputo S. Causes of Treatment Discontinuation (TD) and Durability of Dual Regimens with 3TC Plus PI/r in Patients from Clinical Practice Enrolled in ARCA. 16th European AIDS Conference October 25-27, 2017 - Milan, Italy.
296. De Luca A, Pezzotti P, Boucher C, Döring M, Incardona F, Kaiser R, Lengauer T, Pfeiffer N, Schülter E, Vandamme AM, Zazzi M, Geretti AM, EucoHIV Study Group. Efficacy and Durability of Maraviroc (MVC) in Antiretroviral Treatment (ART) Regimens across Europe. 16th European AIDS Conference October 25-27, 2017 - Milan, Italy.
297. Sterrantino G, Borghi V, Callegaro A, Bruzzone B, Saladini F, Maggiolo F, Orani A, Maffongelli G, Andreoni M, De Gennaro M, Gianotti N, Bagnarelli P, Antinori A, Zazzi M, Zaccarelli M. Prevalence and Correlates of Doravirine Resistance in NNRTI Experienced Patients. 16th European AIDS Conference October 25-27, 2017 - Milan, Italy.
298. Modica S, Rossetti B, Lombardi F, Lagi F, Maffeo M, D'aulilia R, Pecorari M, Vicenti I, Bruzzone B, Magnani G, Paolucci S, Francisci D, Penco G, Sacchini D, Zazzi M, De Luca A, Di Biagio A. Prevalence of Resistance Mutations to Integrase Inhibitors in INSTI-experienced HIV-1 Infected Patients in a Large Italian Cohort. 16th European AIDS Conference October 25-27, 2017 - Milan, Italy.
299. Redi D, Spertilli Raffaelli C, Di Carlo D, D'Avino A, Postorino MC, Bezenchek A, Scutari R, Emiliozzi A, Digaetano M, Barbaliscia S, Fanti I, Di Giambenedetto S, Borghi V, Zazzi M, Santoro MM. Virological Response and Resistance Profile in HIV-1 Infected Patients Starting a First-Line Regimen Containing a Protease Inhibitor or an Integrase Inhibitor in Clinical Settings. 16th European AIDS Conference October 25-27, 2017 - Milan, Italy.
300. B. Rossetti, G. Marri, A. Gonnelli, L. Toscano, D. Marri, P. Galluzzi, F. Pippi, N. Carnicelli, C. Malcontenti, C. Puttini, R. Gagliardini, F. Montagnani, G. Zanelli, M. Zazzi, A. De Luca. Efficacy and safety of 2-drug combination antiretroviral therapy in clinical practice: results from a single center study. 10th Italian Conference on AIDS and Antiviral Research (ICAR). Roma, 22-24 Maggio 2018.

301. A. De Luca, G. Marchetti, M.B. Pasticci, G. Baldin, E. Merlini, I. Vicenti, L. Mundo, R. Ricci, A. Borghetti, F. Saladini, R. Gagliardini, S. Di Giambenedetto, M. Zazzi. Characterization of treated acute HIV-1 infections with late or absent seroconversion. 10th Italian Conference on AIDS and Antiviral Research (ICAR). Roma, 22-24 Maggio 2018.
302. F. Saladini, A. Giannini, J. Dzemic, A. Boccuto, F. Dragoni, I. Vicenti, M. Zazzi. In vitro susceptibility of CRF02\_AG to fostemsavir. 10th Italian Conference on AIDS and Antiviral Research (ICAR). Roma, 22-24 Maggio 2018.
303. D Redi, E Giombini, S Modica, R Gagliardini, A Bezenchek, D Di Carlo, F Maggiolo, S Di Giambenedetto, F Lombardi, A Callegaro, M R Gismondo, M Zazzi, A De Luca, B Rossetti, N Gianotti. Virological and immunological efficacy of antiretroviral regimens containing elvitegravir in patients in clinical practice. 10th Italian Conference on AIDS and Antiviral Research (ICAR). Roma, 22-24 Maggio 2018.
304. F. Lombardi, A. Borghetti, A. D'Avino, D. Moschese, A Bezenchek, A. Shallvari, A. Di Biagio, F. Del Puente, S. Bonelli, M. Trezzi, M. Zazzi, De Luca, S. Di Giambenedetto. Historical genotype predicts virological failure in HIV+ patients with low level viremia: a retrospective study from the ARCA cohort. 10th Italian Conference on AIDS and Antiviral Research (ICAR). Roma, 22-24 Maggio 2018.
305. R. Scutari, D. Di Carlo, I. Vicenti, C. Alteri, V. Zuccaro, A. Cascio, F. Incardona, V. Borghi, A. Bezenchek, M. Andreoni, A. Antinori, C.F. Perno, A. De Luca, M. Zazzi, M.M. Santoro. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors. 10th Italian Conference on AIDS and Antiviral Research (ICAR). Roma, 22-24 Maggio 2018.
306. Lombardi F, Borghetti A, D'Avino A, Moschese D, Bezenchek A, Shallvari A, Di Biagio A, Del Puente F, Bonelli S, Trezzi M, Zazzi M, De Luca A. Resistance mutations to different classes of antiretroviral agents predict virological failure in HIV+ patients with low level viremia: a retrospective study from the ARCA cohort. 16th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance. 30 May - 1 June 2018, Rome, Italy.
307. Redi D, Giombini E, Modica S, Gagliardini R, Bezenchek A, Di Carlo D, Maggiolo F, Di Giambenedetto S, Lombardi F, Callegaro A, Gismondo M, Zazzi M, De Luca A, Rossetti B, Gianotti N. Virological efficacy of antiretroviral regimens containing elvitegravir in treatment-experienced patients in clinical practice. 16th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance. 30 May - 1 June 2018, Rome, Italy.
308. Ruggiero T, Cento V, Aragri M, Arosio M, Baldanti F, Brunetto M, Bruzzone B, Boeri E, Cavallone D, Coppola N, Di Stefano M, Ghisetti V, Callegaro A, Capobianchi M, Caudai C, Cuomo N, Galli S, Galmozzi E, Garbuglia A, Gennari W, Lai A, Menzo S, Micheli V, Minosse C, Monno L, Paolucci S, Pollicino T, Raddi A, Raffa G, Raimondo G, Sanguinetti M, Santangelo R, Santantonio T, Soldini S, Starace M, Vatteroni M, Craxi A, Perno C, Ceccherini-Silberstein F, Zazzi M. National Quality Control and Validation of Hepatitis C NS3, NS5A and NS5B Genotypic Resistance Testing in Italy. 16th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance. 30 May - 1 June 2018, Rome, Italy.
309. Saladini F, Giannini A, Dzemic J, Boccuto A, Dragoni F, Vicenti I, Zazzi M. In vitro susceptibility of CRF02\_AG to fostemsavir. 16th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance. 30 May - 1 June 2018, Rome, Italy.
310. F Olearo, H Nguyen, F Bonnet, G Wandeler, M Stoeckle, V B€attig, M Cavassini, A Scherrer, P Schmid, H Bucher, H Gunthard, J Boni, S Yerly, A D'Armino Monforte, M Zazzi, P Bellerive, B Rijnders, P Reiss, F Wit, R Kouyos, A Calmy. The impact of M184V/I mutation on the efficacy of abacavir/lamivudine/dolutegravir regimens prescribed in treatment-experienced patients. HIV Drug Therapy. Glasgow, 28–31 October 2018.
311. B Rossetti, D Redi, A Ciccullo, F Lombardi, S Paolucci, L Bellazzai, A Di Biagio, G Penco, L Lepore, L Monno, S Rusconi, T Carli, S Modica, R Gagliardini, M Zazzi, A De Luca. Predicting two-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study. HIV Drug Therapy. Glasgow, 28–31 October 2018.
312. R Gagliardini, S Modica, D Redi, E Giombini, A Bezenchek, D Di Carlo, F Maggiolo, F Lombardi, A Borghetti, A Callegaro, M Gismondo, M Colafigli, G Sterrantino, A Costantini, S Ferrara, S Rusconi, S Di Giambenedetto, M Zazzi, A De Luca, B Rossetti, N Gianotti. Impact of NRTI mutations on virological efficacy of antiretroviral regimens containing elvitegravir: an ARCA-ECCO cohort study. HIV Drug Therapy. Glasgow, 28–31 October 2018.
313. Boccuto, I. Vicenti, F. Saladini, A. Giannini, F. Dragoni, M. Zazzi. In vitro evaluation of the ZIKA virus genetic barrier to sofosbuvir, a potent nucleotide analog inhibitor approved by FDA for the treatment of HCV infection. Second National Congress of the Italian Society for Virology. Rome, November 28-30, 2018.

314. F. Saladini, A. Giannini, A. Boccutto, F. Dragoni, A. Appendino, E. Albanesi, I. Vicenti, M. Zazzi. Comparable predicted and phenotypic susceptibility to dolutegravir and bictegravir in first generation INSTI resistant HIV-1. Second National Congress of the Italian Society for Virology. Rome, November 28-30, 2018.
315. I. Vicenti, F. Dragoni, A. Boccutto, M. Pavone, G. Guareschi, M. Zazzi, M. Radi. In vitro evaluation of antiviral compounds simultaneously inhibiting Zika and Dengue virus replication using a cell based flavivirus immunodetection assay. Second National Congress of the Italian Society for Virology. Rome, November 28-30, 2018.
316. Scutari R, Di Carlo D, Vicenti I, Alteri C, Zuccaro V, Cascio A, Incardona F, Borghi V, Bezenchek A, Andreoni M, Antinori A, Perno C, De Luca A, Zazzi M, Santoro M. HIV-1 integrase drug-resistance emergence and evolution in patients treated with integrase inhibitors. 16th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance. 30 May - 1 June 2018, Rome, Italy. Francesco Saladini, Alessia Giannini, Franco Maggiolo, Francesca Vichi, Giulio M. Corbelli, Andrea Galli, Alba Bigoloni, Maria M. Santoro, Maurizio Zazzi, Antonella Castagna. Genotypic and phenotypic susceptibility to fostemsavir in multidrug-resistant HIV-1. Conference on Retroviruses and Opportunistic Infections (CROI) 2019. Seattle, Washington, March 4-7, 2019.
317. Francesco Saladini, Alessia Giannini, Adele Boccutto, Filippo Dragoni, Alice Appendino, Edoardo Albanesi, Ilaria Vicenti, Maurizio Zazzi. In vitro activity of DTG/BIC/CAB on first-generation INSTI-resistant HIV-1. Conference on Retroviruses and Opportunistic Infections (CROI) 2019. Seattle, Washington, March 4-7, 2019.
318. Rossetti B, Modica S, Gagliardini R, Redi D, Montagnani F, Zanelli G, Di Giambenedetto S, Lombardi F, Pecorari M, Borghi V, Meraviglia P, Maggiolo F, Micheli V, Zazzi M, De Luca A. Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study. 17th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance. 22 – 24 May 2019, Rome, Italy.
319. Di Maio V, Aragri M, Masetti C, Paolucci S, Bruzzone B, Degasperis E, Barbaliscia S, Pollicino T, Minichini C, Calvaruso V, Rendina M, Cento V, Teti E, Micheli V, Ghisetti V, Polilli E, Pace Palitti V, Landonio S, Lenci I, Donnarumma L, Nicolini L, Bertoli A, Starace M, Pasquazzi C, Callegaro A, Morisco F, Cenderello G, Marengo S, Gulminetti R, Novati S, Guarneri V, Andreone P, Galli S, Ciancio A, Sangiovanni V, Cuomo N, Raddi A, Morsica G, Borghi V, Maida I, Brunetto M, Colombatto P, Cozzolongo R, De Santis A, Lichtner M, Babudieri S, Biliotti E, Taliani G, Santantonio T, Di Stefano M, Paternoster C, Ganga R, Puoti M, Rizzardini G, Pellicelli A, Milano E, Mastroianni C, Licata A, Di Lorenzo F, Giorgini A, Sighinolfi L, Dentone C, Lleo A, Lampertico P, Parruti G, Coppola N, Zazzi M, Raimondo G, Andreoni M, Craxi A, Angelico M, Perno C, Ceccherini-Silberstein F. Retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen after performing a genotypic resistance test: the Italian Vironet C real life experience. 17th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance. 22 – 24 May 2019, Rome, Italy.
320. Vicenti I, Dragoni F, Monti M, Giannini A, Ciabattini A, Rossetti B, De Luca A, Medagliani D, Montomoli E, Zazzi M. Maraviroc as a Latency Reversing Agent in cell line models. 17th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance. 22 – 24 May 2019, Rome, Italy.
321. Gagliardini R, Rossetti B, Redi D, Modica S, Montagnani F, Zanelli G, Di Giambenedetto S, Lombardi F, Pecorari M, Borghi V, Callegaro A, Micheli V, Annovazzi Lodi M, De Luca A, Zazzi M. Impact of resistance mutations on virological efficacy of DTG-based maintenance two-drug regimens: a cohort study. 17th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance. 22 – 24 May 2019, Rome, Italy.
322. Koppe U, Böhm M, Jovanovic L, Beyene Tufa T, Büch J, Lengauer T, Zazzi M, De Luca A, Sönnnerborg A, Incardona F, Bezenchek A, Kaiser R, Doering M, Lennartz S, Obermeier M. A retrospective analysis of the EuResist data set assessing if NRTI resistance impairs INSTI based treatment with NRTI backbone. 17th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance. 22 – 24 May 2019, Rome, Italy.
323. Elvstam O, Böhm M, Schmidt D, Mlakar J, Moench E, Prifert C, Gehring T, Popping S, Moseholm Larsen E, Bisaso K, Büch J, Lengauer T, Zazzi M, De Luca A, Sönnnerborg A, Incardona F, Bezenchek A, Lennartz S, Kaiser R. A retrospective analysis of the EuResist data set assessing dual therapy success in a real-life context. 17th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance. 22 – 24 May 2019, Rome, Italy.
324. Maria M. Santoro, Chiara Fornabaio, Marina Malena, Laura Galli, Andrea Poli, Simone Marcotullio, Marianna Menozzi, Maurizio Zazzi, Kirsten L. White, Antonella Castagna. Susceptibility to bictegravir in highly ARV-experienced patients after INSTI failure. Conference on Retroviruses and Opportunistic Infections (CROI) 2019. Seattle, Washington, March 4-7, 2019.

- 325.S. Barbaliscia, V.C. Di Maio, E. Teti, M. Aragri, S. Paolucci, C. Masetti, R. D'Ambrosio, E. Degaspero, E. Polilli, V. Pace Palitti, G. Fiorentino, L. Foroghi, V. Cento, R. Scutari, B. Bruzzone, V. Calvaruso, N. Coppola, G.B. Gaeta, G. Morsica, T. Ruggiero, V. Ghisetti, A. Bertoli, M. Milana, L.A. Nicolini, W. Gennari, S. Galli, C.F. Magni, V. Micheli, A. Lleo, A. Aghemo, R. Maserati, S. Bonora, N. Iapadre, F. Morisco, M. Siciliano, V. Guarneri, B. Rossetti, M. Lichtner, V. Borghi, T. Pollicino, C. Caudai, L. Sarmati, M. Puoti, A. Pellicelli, S. Babudieri, G. Rizzardini, G. Taliani, G. Parruti, M. Zazzi, P. Lampertico, G. Raimondo, C. Pasquazzi, M. Angelico, F. Baldanti, M. Andreoni, C.F. Perno, A. Craxi, F. Ceccherini-Silberstein on behalf of HCV Virology Italian Resistance Network (Vironet C). Analysis of baseline factors associated with treatment outcome in HCV-infected patients starting a first-line DAA-treatment containing a NSA inhibitor: particular focus on natural resistance. 11th Italian Conference on AIDS and Antiviral Research (ICAR). Milano, 5-7 Giugno 2019.
- 326.R. Gagliardini, B. Rossetti, D. Redi, S. Modica, F. Montagnani, G. Zanelli, S. Di Giambenedetto, F. Lombardi, M. Pecorari, V. Borghi, A. Callegaro, V. Micheli, M. Annovazzi Lodi, A. De Luca, M. Zazzi. Impact of resistance mutations on virological efficacy of DTG-based maintenance two-drug regimens: an ARCA cohort study. 11th Italian Conference on AIDS and Antiviral Research (ICAR). Milano, 5-7 Giugno 2019.
- 327.F. Saladini, F. Giammarino, A. Giannini, A. Boccutto, F. Dragoni, I. Vicenti, R.W. Shafer, M. Zazzi. In vitro analysis of doravirine activity on HIV-1 clones harboring multiple NNRTI resistance mutations. 11th Italian Conference on AIDS and Antiviral Research (ICAR). Milano, 5-7 Giugno 2019.
- 328.M.R. Parisi, A. Poli, M. Menozzi, M. Fiscon, E. Garlassi, D. Francisci, A. Di Biagio, G. Sterrantino, C. Fornabaio, A. Degli Antoni, G. Angarano, F.M. Fusco, A. D'Arminio Monforte, G.M. Corbelli, M.M. Santoro, M. Zazzi, A. Castagna, on behalf of the PRESTIGIO Study Group. Burden of disease in PLWH harbouring a -class drug resistant virus: data from PRESTIGIO Registry. 11th Italian Conference on AIDS and Antiviral Research (ICAR). Milano, 5-7 Giugno 2019.
- 329.D. Redi, B. Rossetti, V.C. Di Maio, M. Aragri, S. Paolucci, C. Masetti, L. Paglicci, B. Bruzzone, C. Minichini, F. Montagnani, V. Micheli, S. Landonio, E. Degaspero, G. Zanelli, R. Maserati, I. Maida, A.P. Callegaro, S. Barbaliscia, A. Bertoli, C. Paternoster, S. Marengo, F. Morisco, V. Calvaruso, G. Taliani, M. Puoti, G. Cenderello, A. De Santis, M. Lichtner, N. Coppola, R. Gulminetti, V. Cento, M. Rendina, E. Teti, G. Parruti, T. Ruggiero, V. Ghisetti, C. Pasquazzi, L.A. Nicolini, V. Vullo, A. Pellicelli, T. Prestileo, R. Cozzolongo, V. Sangiovanni, M. Biolato, I. Lenci, A. Licata, A. Ciaccio, V. Pace Palitti, A. Giorgini, G. Cariti, A. Ciancio, A. Aghemo, V. Borghi, P. Andreone, M. Brunetto, T. Pollicino, T. Santantonio, N. Cuomo, C. Caudai, S. Babudieri, P. Lampertico, G.B. Gaeta, G. Raimondo, M. Andreoni, G. Rizzardini, M. Angelico, C.F. Perno, A. Craxi, M. Zazzi, F. Ceccherini-Silberstein on behalf of HCV Virology Italian Resistance Network (Vironet C). Decline of Prevalence of Resistance Associated Substitutions to NS and NSA inhibitors at DAA-failure in Hepatitis C Virus in Italy over the years 2015 to 2018. 11th Italian Conference on AIDS and Antiviral Research (ICAR). Milano, 5-7 Giugno 2019.
- 330.V.C. Di Maio, M. Aragri, C. Masetti, S. Paolucci, B. Bruzzone, E. Degaspero, S. Barbaliscia, T. Pollicino, C. Minichini, V. Calvaruso, M. Rendina, V. Cento, E. Teti, V. Micheli, V. Ghisetti, E. Polilli, V. Pace Palitti, S. Landonio, I. Lenci, S. Francioso, L. Donnarumma, L.A. Nicolini, A. Bertoli, M. Starace, C. Pasquazzi, A.P. Callegaro, F. Morisco, G. Cenderello, S. Marengo, R. Gulminetti, S. Novati, A. Scuteri, P. Andreone, S. Galli, A. Ciancio, V. Sangiovanni, N. Cuomo, A. Raddi, G. Morsica, H. Hamid, V. Borghi, I. Maida, M. Brunetto, P. Colombatto, R. Cozzolongo, A. De Santis, M. Lichtner, S. Babudieri, E. Biliotti, G. Taliani, T. Santantonio, M. Di Stefano, C. Paternoster, R. Ganga, M. Puoti, G. Rizzardini, A. Pellicelli, E. Milano, C. Mastroianni, A. Licata, F. Di Lorenzo, A. Giorgini, L. Sighinolfi, C. Dentone, A. Lleo, B. Rossetti, I. Beretta, P. Lampertico, G. Parruti, N. Coppola, M. Zazzi, G. Raimondo, M. Andreoni, A. Craxi, M. Angelico, C.F. Perno, F. Ceccherini-Silberstein on behalf of HCV Virology Italian Resistance Network (Vironet C). High efficacy of resistance-guided retreatment in HCV infected patients who previously failed a NSA inhibitor-containing regimen: the Italian Vironet C real life experience. 11th Italian Conference on AIDS and Antiviral Research (ICAR). Milano, 5-7 Giugno 2019.
- 331.I. Vicenti, F. Dragoni, M. Monti, A. Giannini, A. Ciabattini, B. Rossetti, A. De Luca, D. Medagliani, E. Montomoli, M. Zazzi. Maraviroc as a Latency Reversing Agent in cell line models. 11th Italian Conference on AIDS and Antiviral Research (ICAR). Milano, 5-7 Giugno 2019.
- 332.D. Canetti, L. Galli, N. Gianotti, A. Celotti, L. Calza, R. Gagliardini, S. Rusconi, S. Modica, G. Cenderello, M. Ferrara, M. Santoro, M. Zazzi, A. Castagna, on behalf of the PRESTIGIO Study Group. Simplification to high-genetic-barrier DR in PLWH harbouring -class drug-resistant HIV-1 enrolled in the PRESTIGIO Registry. 11th Italian Conference on AIDS and Antiviral Research (ICAR). Milano, 5-7 Giugno 2019.
- 333.B. Rossetti, S. Modica, R. Gagliardini, D. Redi, F. Montagnani, G. Zanelli, S. Di Giambenedetto, F. Lombardi, M. Pecorari, V. Borghi, P. Meraviglia, F. Maggiolo, V. Micheli, M. Zazzi, A. De Luca, on behalf of ARCA study

- group. Predicting -drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study. 11th Italian Conference on AIDS and Antiviral Research (ICAR). Milano, 5-7 Giugno 2019.
334. I. Vicenti, F. Dragoni, M. Monti, A. Giannini, A. Ciabattini, B. Rossetti, A. De Luca, D. Medaglini, E. Montomoli, M. Zazzi. Maraviroc as a Latency Reversing Agent in cell line models. Third National Congress of the Italian Society for Virology. Padova, 12-14 September 2019.
335. A. Boccuto, A. Brai, F. Saladini, N. Palombi, I. Vicenti, C. Ardino, M. Zazzi, M. Botta. Evaluation of broad-spectrum antivirals targeting viral envelopes of Dengue and Zika viruses. Third National Congress of the Italian Society for Virology. Padova, 12-14 September 2019.
336. F. Dragoni, A. Boccuto, A. Giannini, F. Saladini, M. Zazzi, I. Vicenti. Evaluation of antiviral activity and resistance profile of sofosbuvir against West Nile Virus in vitro. Third National Congress of the Italian Society for Virology. Padova, 12-14 September 2019.
337. F. Saladini, F. Giammarino, A. Giannini, A. Boccuto, F. Dragoni, I. Vicenti, R. W. Shafer, M. Zazzi. Impact of RAMs selected by older NNRTI on the susceptibility to doravirine in vitro. Third National Congress of the Italian Society for Virology. Padova, 12-14 September 2019.
338. A. Borghetti, M. B. Whalen, P. Cattani, V. De Simone, S. Marchetti, M. Goglia, F. Lombardi, D. Moschese, G. Baldin, A. Cingolani, C. Ratto, M. Zazzi, S. Di Giambenedetto. Anal HPV infections do not associate with rectal HIV-RNA shedding in HIV+ patients. CROI 2020, 8-11 March 2020, virtual.
339. S. Rusconi, F. Saladini, S. Barbaliscia, A. Poli, L. Galli, R. Gagliardini, L. Gazzola, D. Francisci, F. Vichi, E. Focà, M. Zazzi, M. M. Santoro, A. Gabrieli, A. Castagna, for the PRESTIGIO Registry Study Group. PRO 140 in vitro activity in hte subjects with a 4-class drugresistant HIV-1 virus. CROI 2020, 8-11 March 2020, virtual.
340. F. Saladini, F. Giammarino, F. Maggiolo, M. Ferrara, G. Cenderello, BM Celesia, F. Martellotta, V. Spagnuolo, GM Corbelli, N. Gianotti, MM Santoro, S. Rusconi, M. Zazzi, A. Castagna, for the PRESTIGIO Study Group. Phenotypic doravirine susceptibility after NNRTI exposure in the prestigio registry. CROI 2020, 8-11 March 2020, virtual.
341. J. Vercauteren, AM Vandamme, B. Rossetti, M. Fabbiani, F. Incardona, K. Theys, A. Abecasis, C. Devaux, R. Kaiser, A. Sönnnerborg, M. Zazzi, for the EuResist Network Study Group. Four-class resistance is rare in treatment-experienced patients across Europe. CROI 2020, 8-11 March 2020, virtual.
342. A. Emiliozzi, F. Lombardi, B. Rossetti, C. Spertilli Raffaelli, S. Belmonti, A. Ciccullo, A. Dusina, A. D'Angelillo, M. D. Di Trapani, G. Zanelli, F. Montagnani, F. Saladini, M. Zazzi, S. Di Giambenedetto, M. Fabbiani. Does dual therapy have an impact on hiv-dna decay in virologically-suppressed patients compared to triple therapy? Results from a multicentric study. 12° Congresso Nazionale ICAR – Italian Conference on AIDS and Antiviral Research. Web, 12-16 Ottobre 2020.
343. T. Clemente, R. Caccia, V. Spagnuolo, L. Galli, A. Poli, A. Galli, G. Marchetti, M. Andreoni, A. Bandera, M. Puoti, M. Zazzi, M.M. Santoro, P. Cinque, A. Castagna, on the behalf of the PRESTIGIO Study Group. Inflammatory burden in people living with four-class drug resistant hiv: data from the Prestigio Registry. 12° Congresso Nazionale ICAR – Italian Conference on AIDS and Antiviral Research. Web, 12-16 Ottobre 2020.
344. V.C. Di Maio, S. Barbaliscia, E. Teti, S. Paolucci, C. Minichini, K. Yu La Rosa, M. Aragri, L. Foroghi, G. Fiorentino, F. Novazzi, M. Milana, T. Pollicino, V. Di Marco, A. Pieri, V. Pace Palitti, B. Bruzzzone, V. Micheli, A. Bertoli, L. Campogiani, A.P. Callegaro, A. Pellicelli, F. Morisco, R. Gulminetti, S. Novati, M. Lichtner, C. Mastroianni, F. Di Lorenzo, P. Andreone, B. Rossetti, S. Marengo, G. Taliani, E. Boeri, H. Hasson, L. Monno, L.A. Nicolini, S. Landonio, C. Paternoster, A. Licata, S. Babudieri, L. Carioti, M. Ciotti, G. De Simone, I. Lenci, A. Bosa, T. Mulas, E. Degaspero, L. Ippolito, M. Quartini, N. Iapadre, R. Cozzolongo, V. Sangiovanni, R. Schiavo, A. Soria, C. Caudai, P. Lampertico, G. Parruti, L. Sarmati, N. Coppola, M. Puoti, G. Raimondo, C. Pasquazzi, F. Baldanti, M. Angelico, M. Zazzi, C.F. Perno, A. Craxi, M. Andreoni, F. Ceccherini-Silberstein on behalf of HCV Virology Italian Resistance Network (Vironet C). Prevalence and resistance analysis of “unusual” hepatitis c virus (hcv) subtypes within the Italian resistance network VIRONET-C. 12° Congresso Nazionale ICAR – Italian Conference on AIDS and Antiviral Research. Web, 12-16 Ottobre 2020.
345. I. Vicenti, F. Dragoni, A. Giannini, A. Callegaro, G. Napolitano, O. Turriziani, D. Di Carlo, S. Di Giambenedetto, F. Lombardi, S. Belmonti, F. Ceccherini-Silberstein, R. Scutari, C. Alteri, A. Lai, A. Bergna, S. Racca, A. Ardemagni, A. Casabianca, C. Orlandi, I. Bon, A. Bertoldi, P. Bagnarelli, L. Di Sante, I. Abbate, G. Rozera, M.R. Capobianchi, S. Paolucci, G. Campanini, F. Saladini, M. Zazzi. Creation of an Italian HIV DNA network for the validation and clinical use of HIV-1 DNA quantification assays. 12° Congresso Nazionale ICAR – Italian Conference on AIDS and Antiviral Research. Web, 12-16 Ottobre 2020.
346. M.M. Santoro, D. Armenia, M.C. Bellocchi, L. Carioti, L. Galli, A. Galli, R. Scutari, E. Salsi, C. Mussini, G. Sterrantino, L. Calza, B. Rossetti, M. Zazzi, A. Castagna, on behalf of the PRESTIGIO Registry Study Group. HIV-1 RNA and DNA mutational load in hte patients with mdr virus: a tool for deciding OBR? 12° Congresso Nazionale ICAR – Italian Conference on AIDS and Antiviral Research. Web, 12-16 Ottobre 2020.



347. C. Caudai, P. Pierotti, P. Galluzzi, B. Rossetti, P. Blanc, M. Zazzi. Genotyping and treatment issues with unusual 1e and 1g HCV subtypes from African subjects: report of two cases. 12<sup>o</sup> Congresso Nazionale ICAR – Italian Conference on AIDS and Antiviral Research. Web, 12-16 Ottobre 2020.
348. A. Giannini, F. Giammarino, A. Antonova, E. Ozhmegova, R. Kaiser, F. Dragoni, A. Boccuto, I. Vicenti, A. Sönnnerborg, M. Bobkova, M. Zazzi, F. Saladini. Susceptibility to HIV-1 integrase inhibitors in HIV-1 sub-subtype A6 isolates. 12<sup>o</sup> Congresso Nazionale ICAR – Italian Conference on AIDS and Antiviral Research. Web, 12-16 Ottobre 2020.
349. F. Saladini, F. Giammarino, F. Maggiolo, M. Ferrara, G. Cenderello, B.M. Celesia, F. Martellotta, V. Spagnuolo, G.M. Corbelli, N. Gianotti, M. M. Santoro, S. Rusconi, M. Zazzi, A. Castagna, for the PRESTIGIO STUDY GROUP. Residual phenotypic susceptibility to second generation nrti in multidrug resistant HIV-1 from the Prestigio Registry. 12<sup>o</sup> Congresso Nazionale ICAR – Italian Conference on AIDS and Antiviral Research. Web, 12-16 Ottobre 2020.
350. F. Giammarino, F. Saladini, M. Tavio, A.M. Cattelan, B. Menzaghi, E. Garlassi, F. Ortu, G.M. Corbelli, A. Poli, M.M. Santoro, M. Zazzi, A. Castagna, for the PRESTIGIO STUDY GROUP. In vitro activity of islatravir against HIV-1 mutants harboring multiple nrti resistance mutations. 12<sup>o</sup> Congresso Nazionale ICAR – Italian Conference on AIDS and Antiviral Research. Web, 12-16 Ottobre 2020.
351. A. Borghetti, C. Picarelli, A. Ciccullo, V. Borghi, P. Laghetti, S. Rusconi, L. Monno, W. Gennari, F. Maggiolo, B. Bruzzone, I. Vicenti, A. Callegaro, A. Di Biagio, M. Zazzi, S. Di Giambenedetto. efficacy of dolutegravir versus darunavir in first-line regimens according to resistance mutations and viral subtype. 12<sup>o</sup> Congresso Nazionale ICAR – Italian Conference on AIDS and Antiviral Research. Web, 12-16 Ottobre 2020.
352. R. Gagliardini; A. Cozzi-Lepri; M. Zazzi; A. Tavelli; M. Santoro; D. Armenia; A. Castagna; W. Gennari; S. Rusconi; C. Mussini; P. Laghetti; C. Perno; A. D'Arminio Monforte and A. Antinori. Impact of multi-drug resistance on mortality: a multi-cohort Italian study. HIV Glasgow – Virtual, 5–8 October 2020.
353. C. Cassol; G. Dolci; A. Emiliozzi; W. Gennari; B. Bruzzone; I. Vicenti; V. Micheli; V. Borghi; A. Callegaro; L. Monno; S. Rusconi; P. Laghetti; F. Lombardi; M. Zazzi and M. Fabbiani. Efficacy and durability of raltegravir-based dual therapy. HIV Glasgow – Virtual, 5–8 October 2020.
354. B. Rossetti; D. Di Carlo; M. Fabbiani; G. Stella; I. Vicenti; F. Maggiolo; W. Gennari; D. Francisci; M. Santoro and M. Zazzi. Impact of resistance to antiretroviral drugs on predicted HIV-1 susceptibility to current single-tablet regimens (STRs). HIV Glasgow – Virtual, 5–8 October 2020.
355. Santoro M, Armenia D, Bellocchi M, Carioti L, Galli L, Galli A, Scutari R, Salsi E, Mussini C, Sterrantino G, Calza L, Rossetti B, Zazzi M, Castagna A. Evaluation of HIV-1 RNA and DNA mutational load in HIV-1 infected heavily treatment-experienced patients harbouring multi-drug resistant strains. 18<sup>th</sup> European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance 28-30 October 2020, virtual meeting.
356. Di Maio V, Barbaliscia S, Teti E, Paolucci S, Fabeni L, Minichini C, Yu La Rosa K, Aragri M, Foroghi L, Fiorentino G, Novazzi F, Milana M, Pollicino T, Di Marco V, Pieri A, Pace Palitti V, Bruzzone B, Micheli V, Bertoli A, Compagno M, Callegaro A, Pellicelli A, Morisco F, Gulminetti R, Novati S, Lichtner M, Mastroianni C, Di Lorenzo F, Andreone P, Rossetti B, Marengo S, Taliani G, Boeri E, Hasson H, Monno L, Nicolini L, Landonio S, Paternoster C, Licata A, Babudieri S, Carioti L, Ciotti M, De Simone G, Lenci I, Bosa A, Campogiani L, Degasperis E, Ippolito L, Quartini M, Iapadre N, Cozzolongo R, Sangiovanni V, Schiavo R, Soria A, Caudai C, Lampertico P, Parruti G, Sarmati L, Coppola N, Puoti M, Raimondo G, Pasquazzi C, Baldanti F, Angelico M, Zazzi M, Perno C, Craxi A, Andreoni M, Ceccherini-Silberstein F. Characterization and Resistance Profile of “Unusual” Hepatitis C Virus (HCV) Subtypes in Italy. 18th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance 28-30 October 2020, virtual meeting.
357. Giannini A, Giammarino F, Antonova A, Ozhmegova E, Kaiser R, Dragoni F, Boccuto A, Vicenti I, Sönnnerborg A, Bobkova M, Zazzi M, Saladini F. Susceptibility to HIV-1 integrase inhibitors in HIV-1 sub-subtype A6 isolates. 18th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance 28-30 October 2020, virtual meeting.
358. Saladini F, Giammarino F, Maggiolo F, Ferrara M, Cenderello G, Celesia B, Martellotta F, Spagnuolo V, Corbelli G, Gianotti N, Santoro M, Rusconi S, Zazzi M, Castagna A. Residual phenotypic susceptibility to second generation NNRTI in multidrug resistant HIV-1 from the PRESTIGIO Registry. 18th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance 28-30 October 2020, virtual meeting.
359. Giammarino F, Saladini F, Tavio M, Cattelan A, Menzaghi B, Garlassi E, Ortu F, Corbelli G, Poli A, Santoro M, Zazzi M, Castagna A. In vitro activity of Islatravir against HIV-1 mutants harboring multiple NRTI resistance mutations. 18th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance 28-30 October 2020, virtual meeting.

360. Kuznetsova A, Gromov K, Kazennova E, Bobkova M, Zazzi M, Incardona F, Sönnnerborg A. The efficacy of first-line therapy based on RPV in HIV-infected patients with pre-existing E138A mutation in reverse transcriptase. 18th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance 28-30 October 2020, virtual meeting.
361. Vicenti I, Dragoni F, Giannini A, Callegaro A, Napolitano G, Turriziani O, Di Carlo D, Di Giambenedetto S, Lombardi F, Belmonti S, Ceccherini-Silberstein F, Scutari R, Alteri C, Lai A, Bergna A, Racca S, Ardemagni A, Casabianca A, Orlandi C, Bon I, Bertoldi A, Bagnarelli P, Di Sante L, Abbate I, Rozera G, Capobianchi M, Paolucci S, Campanini G, Saladini F, Zazzi M. Creation of an Italian HIV DNA Network for the validation and clinical use of HIV-1 DNA quantification assays. 18th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance 28-30 October 2020, virtual meeting.
362. Caudai C, Pierotti P, Galluzzi P, Rossetti B, Blanc P, Zazzi M. Genotyping and treatment issues with unusual 1e and 1g HCV subtypes from African subjects: report of two cases. 18th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance 28-30 October 2020, virtual meeting.
363. Dragoni F, Bartolini N, Rossetti B, Fabbiani M, Spertilli Raffaelli C, Lombardi F, Di Giambenedetto S, Vicenti I, De Luca A, Zazzi M, Saladini F. Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG+3TC or ATV/r+3TC dual therapy. European Meeting on HIV and Hepatitis 2021. 26-28 May 2021, virtual.
364. Giammarino F, Giannini A, Sterrantino G, Colao G, Micheli V, Boccutto A, Dragoni F, Vicenti I, Zazzi M, Saladini F. HIV-1 reverse transcriptase natural polymorphism V106I does not alter the susceptibility and the genetic barrier to resistance to doravirine in vitro. European Meeting on HIV and Hepatitis 2021. 26-28 May 2021, virtual.
365. Vicenti I, Dragoni F, Turriziani O, Lombardi F, Scutari R, Alteri C, Lai A, Racca S, Casabianca A, Bertoldi A, Di Sante L, Abbate I, Paolucci S, Zazzi M and Italian HIV DNA Network. Assessment of HIV-1 DNA quantification methods in the Italian HIV DNA Network. European Meeting on HIV and Hepatitis 2021. 26-28 May 2021, virtual.
366. Miranda M, Pingarilho M, Pimentel V, Martins M, Vandamme A, Bobkova M, Böhm M, Devaux C, Paredes R, Rubio R, Zazzi M, Incardona F, Abecasis A. Determinants of HIV-1 late presentation in patients followed in Europe. European Meeting on HIV and Hepatitis 2021. 26-28 May 2021, virtual.
367. Exploration of the possible mechanisms leading to greater mortality in people with limited drug options (LDO). Cozzi-Lepri A, Gagliardini R, Zazzi M, Tavelli A, Santoro M, Armenia D, Castagna A, Gennari W, Rusconi S, Mussini C, Laghetti P, Perno C, d'Arminio Monforte A, Antinori A. European Meeting on HIV and Hepatitis 2021. 26-28 May 2021, virtual.

## **Editorial activity**

### ***Associate Editor***

BMC Infect Dis (2018-present)

### ***Reviewer***

AIDS, AIDS Reviews, Antimicrobial Agents and Chemotherapy, Antiviral Therapy, BMC Infectious Diseases, Clinical Chemistry, Clinical Chemistry and Laboratory Medicine, Clinical Infectious Diseases, Clinical Microbiology and Infection, CNS Drugs, Current HIV Research, EClinicalMedicine, Epidemiology and Infection, HIV Clinical Trials, HIV Medicine, Indian Journal of Medical Research, International Journal of Antimicrobial Agents, Journal of Antimicrobial Chemotherapy, Journal of Clinical Microbiology, Journal of Infectious Diseases, Journal of the International AIDS Society, Journal of Medical Virology, Journal of Translational Medicine, Journal of Virological Methods, Lancet Infectious Diseases, Lancet Microbes, PLoS Computational Biology, PLoS ONE, Retrovirology, Scientific Reports, Virology, Virus Research.


## **Awards**

1. 2008. Scientific coordinator of the EuResist project (FP6-2004-IST-4: Integration of viral genomics with clinical data to predict response to anti-HIV treatment), awarded the Project of the Month honor in November 2008.
2. 2009. Winner of the Computerworld Honors Program (Honoring those who use information technology to benefit society) with a case study based on the EuResist anti-HIV treatment response prediction engine.

## Patents

1. Antiretroscan, 30/10/2002. Method for prediction of susceptibility to antiretroviral drugs. Deposit number RM2002A000544.
2. HIV-1 nucleocapsid inhibitors, 24/10/2016. Patent n. 16186511.8-1452.

Date: 26/05/2021

Signature: 

I hereby authorize the handling of my personal data pursuant to the Personal Data Protection Code – Legislative Decree n. 196/2003.

Date: 26/05/2021

Signature: 